Uses of anti-FAM19A5 antibodies
By using antagonists against FAM19A5 protein to improve retinal potential and reduce vascular abnormalities, the problem of large and limited side effects of existing treatments is solved, and an effective treatment plan is provided for most patients, especially inappropriate for laser therapy. patients.
Patent Information
- Application Number
- CN201980075558.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-16
- Filing Date
- 2019-10-15
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2039-10-15
AI Technical Summary
The existing treatment methods for diabetic retinopathy and age-related macular degeneration have great side effects and limited effects. In particular, laser therapy is not suitable for some patients and cannot effectively improve central vision. The existing technology is difficult to meet the treatment needs of all patients. .
Using antagonists against the 19 member A5 (FAM19A5) proteins, such as anti-FAM19A5 antibodies, to improve retinal potential, reduce pericyte loss and cell-availability, inhibit vascular congestion and neovascularization by administration of FAM19A5 antagonists, Formation, thereby treating diabetic retinopathy and macular degeneration.
By increasing retinal potential, reducing peritoneal cell loss and vascular abnormalities and significantly improving retinal health, it provides a more effective and comprehensive treatment option, reducing the side effects of laser therapy, and is suitable for patients whose traditional methods are not suitable.
Smart Images

Figure BDA0003067482160000221 
Figure BDA0003067482160000241 
Figure BDA0003067482160000541
Abstract
Description
[0001] Cross-references to Related Patent Applications
[0002] This PCT application claims priority to U.S. Provisional Patent Application No. 62 / 746,194, filed on October 16, 2018, which is incorporated herein by reference in its entirety and made a part hereof.
[0003] Reference electronic sequence listing
[0004] An electronic version of the sequence listing in ASCII text file (name: 3763.012PC01_SeqListing_ST25.txt; size: 261,609 bytes; creation date: October 13, 2019) is submitted with this application, and its contents are incorporated herein by reference as a whole and become a part of the present invention. Technical Field
[0005] The present disclosure provides methods of treating retinopathy (e.g., diabetic retinopathy) and / or macular degeneration (e.g., age-related macular degeneration) in an individual (e.g., a human) using antagonists to family of sequence similarity 19, member A5 (FAM19A5) (e.g., anti-FAM19A5 antibodies) or compositions comprising such antagonists. Background Art
[0006] Retinopathy such as diabetic retinopathy (DR) (also known as diabetic eye disease) is caused by damage to the small blood vessels and neurons of the retina. DR is the most common cause of vision loss in the working-age population (e.g., 20-74 years old) worldwide. Lee R. et al. Eye Vis (Lond) 2:17 (2015). In recent years, the incidence of DR has increased dramatically as the life expectancy of patients with diabetes has increased. Roughly speaking, approximately 50% of patients with diabetes develop DR 10 years after the onset of diabetes, 70% of patients with diabetes develop DR 20 years after the onset of diabetes, and 90% of patients with diabetes develop DR 30 years after the onset of diabetes. It is estimated that by 2030, the number of patients with diabetes in the 20-79 age group worldwide will almost double, which means that the number of people diagnosed with DR will further increase. Nentwich MM and Ulbig MW, World J Diabetes 6(3):489-499 (2015).
[0007] While there are treatment options available that can help manage symptoms associated with diabetic retinopathy, these treatments are not curative and can have adverse side effects. For example, laser therapy can cause severe discomfort, permanent retinal scarring, and decreased peripheral vision, color vision, and night vision. See worldwideweb.aao.org / munnerlyn-laser-surgery-center / laser-treatment-of-proliferative-nonproliferative-. Therefore, there is a need for alternative treatment options for diabetic retinopathy.
[0008] Age-related macular degeneration (AMD) is another retinal disease that affects the eye, specifically the central part of the eye (the macula). AMD is caused by hardening of the arteries that nourish the retina, which deprives the retinal tissue of oxygen and leads to decreased central vision. Gheorghe A. et al., Rom J Ophthalmol 59(2):74-77 (2015). AMD is the most common form of macular degeneration, affecting approximately 11 million people in the United States alone and 170 million people worldwide. AMD is the leading cause of visual disability in industrialized countries and the third leading cause of visual disability worldwide. Pennington KL and DeAngelis MM, EyeVis (Lond) 3:34 (2016). Aging is the greatest risk factor; therefore, the number of people with AMD in the United States is expected to increase to 22 million by 2050, and to 288 million worldwide by 2040. Wong WL et al., Lancet Glob Health 2:e106-e116 (2014).
[0009] If diagnosed early, AMD can be treated with a variety of treatment options, including vitamin supplements (e.g., antioxidants), dietary changes (e.g., a low-fat diet), anti-angiogenic drugs (e.g., anti-vascular endothelial growth factor (VEGF) antibodies), laser therapy, surgery (e.g., subretinal surgery), and retinal transposition. Holz F.G. et al., J Clin Invest 124(4):1430-1438 (2014). However, there is currently no known cure for AMD, and many treatment options may not be suitable for all patients with AMD. For example, many patients with choroidal neovascularization (CNV) (i.e., wet AMD) are not suitable for laser therapy because the CNV is too large for laser treatment or its location cannot be accurately determined. In addition, even with treatment, many patients with AMD will gradually lose central vision. Virgili G. and Bini A., Cochrane Database Syst, Rev. 3:CD004763 (2007). Therefore, there is a need for more effective and comprehensive AMD treatment options. Summary of the Invention
[0010] The present invention provides a method for improving the retinal potential in the retina of an individual in need thereof, as compared to a reference value (e.g., the corresponding value of the individual before administration of a FAM19A5 antagonist, or the corresponding value of the individual without administration of a FAM19A5 antagonist), comprising administering to the individual an antagonist directed against a protein of sequence similar family 19, member A5 ("FAM19A5") ("FAM19A5 antagonist"). In certain aspects, the improvement in retinal potential comprises an increase in A waves, B waves, oscillatory potentials, or any combination thereof.
[0011] In some aspects, the individual suffers from a disease or condition associated with decreased retinal potential. In some aspects, the disease or condition is diabetic retinopathy. In other aspects, the disease or condition is age-related macular degeneration of the retina.
[0012] The present invention also provides a method of treating retinopathy and / or maculopathy in a patient in need thereof, comprising administering a subject FAM19A5 antagonist.
[0013] In some aspects, retinopathy refers to diabetic retinopathy. In some aspects, diabetic retinopathy refers to non-proliferative diabetic retinopathy (NPDR). In other aspects, diabetic retinopathy refers to proliferative diabetic retinopathy. In some aspects, diabetic retinopathy is associated with decreased retinal potential, pericyte loss, formation of acellular capillaries, vascular congestion, or any combination thereof within the individual retina.
[0014] In certain aspects, the maculopathy refers to diabetic macular edema. In certain aspects, the diabetic macular edema is associated with decreased retinal potential, pericyte loss, formation of acellular capillaries, vascular congestion, or any combination thereof within the individual's retina.
[0015] In some aspects, a FAM19A5 antagonist can improve the retinal potential of an individual compared to a reference value (e.g., the corresponding value of the individual before the FAM19A5 antagonist is administered, or the corresponding value of the individual without the FAM19A5 antagonist). In some aspects, the improvement in retinal potential includes an increase in A waves, B waves, oscillatory potentials, or any combination thereof. In some aspects, a FAM19A5 antagonist reduces pericyte loss in the retina of an individual. In some aspects, a FAM19A5 antagonist is used to reduce and / or inhibit the formation of acellular capillaries in the retina of an individual. In other aspects, a FAM19A5 antagonist is used to reduce and / or inhibit vascular congestion in the retinal nerve fiber layer of an individual.
[0016] The present disclosure also provides a method for treating macular degeneration in an individual in need thereof, comprising administering to the individual an antagonist to the FAM19A5 protein.
[0017] In some aspects, macular degeneration refers to age-related macular degeneration. In some aspects, age-related macular degeneration refers to dry (atrophic) macular degeneration. In other aspects, age-related macular degeneration refers to wet (neovascular or exudative) macular degeneration. In some aspects, age-related macular degeneration refers to (i) early AMD, (ii) mid-term AMD or (iii) late AMD (geographic atrophy). In more aspects, age-related macular degeneration is related to accumulation or aggregation of drusen in the individual retina, neovascularization, retinal potential reduction, astrocyte formation or any combination thereof.
[0018] In certain aspects, reduced expression of CD31 and / or VEGF indicates that a FAM19A5 antagonist is useful for reducing and / or inhibiting neovascularization in the retina of a subject. In certain aspects, reduced expression of CD31 and / or VEGF indicates that a FAM19A5 antagonist is capable of reducing and / or inhibiting neovascularization in the retina of a mouse with laser-induced choroidal neovascularization. In further aspects, the FAM19A5 antagonist reduces platelet-derived growth factor (PDGF) expression in the nerve fiber layer and ganglion cell layer of the retina of the subject, as compared to a reference value (e.g., the corresponding value in the subject before administration of the FAM19A5 antagonist, or the corresponding value in the subject without administration of the FAM19A5 antagonist). In other aspects, the FAM19A5 antagonist improves retinal electrical potential in the subject, as compared to a reference value (e.g., the corresponding value in the subject before administration of the FAM19A5 antagonist, or the corresponding value in the subject without administration of the FAM19A5 antagonist). In certain aspects, the improvement in retinal electrical potential includes an increase in B waves. In certain aspects, a FAM19A5 antagonist can reduce and / or inhibit the accumulation or aggregation of drusen in the retina of an individual.
[0019] In certain aspects, the FAM19A5 antagonist is an antisense oligonucleotide, siRNA, shRNA, miRNA, dsRNA targeting FAM19A5, aptamer, PNA, or a vector comprising the same.
[0020] In some aspects, the FAM19A5 antagonist is an antibody or antigen-binding portion thereof that specifically binds to the FAM19A5 protein ("anti-FAM19A5 antibody"). In some aspects, the anti-FAM19A5 antibody exhibits a property selected from the following: (a) binding to soluble human FAM19A5 as measured by enzyme-linked immunosorbent assay (ELISA), K D Less than or equal to 10 nM; (b) Binding to membrane-bound human FAM19A5 as measured by ELISA, K D Less than or equal to 10 nM; (c) Both (a) and (b).
[0021] In certain aspects, the anti-FAM19A5 antibody cross-competes with a reference antibody for binding to an epitope of human FAM19A5, wherein the reference antibody is selected from the group consisting of the antibodies in Tables 2-5. In certain aspects, the reference antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, (i) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 27, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 28; or (ii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: The amino acid sequence shown in NO:31.
[0022] In certain aspects, the anti-FAM19A5 antibody specifically binds to the same epitope of FAM19A5 as a reference antibody, wherein the reference antibody is selected from the group consisting of Tables 2-5. In certain aspects, the reference antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, (i) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 27, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 28; or (ii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: The amino acid sequence shown in NO:31.
[0023] In certain aspects, the anti-FAM19A5 antibody specifically binds at least one FAM19A5 epitope, SEQ ID NO:6 or SEQ ID NO:9.
[0024] In certain aspects, the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2 and CDR3 and a light chain CDR1, CDR2 and CDR3, (i) wherein the heavy chain CDR1 comprises CDR1, CDR1 being selected from the group consisting of CDR1 in Table 2; (ii) wherein the heavy chain CDR2 comprises CDR2, CDR2 being selected from the group consisting of CDR2 in Table 2; (iii) wherein the heavy chain CDR3 comprises CDR3, CDR3 being selected from the group consisting of CDR3 in Table 2; (iv) wherein the light chain CDR1 comprises CDR1, CDR1 being selected from the group consisting of CDR1 in Table 3; (v) wherein the light chain CDR2 comprises CDR2, CDR2 being selected from the group consisting of CDR2 in Table 3; and / or (vi) wherein the light chain CDR3 comprises CDR3, CDR3 being selected from the group consisting of CDR3 in Table 3.
[0025] In certain aspects, the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2 and CDR3 and a light chain CDR1, CDR2 and CDR3, (i) wherein the heavy chain CDR1 comprises the amino acid sequence shown in SEQ ID NO: 14 or SEQ ID NO: 17; (ii) wherein the heavy chain CDR2 comprises the amino acid sequence shown in SEQ ID NO: 15 or SEQ ID NO: 18; (iii) wherein the heavy chain CDR3 comprises the amino acid sequence shown in SEQ ID NO: 16 or SEQ ID NO: 19; (iv) wherein the light chain CDR1 comprises the amino acid sequence shown in SEQ ID NO: 26 or SEQ ID NO: 29; (v) wherein the light chain CDR2 comprises the amino acid sequence shown in SEQ ID NO: 27 or SEQ ID NO: 30; and / or (vi) wherein the light chain CDR3 comprises the amino acid sequence shown in SEQ ID NO: 28 or SEQ ID NO: 31.
[0026] In certain aspects, the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, wherein the heavy chain CDR1, CDR2, and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs: 14, 15, and 16, respectively, and the light chain CDR1, CDR2, and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs: 26, 27, and 28, respectively. In other aspects, the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, wherein the heavy chain CDR1, CDR2, and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs: 17, 18, and 19, respectively, and the light chain CDR1, CDR2, and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively.
[0027] In certain aspects, the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), (i) wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 36 or SEQ ID NO: 37; or (ii) wherein the VL comprises the amino acid sequence set forth in SEQ ID NO: 40 or SEQ ID NO: 41. In certain aspects, the VH comprises the amino acid sequence set forth in SEQ ID NO: 36, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 40. In other aspects, the VH comprises the amino acid sequence set forth in SEQ ID NO: 37, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 41.
[0028] In certain aspects, the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO: 36 or SEQ ID NO: 37. In certain aspects, the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VL comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO: 40 or SEQ ID NO: 41.
[0029] In certain aspects, the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), (i) wherein the VH comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO: 36 or SEQ ID NO: 37; and (ii) wherein the VL comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO: 40 or SEQ ID NO: 41.
[0030] In some aspects, the anti-FAM19A5 antibody comprises a Fab, Fab', F(ab')2, Fv or single-chain Fv (scFv). In some aspects, the anti-FAM19A5 antibody is selected from the group consisting of IgG1, IgG2, IgG3, IgG4 and variants thereof. In some aspects, the anti-FAM19A5 antibody is IgG2, IgG4 or a combination thereof. In more aspects, the anti-FAM19A5 antibody comprises an IgG2 / IgG4 isotype antibody. In some aspects, the anti-FAM19A5 antibody comprises a constant region that does not have Fc function. In some aspects, the anti-FAM19A5 antibody is a chimeric antibody, a human antibody or a humanized antibody.
[0031] In certain aspects, a FAM19A5 antagonist is linked to a molecule having a second binding moiety, thereby forming a bispecific molecule. In certain aspects, a FAM19A5 antagonist is linked to an agent, thereby forming an immunoconjugate.
[0032] In certain aspects, the FAM19A5 antagonists disclosed herein are formulated with a pharmaceutically acceptable carrier. In certain aspects, the FAM19A5 antagonists are administered intraocularly. In certain aspects, intraocular administration includes intravitreal administration. In certain aspects, the FAM19A5 antagonists are administered by intravenous injection.
[0033] In certain aspects, the methods disclosed herein further comprise administering a therapeutic agent. In certain aspects, the individual receiving the disclosed treatment is a human.
[0034] The present disclosure also provides a pharmaceutical composition for preventing and treating retinopathy and / or maculopathy, comprising a pharmaceutically effective amount of an antagonist against the FAM19A5 protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1A 、 1B Figures 1 and 1C show the effect of anti-FAM19A5 antibody on the recovery of retinal potential in 25-week-old db / db mice. Mice were treated with human IgG control antibody ("IgG") or anti-FAM19A5 antibody (clone "1-65" or "3-2"). Normal (i.e., non-diabetic) mice were used as controls. Each group of mice was exposed to three different flash intensities (-1, 0.2, and 0.8 log cds / m 2 ) under white light, then measure the A wave (μV) ( Figure 1A )、B wave (μV) ( Figure 1B ) and oscillation potential (μV)( Figure 1C ). Data are expressed as mean ± SD.
[0036] Figure 2A and 2B The protective effect of anti-FAM19A5 antibodies on retinal microvasculature in 25-week-old db / db mice is shown. Mice were treated with a human IgG control antibody ("IgG") or anti-FAM19A5 antibodies (clones "1-65" or "3-2"). Normal (i.e., non-diabetic) healthy mice served as controls. Figure 2A Shown are microscopic images (100x magnification) of representative retinal areas of mice in each of the different treatment groups after periodic acid-Schiff (PAS) staining: (i) normal (i.e., non-diabetic) (upper left panel), (ii) human IgG control (upper right panel), and (iii) anti-FAM19A5 antibody (clone 1-65, lower left panel; clone 3-2, lower right panel). Black arrows indicate endothelial cells, white arrows indicate pericytes, and gray arrows indicate acellular capillaries. Figure 2BShown is a comparison of the endothelial cell to pericyte ratio ("E / P ratio") observed throughout the analyzed retinal area of mice in the different treatment groups. To determine the E / P ratio, the number of endothelial cells and pericytes in each captured image was counted. Data are presented as mean ± SD. "***" above the bar indicates a statistically significant difference compared to the IgG-treated group (p < 0.001).
[0037] Figure 2C Comparison of the number of acellular capillaries observed throughout the analyzed retinal area of mice in the different treatment groups is shown. Data are presented as mean ± SD. "*" above the bars indicates a statistically significant difference compared to the IgG-treated group (p < 0.05).
[0038] Figure 2D Comparison of observed cell-free capillary lengths is shown. Data are presented as mean ± SD. "**" and "***" above the bars indicate statistically significant differences compared to the IgG-treated group (p < 0.01 and p < 0.001, respectively).
[0039] Figure 3 The effect of anti-FAM19A5 antibody treatment on intraretinal vascular congestion in 25-week-old db / db mice is shown using hematoxylin and eosin (H&E) staining. Mice were treated with a human IgG control antibody ("IgG", upper right panel) or an anti-FAM19A5 antibody (clone "1-65", lower left panel, or clone "3-2", lower right panel). Normal (i.e., non-diabetic) healthy mice (upper left panel) served as controls. Arrows indicate examples of vascular congestion. The different retinal layers shown include: (i) ganglion cell layer (GCL), (ii) inner plexiform layer (IPL), (iii) inner nuclear layer (INL), (iv) outer nuclear layer (ONL), and (v) retinal pigment epithelium (PE).
[0040] Figure 4 Figure 2 shows the protective effect of anti-FAM19A5 antibody treatment on retinal cells in 25-week-old db / db mice using TUNEL assay. Mice were treated with a human IgG control antibody ("IgG") or an anti-FAM19A5 antibody (clone "1-65" or "3-2"). Normal (i.e., non-diabetic) healthy mice were used as controls. The red arrows below the middle column ("TUNEL") indicate that retinal cells are undergoing apoptosis. The intensity of TUNEL staining correlates with the degree of apoptosis (e.g., a decrease in intensity indicates partial apoptosis). The different retinal layers shown include: (i) ganglion cell layer (GCL), (ii) inner nuclear layer (INL), (iii) outer nuclear layer (ONL), and (iv) retinal pigment epithelium (PE).
[0041] Figure 5 Figure 2 shows the inhibitory effect of anti-FAM19A5 antibody on retinal neovascularization in 25-week-old db / db mice, as assessed by immunohistochemical staining for CD31 and VEGF expression. Mice were treated with a human IgG control antibody ("IgG") or anti-FAM19A5 antibody (clone "1-65" or "3-2"). Normal (i.e., non-diabetic) healthy mice served as controls. Arrows indicate positive CD31 (top row) or VEGF (bottom row) staining.
[0042] Figure 6A A picture of the image-guided laser system used in Example 8 is shown. Figure 6B Shows exposure to Figure 6A An exemplary image of the retina produced by laser light from an image-guided laser system is shown.
[0043] Figure 7A and 7B The results show the inhibitory effect of anti-FAM19A5 antibody (clone 3-2) on choroidal neovascularization (CNV) using fluorescein angiography (FFA) analysis. CNV-induced mice receiving human IgG antibody served as controls. Figure 7A Representative retinal images are shown, showing four wet AMD-like lesions (indicated by arrows in the left column of images) from mice treated with human IgG antibody (top row) or anti-FAM19A5 (clone 3-2) (bottom row) on the day of CNV induction (“Day 0”) and 13 days after CNV induction. Figure 7B Comparison of corrected total fluorescence (CTF) values at day 13 after CNV induction in mice treated with human IgG antibody ("IgG") or anti-FAM19A5 antibody (clone "3-2"). Data are presented as both mean and individual values. "*" indicates a statistically significant difference compared to the IgG-treated group (p < 0.05).
[0044] Figure 8A 、 8B Figures 8 and 8C show the inhibitory effect of anti-FAM19A5 antibody (clone 3-2) on choroidal neovascularization (CNV) using optical coherence tomography (OCT) analysis. CNV-induced mice receiving human IgG antibody served as controls. Figure 8A Representative retinal images are provided, showing four wet AMD-like lesions (numbered 1, 2, 3, and 4) in mice treated with human IgG antibodies (top row) or anti-FAM19A5 (clone 3-2) (bottom row) at day 13 after CNV induction. Columns labeled 1, 2, 3, and 4 provide OCT images of the corresponding lesions shown in the leftmost image. Figure 8B Scale bars used to quantify lesion size are shown. Figure 8CComparison of CNV lesion size observed on day 13 after CNV induction in mice treated with human IgG control antibody or anti-FAM19A5 antibody (clone 3-2) is provided. Data are presented as both mean and individual values. "***" indicates a statistically significant difference compared to the IgG-treated group (p < 0.001).
[0045] Figure 9 This study shows the effect of anti-FAM19A5 antibodies on B-wave recovery in mice with CNV. Mice with CNV were treated with a human IgG control antibody ("IgG") or an anti-FAM19A5 antibody (clone "3-2"). Normal (i.e., non-diabetic) mice served as controls. Data are presented as mean ± SD. "*" indicates a statistically significant difference compared to the IgG-treated group (p < 0.05).
[0046] Figure 10A and 10B Shown is the inhibitory effect of anti-FAM19A5 antibody (clone 3-2) on choroidal neovascularization (CNV). Figure 10A The different retinal layers were identified using H&E analysis (left) or OCT analysis (right). The retinal layers shown include: (i) retinal nerve fiber layer / ganglion cell layer (RNFL / GCL); (ii) inner plexiform layer; (iii) inner nuclear layer; (iv) outer plexiform layer; (v) outer nuclear layer, (vi) inner / outer photoreceptor segments (IS / OS), and (vii) retinal pigment epithelium (RPE). Figure 10B Representative H&E images of retinal cell layers from different groups of mice are shown: (i) normal healthy animals, (ii) CNV-induced mice treated with human IgG antibodies, and (iii) CNV-induced mice treated with anti-FAM19A5 antibodies. Arrows indicate choroidal neovascularization areas.
[0047] Figure 11 Figure 2 shows the inhibitory effect of anti-FAM19A5 antibody on PDGF expression in the inner nerve fiber layer and ganglion cell layer of the retina using IHC analysis. Mice induced with CNV were treated with a human IgG control antibody ("IgG") or an anti-FAM19A5 antibody (clone "3-2"). Normal (i.e., non-diabetic) mice served as controls. Arrows indicate PDGF-positive staining.
[0048] Figure 12The inhibitory effect of anti-FAM19A5 antibodies on the formation of oligomeric Aβ and choroidal drusen in APP / PS-1 / tau transgenic mice (dementia model) using immunofluorescence microscopy is shown. APP / PS-1 / tau transgenic mice did not receive (middle row) or received anti-FAM19A5 antibody treatment (bottom row). Wild-type C57BL / 6 blank mice were used as negative controls (top row). The column labeled "H33342" (nucleic acid staining) shows cells in retinal tissue. The column labeled "QD525-oAβ" shows oligomeric Aβ. The column labeled "647 Alexa Phalloidin" shows the formation of choroidal drusen, with exemplary choroidal drusen indicated by arrows. The column labeled "Merge" shows the merged image of each treatment group in the above three columns.
[0049] Figures 13A-13C This study compares the retinal microvascular protection of an anti-FAM19A5 antibody (clone 1-30) following intravitreal or intravenous injection in a mouse model of diabetic retinopathy. Mice were injected with one of the following: (i) a human IgG control antibody ("human IgG"), (ii) aflibercept, (iii) intravitreal anti-FAM19A5 antibody ("IVT"), or (iv) intravenous anti-FAM19A5 antibody ("IV"). Normal (i.e., non-diabetic) healthy mice served as controls. Figure 13A Provided are microscopic images (100x magnification) of representative retinal areas of mice in various treatment groups after periodic acid-Schiff (PAS) staining. Black arrows indicate endothelial cells, white arrows indicate pericytes, and black arrows indicate acellular capillaries. Figure 13B A comparison of the number of acellular capillaries observed throughout the analyzed retinal area in mice from the different treatment groups is provided. Figure 13C A comparison of the endothelial cell to pericyte ratio ("E / P ratio") observed throughout the analyzed retinal area of mice in the different treatment groups is provided. To determine the E / P ratio, the number of endothelial cells and pericytes in each captured image was counted. Figure 13B and 13C Data are presented as mean ± SD. “*” and “***” above the bars indicate statistically significant differences compared with the blank mice (p < 0.05 and p < 0.001, respectively). “##” and “###” above the bars indicate statistically significant differences compared with the human IgG antibody treatment group (p < 0.01 and p < 0.001, respectively). Indicates a statistically significant difference compared to the aflibercept treatment group (p<0.001). "§" above the bar indicates a statistically significant difference compared to the IVT group (p<0.05).
[0050] Figure 14 The results showed that anti-FAM19A5 antibody inhibited the formation of intraretinal vascular congestion in diabetic retinopathy mice after intravenous and intravitreal administration. Figures 13A-13C The arrows indicate examples of vascular congestion.
[0051] Figure 15 The retinal cell protective effect of anti-FAM19A5 antibody was shown when injected intravitreally or intravenously as measured by TUNEL. Figures 13A-13C The arrows below the middle row ("TUNEL") indicate that retinal cells are undergoing apoptosis. The intensity of TUNEL staining is correlated with the degree of apoptosis (eg, decreased intensity indicates partial apoptosis).
[0052] Figure 16A and 16B The results showed that anti-FAM19A5 antibody inhibited retinal neovascularization in diabetic retinopathy mice after intravitreal and intravenous administration. Figures 13A-13C The same as described above. Using VEGF ( Figure 16A ) and CD31( Figure 16B Arrows indicate VEGF or CD31 positive staining. DETAILED DESCRIPTION
[0053] To facilitate understanding of the disclosure herein, a number of terms and phrases are defined. Additional definitions are set forth throughout the detailed description.
[0054] I. Definition
[0055] In the present disclosure, "an" entity refers to one or more of the entity; for example, "an antibody" can be understood to represent one or more antibodies. Therefore, "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein.
[0056] Furthermore, “and / or”, when used herein, should be construed as a specific disclosure of each of the two specified features or components (with or without the other). Thus, the term “and / or” as used in phrases such as “A and / or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Similarly, the term “and / or” as used in phrases such as “A, B, and / or C” is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0057] It should be understood that whatever aspects are described herein using the language "comprising," similar aspects described within the terms "consisting of" and / or "consisting essentially of" are also provided.
[0058] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure relates. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and Oxford Dictionary of Biochemistry and Molecular Biology, Revised ed., 2000, Oxford University Press, provide a general dictionary of many of the terms used in the present disclosure for those skilled in the art.
[0059] Units, prefixes and symbols are expressed in the form accepted by the International System of Units (SI). Numerical ranges include the numbers that define the range. Unless otherwise indicated, amino acid sequences are written from left to right in the direction of amino to carboxyl groups. The headings provided herein are not limitations of the various aspects of the disclosure, and can be obtained by reference to the specification as a whole. Therefore, by reference to the specification, the terms defined below are more fully defined as a whole.
[0060] As used herein, the term "about" is used to mean approximately, roughly, around, or in the region of. When the term "about" is used in conjunction with a numerical range, it modifies that range by expanding the boundaries above and below the numerical values set forth. The term "about" generally modifies a numerical value above and below the stated value by a variable, such as an increase or decrease, up or down (e.g., 10%).
[0061] As used herein, the term "retinal disease" refers to disease, inflammation, or damage to the retina (ie, the tissue lining the inside surface of the back of the eye that captures images of the body) that passes through the cornea and lens.
[0062] As used herein, the term "diabetic retinopathy" (DR) refers to retinopathy caused by diabetic complications. Depending on the severity of the disease, DR can be asymptomatic, cause mild vision problems, or lead to blindness. DR is caused by changes in the retinal microvasculature. Hyperglycemia-induced pericyte death and basement membrane thickening within the retina can lead to vascular wall dysfunction. These damages can alter the formation of the blood-retinal barrier and increase retinal vascular permeability. Pericyte death occurs when persistent hyperglycemia activates protein kinase C-δ (PKC-δ, encoded by Prkcd) and p38 mitogen-activated protein kinase (MAPK), increasing expression of PKC-δ signaling and Src homology 2 domain-containing phosphatase-1 (SHP-1), a previously unknown target of protein tyrosine phosphatases. This signaling cascade leads to dephosphorylation of the PDGF receptor and reduced downstream signaling from the receptor, resulting in pericyte apoptosis. Small blood vessels, such as those within the eye, are particularly susceptible to poor glycemic control. Excessive accumulation of glucose and / or fructose can damage the tiny blood vessels within the retina.
[0063] DR can be divided into two separate stages. Wu L. et al., World J Diabetes 4(6):290-294 (2013). The first stage is called non-proliferative diabetic retinopathy (NPDR) and is associated with early diabetic retinopathy. NPDR is generally asymptomatic or accompanied by mild visual distortion (caused by fluid leaking into the tissue surrounding blood vessels). The only way to detect NPDR is through fundus photography, which can reveal microaneurysms (tiny bulges filled with blood in the artery walls). If left untreated, DR can progress to the second and more advanced stage, called proliferative diabetic retinopathy (PDR). PDR is characterized by abnormal formation of new blood vessels (i.e., neovascularization), which can rupture and bleed, causing blurred vision. Other symptoms of PDR include, but are not limited to: dark spots or lines floating in the field of vision ("floaters"), fluctuations in vision, impaired color vision, dark or blank areas in the field of vision, pain, patchy visual fields, and complete vision loss.
[0064] The term "diabetic retinopathy" includes all types of diabetic retinopathy, including but not limited to non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), diabetic maculopathy, and diabetic macular edema.
[0065] In some aspects, PDR occurs after the onset of NPRD (e.g., an individual is first diagnosed with NPRD and then develops PDR). In other aspects, the occurrence of PDR is independent of NPRD. As used herein, the term "diabetic retinopathy" also includes all types of diabetic retinopathy, without regard to the cause of diabetic retinopathy and all its symptoms. Non-limiting examples of risk factors for diabetic retinopathy include: duration of diabetes, genetics, excessive drinking, smoking, hypertension, obesity, dyslipidemia, hypercholesterolemia, kidney disease, pregnancy, and kidney damage.
[0066] As used herein, the term "maculopathy" refers to any pathological condition of the macula (i.e., the central area of the retina associated with highly sensitive, accurate vision). In some aspects, the terms "maculopathy" and "retinopathy" can be used interchangeably (i.e., only the macula is affected). In some aspects, the maculopathy is diabetic maculopathy.
[0067] "Diabetic maculopathy" occurs when the macula is affected by retinal changes caused by diabetes. This term refers to two different eye diseases: diabetic macular edema and diabetic ischemic maculopathy. These two types of maculopathy often coexist, that is, patients with macular edema often also have ischemic maculopathy. Even mild macular edema can occur with ischemic maculopathy combined with macular edema. In certain aspects, retinal changes associated with diabetic maculopathy in an individual's retina include: decreased retinal electrical potential, loss of pericytes, formation of acellular capillaries, vascular congestion, impaired vascular function, vascular leakage, vascular occlusion, tissue swelling (edema), tissue hypoxia, or any combination thereof.
[0068] As used herein, the term "acellular capillaries" refers to capillary-sized blood vessels that lack cell nuclei anywhere along their length.
[0069] As used herein, the term "vascular congestion" refers to a type of vascular damage that is an important factor in the pathogenesis of various ocular conditions disclosed herein, such as diabetic macular edema. Vascular congestion is associated with the accumulation of fluid within vascular tissue (e.g., blood within blood vessels). In certain aspects, vascular congestion can be caused by hyperglycemia (i.e., high blood sugar).
[0070] As used herein, the term "macular degeneration" refers to any number of diseases and conditions in which the macula degenerates or loses functional activity. For example, the degeneration or loss of functional activity can be caused by cell death, cell proliferation reduction, loss of normal biological function, or the combination described above. Macular degeneration can cause and / or manifest as a change in the structural integrity of macular cells and / or extracellular matrix, a change in the construction of normal cells and / or extracellular matrix, and / or the loss of macular cell function. The cell can be any cell type that is typically present in or near the macula, including RPE cells, photoreceptors, and / or capillary endothelial cells. Age-related macular degeneration is modal macular degeneration, but the term "macular degeneration" does not necessarily exclude macular degeneration in non-elderly patients. Non-limiting examples of macular degeneration include: age-related macular degeneration (wet or dry); Best macular dystrophy, Sorsby fundus dystrophy, Mallatia Leventinese, Doyne honeycomb retinal dystrophy, Stargardt's disease (also known as Stargardt macular dystrophy, juvenile macular degeneration or fundus xanthophy), and pigment epithelial detachment-related macular degeneration.
[0071] As used herein, term " age-related macular degeneration " (AMD) refers to the retinopathy that usually has an impact on the elderly, is relevant to central vision loss, arises from the central part of the retina (i.e. macula) damage. Generally speaking, AMD is characterised in that the gradual accumulation or aggregation of yellow insoluble extracellular deposits in the macula (mainly between retinal pigment epithelium (RPE) and underlying choroid) are called drusen (accumulation of extracellular proteins, such as beta amyloid and lipids). The accumulation or aggregation of these deposits in the macula can cause the macula to gradually degenerate, thereby causing central vision damage. As used herein, term " macula " refers to the central part of the retina responsible for central high-resolution colour vision.
[0072] The pathogenesis of age-related macular degeneration is currently unclear, although several theories have been proposed, including oxidative stress, mitochondrial dysfunction, and inflammatory processes. An imbalance between the production and degradation of damaged cellular components leads to the accumulation of harmful products, such as intracellular lipofuscin and extracellular drusen. Initial atrophy is marked by areas of thinning or depigmentation of the retinal pigment epithelium (RPE) (preceding geographic atrophy in the early stages of AMD). In late AMD, RPE atrophy (geographic atrophy) and / or neovascularization develop, leading to photoreceptor death and loss of central vision. In dry (non-exudative) AMD, cellular debris called drusen accumulate between the retina and the choroid, leading to retinal atrophy and scarring. In the more severe wet (exudative) AMD, blood vessels grow from the choroid behind the retina (neovascularization), which can lead to exudate and fluid leakage, and can also cause bleeding.
[0073] Depending on the extent of existing drusen, AMD can be divided into three main stages: (i) early, (ii) intermediate, and (iii) late. Early AMD is characterized by the presence of several small (e.g., less than about 63 microns in diameter) drusen, or several medium-sized (e.g., between about 63 and 124 microns in diameter). Patients have no obvious symptoms and vision loss in the early stages. Intermediate AMD is characterized by the presence of many medium-sized drusen, or one or more large (e.g., greater than about 125 microns in diameter). At this stage, some patients may begin to experience blurry spots in the center of their visual field. Late AMD is characterized by extensive damage to retinal tissue, resulting in a central blind spot and ultimately loss of central vision. Late AMD can be further divided into two isotypes based on the type of damage (e.g., the presence or absence of neovascularization): (i) geographic atrophy (also known as atrophic AMD) and (ii) wet AMD (also known as neovascular or exudative AMD).
[0074] AMD has two main forms: (i) dry AMD and (ii) wet AMD. Unless otherwise specified, the term "age-related macular degeneration" includes dry AMD and wet AMD. The term "age-related macular degeneration" as used herein also includes all types of age-related macular degeneration, without considering the cause of the age-related macular degeneration and all its symptoms. Non-limiting examples of symptoms associated with macular degeneration (such as age-related macular degeneration) include: loss of central vision, distortion, decreased contrast sensitivity, blurred vision, difficulty adapting to dim light, sudden onset of symptoms and rapid worsening of symptoms, and decreased color vision. In some aspects, macular degeneration (such as age-related macular degeneration) can lead to macular edema (i.e., fluid and protein deposits above or below the macula, causing swelling of the macula).
[0075] As used herein, the term "dry AMD" (also called atrophic age-related macular degeneration or non-exudative AMD) refers to all forms of AMD that are not wet (neovascular) AMD. This includes early and intermediate forms of AMD, as well as a late-stage dry AMD called geographic atrophy. People with dry AMD tend to have mild symptoms early on; if the disease progresses to geographic atrophy, the incidence of visual loss is higher.
[0076] Term used herein " wet AMD " (also referred to as neovascular age-related macular degeneration or exudative AMD) refers to the retinal state characterized by the presence of retinal neovascularization, is the most advanced form of AMD. In wet AMD, blood vessel grows out from the choroidal capillaries by the defect of Bruch's membrane, in some cases, by the underlying retinal pigment epithelium (choroidal neovascularization or angiogenesis). The tissue of the serous or hemorrhagic exudate flowing out from these blood vessels can cause the fibrous vascular scar formation in the macula, and with detachment and tearing, vitreous hemorrhage and permanent central vision loss of neuroretinal degeneration, retinal pigment epithelium.
[0077] As used herein, term "neovascularization" refers to that different parts of the eye grow new abnormal blood vessels, which can cause hemorrhage and vision loss. As used herein, term "choroidal neovascularization" refers to the abnormal growth of new blood vessels in the choroid (that is, the eye vascular layer containing connective tissue between the retina and the sclera). In wet AMD, new blood vessels can grow through the retinal pigment epithelium (RPE) and choroid, enter the retina, and due to blood and lipid leakage, can damage visual function. As used herein, term "retinal neovascularization" refers to the abnormal development, proliferation and / or growth of blood vessels on or in the retina (such as the surface of the retina) of the retina. Retinal neovascularization can develop in many retinal diseases, such as retinopathy associated with retinal ischemia and / or inflammatory diseases (e.g., diabetic retinopathy, sickle cell retinopathy, Eales' disease, ocular ischemic syndrome, carotid cavernous fistula, familial exudative vitreoretinopathy, hyperviscosity syndrome, idiopathic occlusive arteritis, radiation retinopathy, retinal vein occlusion, retinal artery occlusion, retinal embolism, scattered retinal choroidopathy, retinal vasculitis, sarcoidosis, toxoplasmosis, uveitis, choroidal melanoma, chronic retinal detachment, anterior ischemic optic neuropathy (AION), non-arteritic anterior ischemic optic neuropathy (NAION), and incontinentia pigmenti). Neovascularization detection methods known in the art include, but are not limited to, detecting the expression of CD31 (also known as platelet endothelial cell adhesion molecule, PECAM-1) and vascular endothelial growth factor (VEGF) in tissues. For example, see Schluter A. et al., BMC Cancer 18(1): 272 (2018).
[0078] The retinal pigment epithelium (RPE) is a single layer of epithelial cells located at the back of the vertebrate eye, between the choroidal blood supply (choriocapillaris) and the retinal neural layer. The RPE is a component of the blood-retinal barrier and plays an important role in maintaining the visual circulation, phagocytosis of photoreceptor outer segments, and transport of nutrients, metabolic waste products, ions, and fluid between the distal retina and the choriocapillaris.
[0079] The term "intraocular" refers to the inside or below of the eye tissue. As used herein, the term "intraocular administration" refers to any administration that can deliver a composition (e.g., an anti-FAM19A5 antibody disclosed herein) to the subfascial, subconjunctival, suprachoroidal, or intravitreal portion of the eye. In certain aspects, intraocular administration includes intravitreal administration.
[0080] The term "ocular condition" refers to a disease, nutrient, or condition that affects or involves the eye or a part or region of the eye, such as a retinal disease. In certain aspects, ocular conditions that can be treated by the present disclosure include diabetic retinopathy and age-related macular degeneration. Other ocular conditions that can be treated by the compositions and methods disclosed herein include diabetic macular edema, anterior ischemic optic neuropathy (AION), non-arteritic anterior ischemic optic neuropathy (NAION), retinal vein occlusion, retinal artery occlusion, or a combination thereof.
[0081] As used herein, the term "eye" includes the eyeball and the tissues and fluids that make up the eyeball (such as the sclera, cornea, anterior and posterior eye chambers, iris / pupil, lens, vitreous humor, retina, fovea, macula, and choroid), the muscles around the eye (such as the oblique and rectus muscles), and the portion of the optic nerve within or near the eyeball.
[0082] The term "optic nerve damage" refers to changes in the normal structure or function of the optic nerve. Changes in the normal structure or function of the optic nerve may be caused by any disease, disorder or injury, including glaucoma. Changes in the normal function of the optic nerve include any changes in the ability of the optic nerve to work properly, such as transmitting visual information from the retina to the brain. Functional changes can manifest as, for example, loss of visual field, impaired central vision, abnormal color vision, etc. Examples of structural changes include loss of nerve fibers in the retina, abnormal enlargement of the optic cup of the optic nerve, and / or loss of cells in the retinal ganglion cell layer. "Optic nerve damage" as used herein can include optic nerve damage to one or both optic nerves of an individual.
[0083] As used herein, the terms "treat," "treating," and "treatment" refer to any type of intervention or process performed on an individual or administered to an individual with the intent to reverse, alleviate, ameliorate, inhibit, slow, or prevent the progression, development, severity, or recurrence of symptoms, complications, conditions, or biochemical indicators associated with a disease. Treatment can be treatment of an individual with a disease or an individual without a disease (e.g., for prevention).
[0084] As used herein, the term "administer" refers to the use of any of the various methods and delivery systems known to those skilled in the art to physically introduce a therapeutic agent or a composition comprising a therapeutic agent into an individual. The different routes of administration of the antibodies described herein include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal or other parenteral routes of administration, such as by injection or infusion. As used herein, the phrase "parenteral administration" refers to a mode of administration other than enteral and topical administration, typically by injection, including but not limited to intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardial, intradermal, transtracheal, intratracheal, pulmonary, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraventricular, intravitreal, epidural and intrasternal injection and infusion, and in vivo electroporation. The antibodies described herein can also be administered via non-parenteral routes, such as topical, epidermal or mucosal routes of administration, such as intranasal, oral, vaginal, rectal, sublingual or topical administration. For example, administration can also be performed once, multiple times and / or over one or more extended time periods.
[0085] As used herein, the term "therapeutically effective amount" refers to an amount of a drug, alone or in combination with another therapeutic agent, that is effective to "treat" a disease or condition in an individual or to reduce the risk, potential, likelihood, or occurrence of a disease or condition (e.g., glaucoma). A "therapeutically effective amount" includes an amount of a drug or therapeutic agent that provides some improvement or benefit to an individual suffering from a disease or condition (e.g., glaucoma disclosed herein) or an individual at risk of suffering from the disease or condition. Thus, a "therapeutically effective" amount is an amount that reduces the risk, potential, likelihood, or occurrence of a disease, or provides a condition or some alleviation, alleviation, and / or reduction of at least one indicator (e.g., increased inflammation) and / or reduction of at least one clinical symptom of a disease or condition.
[0086] As used herein, the term "individual" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.
[0087] The term "family of sequence similarity 19 member A5" or "FAM19A5" refers to a protein belonging to the TAFA family (also known as the FAM19 family) of five highly homologous proteins. Tang T.Y. et al., Genomics 83(4):727-34 (2004). These proteins contain conserved cysteine residues at fixed positions and are distantly related to macrophage inflammatory protein 1-alpha (MIP-1-alpha), a member of the CC-chemokine family. TAFA proteins are expressed in specific regions of the brain and spinal cord. Studies have shown that these proteins are produced and secreted by adult neural stem cells during neurogenesis. FAM19A5 is also known as TAFA5 or chemokine-like protein TAFA-5.
[0088] It is believed that FAM19A5 is of great significance for the development, differentiation and formation of the complete central nervous system. FAM19A5 also plays an important role in the pathogenesis of many central nervous system injuries and / or degenerative brain diseases (such as Huntington's disease, Parkinson's disease, Alzheimer's disease, spinal cord injury, stroke and brain tumors). After central nervous system damage, neural stem cells produce FAM19A5, which induces normal astrocytes to differentiate into reactive astrocytes. These reactive astrocytes (together with microglial cells) can express a variety of ECMs (such as proteoglycans) and induce glial scar formation, which surrounds the damaged area of the central nervous system in a reticular form, preventing neuronal regeneration. Antagonists for FAM19A5 (such as anti-FAM19A5 antibodies) can be used to prevent and / or treat central nervous system damage and / or diseases. Referring to U.S. Patent No. 9,579,398.
[0089] However, for some diseases, especially those associated with vascular abnormalities, a recent study suggests that FAM19A5 antagonists may not be a viable treatment option. Wang et al., Circulation 138(1): 48-63 (2018). Wang et al. pointed out that FAM19A5 is produced in the adipose tissue of normal healthy individuals and transmits signals through sphingosine-1-phosphate receptor 2 (S1PR2), inhibiting the proliferation and migration of vascular smooth muscle cells (VSMCs) and reducing the formation of new intima after injury. However, in obese individuals, FAM19A5 expression (mRNA and protein) in adipose tissue is significantly reduced. Wang et al. concluded that reduced FAM19A5 activity is the cause of the accelerated development of cardiovascular disease in many obese individuals.
[0090] The human genetically encoded FAM19A5 is located on chromosome 22. There are three human FAM19A5 (UniProt: Q7Z5A7) isoforms, which are believed to be produced by alternative splicing: isoform 1 (UniProt: Q7Z5A7-1), consisting of 132 amino acids; isoform 2 (UniProt: Q7Z5A7-2), consisting of 125 amino acids; and isoform 3 (UniProt: Q7Z5A7-3), consisting of 53 amino acids. The human FAM19A5 protein is believed to exist in membrane-bound and soluble (secreted) forms. Isoform 1 is believed to be a membrane protein with one transmembrane region. Isoform 2, which was reported as a secreted protein (soluble) in Tang T.Y. et al., Genomics 83(4): 727-34 (2004), contains a signal peptide at amino acids 1-25. Isoform 3 is predicted based on EST data. Below are the amino acid sequences of the three known human FAM19A5 isoforms.
[0091] (I) Isoform 1 (UniProt: Q7Z5A7-1, transmembrane protein): This isoform was selected as the canonical sequence.
[0092] MAPSPRTGSR QDATALPSMS STFWAFMILA SLLIAYCSQL AAGTCEIVTL DRDSSQPRRTIARQTARCAC RKGQIAGTTR ARPACVDARI IKTKQWCDML PCLEGEGCDL LINRSGWTCTQPGGRIKTTTVS(SEQ ID NO: 1)
[0093] (II) Isoform 2 (UniProt: Q7Z5A7-2, soluble protein):
[0094] MQLLKALWAL AGAALCCFLV LVIHAQFLKE GQLAAGTCEI VTLDRDSSQP RRTIARQTARCACRKGQIAG TTRARPACVD ARIIKTKQWC DMLPCLEGEG CDLLINRSGW TCTQPGGRIK TTTVS(SEQID NO: 2)
[0095] (III) Isoform 3 (UniProt: Q7Z5A7-3):
[0096] MYHHREWPAR IIKTKQWCDM LPCLEGEGCD LLINRSGWTC TQPGGRIKTT TVS(SEQ ID NO: 3)
[0097] The term "FAM19A5" includes any variant or isoform of FAM19A5 naturally expressed by cells. Thus, the antibodies described herein may cross-react with different isoforms in the same species (e.g., different isoforms of human FAM19A5), or cross-react with FAM19A5 from non-human species (e.g., mouse FAM19A5). Alternatively, the antibody may be specific for human FAM19A5 and may not exhibit any cross-reactivity with other species. FAM19A5 or any of its variants and isoforms may be isolated from cells or tissues that naturally express them, or recombinantly produced. The polynucleotide encoding human FAM19A5 has GenBank accession number BC039396 and the following sequence:
[0098] Table 1A. Polynucleotide sequence of human FAM19A5
[0099]
[0100] The term "antagonist against FAM19A5 protein" refers to all antagonists that inhibit and / or neutralize the expression and / or activity of FAM19A5 protein. Such antagonists can be peptides, nucleic acids, or compounds. More specifically, the antagonist can be an antisense oligonucleotide, siRNA, shRNA, miRNA, dsRNA, aptamer, PNA (peptide nucleic acid) targeting FAM19A5, or a vector comprising the same. In certain aspects, the antagonist can be an antibody or antigen-binding portion thereof that specifically binds to FAM19A5 protein.
[0101] The terms "antibody" and "antibodies" are terms of the art and are used interchangeably herein to refer to molecules with an antigen binding site that specifically binds to an antigen. The terms used herein include complete antibodies and any antigen-binding fragments thereof (i.e., "antigen-binding portion") or single chains. In one aspect, an "antibody" refers to a glycoprotein or antigen-binding portion thereof comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. On the other hand, an "antibody" refers to a single-chain antibody comprising a single variable domain (e.g., a VHH domain). Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. In some naturally occurring antibodies, the heavy chain constant region consists of three domains, CH1, CH2, and CH3. In some naturally occurring antibodies, each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region consists of one domain, CL.
[0102] The VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0103] The term "Kabat numbering" and similar terms are art-recognized terms that refer to a system for numbering amino acid residues in the heavy and light chain variable regions of an antibody or its antigen-binding portion thereof. In certain aspects, the CDRs of an antibody can be determined according to the Kabat numbering system (e.g., see Kabat EA and Wu TT (1971) Annals of the New York Academy of Sciences (Ann NY Acad Sci) 190: 382-391 and Kabat EA et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Using the Kabat numbering system, the CDRs within an antibody heavy chain molecule are typically present at amino acids 31 to 35 (which optionally may include one or two additional amino acids), (following position 35 (referred to as 35A and 35B in the Kabat numbering scheme) (CDR1), amino acids 50 to 65 (CDR2), and amino acids 95 to 102 (CDR3). Using the Kabat numbering system, the CDRs within an antibody light chain molecule are typically present at amino acids 24 to 34 (CDR1), amino acids 50 to 56 (CDR2), and amino acids 89 to 97 (CDR3). In a specific aspect, the antibody CDRs described herein have been identified according to the Kabat numbering scheme.
[0104] The phrases "amino acid position numbering as in Kabat," "Kabat position," and grammatical variants thereof refer to the numbering system for heavy chain variable domains or light chain variable domains as used in the compilation of antibodies in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, Public Health Service, National Institutes of Health, Bethesda, Maryland (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or more amino acids, corresponding to shortening of the variable domain FW or CDR, or to insertions into the FW or CDR. For example, the heavy chain variable domain may include a single amino acid insertion after residue 52 of H2 (residue 52a according to Kabat) and inserted residues after heavy chain FW residue 82 (e.g., residues 82a, 82b, and 82c, etc., according to Kabat). See Table 1B.
[0105] Table 1B
[0106]
[0107] For a given antibody, the Kabat numbering of residues can be determined by aligning the homologous region of the antibody sequence with the "standard" Kabat numbering sequence. Chothia refers to the position of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). When numbering using the Kabat numbering convention, the ends of the Chothia CDR-H1 loop vary between H32 and H34, depending on the length of the loop (because the Kabat numbering scheme places the insertion at H35A and H35B; if both 35A and 35B are absent, the loop ends at 32; if only 35A is present, the loop ends at 33; and if both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions represent a compromise between the Kabat CDRs and the Chothia structural loops and are employed by Oxford Molecular's AbM antibody modeling software.
[0108] IMGT (ImMunoGeneTics) also provides a numbering system for immunoglobulin variable regions (including CDRs). See, for example, Lefranc, MP et al., Dev. Comp. Immunol. 27:55-77 (2003), which is incorporated herein by reference. The IMGT numbering system is based on alignments of over 5,000 sequences, structural data, and characterization of hypervariable loops, making it easy to compare variable and CDR regions across all species. According to the IMGT numbering scheme, VH-CDR1 is at positions 26 to 35, VH-CDR2 is at positions 51 to 57, VH-CDR3 is at positions 93 to 102, VL-CDR1 is at positions 27 to 32, VL-CDR2 is at positions 50 to 52, and VL-CDR3 is at positions 89 to 97.
[0109] For all heavy chain constant region amino acid positions discussed in this disclosure, numbering is according to the EU index first described in Edelman et al. (1969) Proc. Natl. Acad. Sci. 63(1):78-85, which describes the amino acid sequence of the myeloma protein EEG, the first human IgG1 sequenced. The EU index of Edelman et al. is also set forth in Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed. (Public Health Service, National Institutes of Health, Bethesda, MD). Thus, the phrases "EU index as set forth in Kabat" or "EU index of Kabat" and "position according to the EU index as set forth in Kabat" and grammatical variations thereof refer to the residue numbering system for the human IgG1 EU antibody based on Edelman et al. as set forth in Kabat 1991.
[0110] Kabat 1991 proposed a numbering system for amino acid sequences of variable domains (heavy and light chains) and light chain constant regions.
[0111] The antibody can be an immunoglobulin molecule of any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any class (e.g., IgD, IgG2, IgG3, IgG4, IgA1, or IgA2), or any subclass (e.g., human IgG1, IgG2, IgG3, and IgG4; and mouse IgG1, IgG2a, IgG2b, and IgG3). Immunoglobulins (e.g., IgG1) exist in several allotypes that differ from each other in at most a few amino acids. The antibodies disclosed herein can be from any commonly known isotype, class, subclass, or allotype. In some aspects, the antibodies described herein are antibodies of the IgG1, IgG2, IgG3, or IgG4 subclass, or any hybrid thereof. In some aspects, the antibodies are antibodies of the human IgG1 subclass, or human IgG2, or human IgG4 subclass.
[0112] "Antibody" includes, for example, naturally occurring and non-naturally occurring antibodies; monoclonal and polyclonal antibodies; chimeric and humanized antibodies; human and non-human antibodies; fully synthetic antibodies; single-chain antibodies; monospecific antibodies; multispecific antibodies (including bispecific antibodies); tetrameric antibodies comprising two heavy chain and two light chain molecules; antibody light chain monomers; antibody heavy chain monomers; antibody light chain dimers, antibody heavy chain dimers; antibody light chain-antibody heavy chain pairs; intrabodies; heteroconjugate antibodies; monovalent antibodies; camelized antibodies; affibodies; anti-idiotypic (anti-Id) antibodies (including, for example, anti-anti-Id antibodies) and single domain antibodies (sdAbs), which include binding molecules composed of a single monomeric variable antibody domain (e.g., a VH domain or a VL domain) that is fully capable of antigen binding. Harmen MM and Haard HJ Appl Microbiol Biotechnol 77(1): 13-22 (2007)).
[0113] As used herein, the term "antigen-binding portion" of an antibody refers to one or more fragments of an antibody that retains the ability to specifically bind to an antigen (e.g., human FAM19A5). Such "fragments" are, for example, about 8 to about 1500 amino acids in length, with a suitable length of about 8 to about 745 amino acids, a suitable length of about 8 to about 300 amino acids, such as about 8 to about 200 amino acids, or about 10 to about 50 or 100 amino acids. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody (e.g., the anti-FAM19A5 antibodies described herein) include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bond at the hinge region; (iii) a Fd fragment, consisting of the VH and CH1 domains; (iv) an Fv fragment, consisting of the VL and VH domains of a single arm of an antibody, and disulfide-linked Fvs (sdFv); (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), consisting of a VH domain; and (vi) isolated complementarity determining regions (CDRs) or (vii) a combination of two or more isolated CDRs, wherein the CDRs are optionally linked by a synthetic linker. In addition, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be connected by synthetic linkers using recombinant methods to form a single protein chain in which the VL and VH regions pair to form a monovalent molecule (called single-chain Fv (scFv)); for example, see Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883). Such single-chain antibodies are also intended to be included in the term "antigen-binding portion" of an antibody. These antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are screened for their utility in the same manner as intact antibodies. Antigen-binding portions can be produced by recombinant DNA technology, or by enzymatic or chemical cleavage of intact immunoglobulins.
[0114] As used herein, the terms "variable region" or "variable domain" are used interchangeably and are commonly used in the art. A variable region generally refers to a portion of an antibody, typically a portion of a light chain or a heavy chain, typically comprising approximately 110 to 120 amino acids at the amino terminus of a mature heavy chain and approximately 90 to 115 amino acids in a mature light chain. These regions differ greatly in sequence between antibodies and are responsible for the binding and specificity of a particular antibody to its specific antigen. The variability in sequence is concentrated in regions known as the complementarity determining regions (CDRs), while the more highly conserved regions of the variable domain are known as the framework regions (FRs).
[0115] Without wishing to be bound by any particular mechanism or theory, it is believed that the CDRs of the light and heavy chains are primarily responsible for the interaction and specificity of the antibody with the antigen. In some aspects, the variable region is a human variable region. In some aspects, the variable region comprises rodent or mouse CDRs and human framework regions (FRs). In specific aspects, the variable region is a primate (e.g., non-human primate) variable region. In some aspects, the variable region comprises rodent or mouse CDRs and primate (e.g., non-human primate) framework regions (FRs).
[0116] As used herein, the term "heavy chain" (HC), when used in reference to an antibody, may refer to any of the different types based on the amino acid sequence of the constant domain, such as α (a), δ (d), ε (e), γ (g), and μ (m), which give rise to IgA, IgD, IgE, IgG, and IgM classes of antibodies, respectively, including the IgG subclasses, such as IgG1, IgG2, IgG3, and IgG4.
[0117] As used herein, the term "light chain" (LC) when used to refer to an antibody can refer to any of the different types based on the amino acid sequence of the constant domain, such as kappa (κ) or lambda (λ). Light chain amino acid sequences are amino acid sequences well known in the art. In specific aspects, the light chain is a human light chain.
[0118] The terms "VL" and "VL domain" are used interchangeably to refer to the light chain variable region of an antibody.
[0119] The terms "VH" and "VH domain" are used interchangeably to refer to the heavy chain variable region of an antibody.
[0120] As used herein, the terms "constant region" or "constant domain" are interchangeable and have their usual meaning in the art. The constant region is the portion of an antibody, such as the carboxyl terminal portion of a light chain and / or a heavy chain, that is not directly involved in binding the antibody to an antigen but can exhibit various effector functions, such as interacting with Fc receptors. The constant region of an immunoglobulin molecule generally has an amino acid sequence that is more conserved than the variable domain of an immunoglobulin.
[0121] "Fc region" (fragment crystallizable region) or "Fc domain" or "Fc" refers to the C-terminal region of the antibody heavy chain, which can mediate the binding of the immunoglobulin to host tissues or factors, including binding to Fc receptors located on various cells of the immune system (such as effector cells), or binding to the first component (C1q) of the classical complement system. Therefore, the Fc region includes the constant region of the antibody, excluding the first constant region immunoglobulin domain (such as CH1 or CL). In IgG, IgA and IgD antibody isotypes, the Fc region includes two identical protein fragments, which are derived from the second (CH2) and third (CH3) constant domains of the two heavy chains of the antibody; IgM and IgEFc regions include three heavy chain constant domains (CH domains 2-4) in each polypeptide chain. For IgG, the Fc region includes the immunoglobulin domains Cγ2 and Cγ3, and the hinge between Cγ1 and Cγ2. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary, the Fc region of a human IgG heavy chain is generally defined as extending from an amino acid residue at position C226 or P230 (or amino acids between these two amino acids) to the carboxyl terminus of the heavy chain, wherein numbering is according to the EU index as in Kabat. The CH2 domain of the human IgG Fc region extends from approximately amino acid 231 to approximately amino acid 340, while the CH3 domain is located on the C-terminal side of the Cm domain in the Fc region, i.e., from approximately amino acid 341 to approximately amino acid 447 of IgG. As used herein, the Fc region can be a native sequence Fc, including any allotypic variants, or a variant Fc (e.g., a non-naturally occurring Fc). Fc can also refer to this region in isolation or within the context of an Fc-containing protein polypeptide, such as an "Fc-containing binding protein," also known as an "Fc fusion protein" (e.g., an antibody or immunoadhesion).
[0122] A "native sequence Fc region" or "native sequence Fc" includes an amino acid sequence that is identical to the amino acid sequence of a naturally occurring Fc region. Native sequence human Fc regions include a native sequence human IgG1 Fc region; a native sequence human IgG2 Fc region; a native sequence human IgG3 Fc region; and a native sequence human IgG4 Fc region and naturally occurring variants thereof. Native sequence Fc includes various Fc allotypes (e.g., see Jefferis et al. (2009) Monoclonal Antibodies (mAbs) 1:1; Vidarsson G. et al. Front Immunol 5:520 (published online October 20, 2014)).
[0123] "Fc receptor" or "FcR" is a receptor that binds to the Fc region of an immunoglobulin. FcRs that bind to IgG antibodies include receptors of the FcγR family, including allelic variants and alternatively spliced forms of these receptors. The FcγR family consists of three activating receptors (mouse FcγRI, FcγRIII, and FcγRIV; human FcγRIA, FcγRIIA, and FcγRIIIA) and one inhibitory receptor (FcγRIIB). Human IgG1 binds to most human Fc receptors and elicits the strongest Fc effector function. In terms of the type of activating Fc receptor it binds, it is considered equivalent to mouse IgG2a. In contrast, human IgG4 elicits minimal Fc effector function. Vidarsson G. et al. Front Immunol 5:520 (published online October 20, 2014).
[0124] For example, the constant region can be manipulated by recombinant technology to eliminate one or more effector functions. "Effector function" refers to the interaction of the antibody Fc region with an Fc receptor or ligand, or the biochemical events resulting therefrom. Exemplary "effector functions" include C1q binding, complement-dependent cytotoxicity (CDC), Fc receptor binding, FcγR-mediated effector functions, such as ADCC and antibody-dependent cell-mediated phagocytosis (ADCP) and downregulation of cell surface receptors (e.g., B cell receptor; BCR). Such effector functions generally require the Fc region to be combined with a binding domain (e.g., an antibody variable domain). Therefore, the term "constant region without Fc function" includes a constant region with reduced effector function mediated by the Fc region or without one or more effector functions.
[0125] The effector functions of antibodies can be reduced or avoided by different methods. By using antibody fragments lacking the Fc region (e.g., Fab, F(ab')2, single-chain Fv (scFv), or sdAbs composed of monomeric VH or VL domains), the effector functions of antibodies can be reduced or avoided. Alternatively, by removing sugars attached to specific residues in the Fc region, so-called non-glycosylated antibodies can be generated to reduce the effector functions of antibodies while retaining other valuable properties of the Fc region (e.g., extended half-life and heterodimerization). For example, glycosylated antibodies can be generated by deleting or changing the residues to which sugars are attached, enzymatically removing sugars, producing antibodies in cells cultured in the presence of glycosylation inhibitors, or expressing antibodies in cells that cannot glycosylate proteins (e.g., bacterial host cells). For example, see U.S. Patent Publication No.: 20120100140. Another approach is to use an Fc region with reduced effector functions from the IgG subclass, for example, IgG2 and IgG4 antibodies are characterized by having lower levels of Fc effector functions than IgG1 and IgG3. In the CH2 domain of the Fc portion, the residues closest to the hinge region are responsible for the antibody's effector function, as this residue contains the most overlapping binding sites for C1q (complement) and IgG-Fc receptors (FcγRs) on effector cells of the innate immune system. Vidarsson G. et al. Front Immunol 5:520 (published online October 20, 2014). Thus, antibodies with reduced or no Fc effector function can be prepared by generating, for example, a chimeric Fc region comprising a CH2 domain from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, or a chimeric Fc region comprising a hinge region from an IgG2 and a CH2 region from an IgG4 (e.g., see Lau C. et al., J. Immunol., 191: 4769-4777 (2013)), or an Fc region with a mutation that results in altered Fc effector function (e.g., reduced or no Fc function). Such Fc regions with mutations are known in the art. For example, see U.S. Patent Publication No. 20120100140 and the U.S. and PCT applications cited therein, and An et al., Monoclonal Antibodies (mAbs), 1: 6, 572-579 (2009); the entire disclosures of which are incorporated herein by reference.
[0126] "Hinge", "hinge domain" or "hinge region" or "antibody hinge region" refers to the domain of the heavy chain constant region that connects the CH1 domain and the CH2 domain, including the upper, middle and lower portions of the hinge (Roux et al., J. Immunol. 1998 161:4083). The hinge provides varying levels of flexibility between the binding and effector regions of an antibody and also provides a site for intermolecular disulfide bonds between the two heavy chain constant regions. For all IgG isotypes, the hinge as used herein begins at Glu216 and ends at Gly237 (Roux et al., 1998, J. Immunol. 161:4083). The sequences of wild-type IgG1, IgG2, IgG3 and IgG4 hinges are known in the art. For example, see Kabat EA et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Vidarsson G. et al., Front Immunol. 5:520 (published online on October 20, 2014).
[0127] The term "CH1 domain" refers to the heavy chain constant region, which connects the variable domain to the hinge in the heavy chain constant domain. The CH1 domain used herein starts at A118 and ends at V215. The term "CH1 domain" includes wild-type CH1 domains and naturally occurring variants thereof (e.g., allotypes). In the art, CH1 domain sequences of IgG1, IgG2, IgG3, and IgG4 (including wild-type and allotypes) are known. For example, see Kabat EA et al., (1991) supra, and Vidarsson G. et al., Front Immunol. 5: 520 (published online on October 20, 2014). Exemplary CH1 domains include CH1 domains with mutations that alter the biological activity (e.g., half-life) of the antibody, such as those described in U.S. Patent No. 20120100140 and the U.S. Patents and publications cited therein and PCT publications.
[0128] The term "CH2 domain" refers to the heavy chain constant region connecting the hinge and CH3 domains in the heavy chain constant domain. As used herein, the CH2 domain begins at P238 and ends at K340. The term "CH2 domain" includes wild-type CH2 domains and naturally occurring variants thereof (e.g., allotypes). CH2 domain sequences of IgG1, IgG2, IgG3, and IgG4 (including wild-type and allotypes) are known in the art. For example, see Kabat EA et al. (1991) supra, and Vidarsson G. et al. Front Immunol. 5:520 (published online on October 20, 2014). Exemplary CH2 domains include CH2 domains with mutations that alter the biological activity of the antibody (e.g., reduced half-life and / or Fc effector function), such as those described in U.S. Patent Publication No. 20120100140 and the U.S. patents and publications cited therein, as well as PCT publications.
[0129] The term "CH3 domain" refers to the heavy chain constant region, which is the C-terminus of the CH2 domain in the heavy chain constant domain. As used herein, the CH3 domain begins at G341 and ends at K447. The term "CH3 domain" includes wild-type CH3 domains and naturally occurring variants thereof (e.g., allotypes). CH3 domain sequences of IgG1, IgG2, IgG3, and IgG4 (including wild-type and allotypes) are known in the art. For example, see Kabat EA et al. (1991) supra, and Vidarsson G. et al. Front Immunol. 5:520 (published online on October 20, 2014). Exemplary CH3 domains include CH3 domains with mutations that alter the biological activity (e.g., half-life) of the antibody, such as those described in U.S. Patent Publication No. 20120100140 and the U.S. patents and publications cited therein, as well as PCT publications.
[0130] As used herein, "isotype" refers to the antibody class encoded by the heavy chain constant region genes (e.g., IgG1, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE antibodies).
[0131] "Isotype" refers to naturally occurring variants within a particular isotype group that differ in a few amino acids (e.g., see Jefferis et al. (2009) Monoclonal Antibodies (mAbs) 1:1). The antibodies described herein can be any allotype. IgG1, IgG2, IgG3, and IgG4 allotypes are known in the art. For example, see Kabat EA et al. (1991) supra; Vidarsson G. et al. Frontiers in Immunology 5:520 (published online on October 20, 2014); and Lefranc MP, Monoclonal Antibodies (mAbs) 1:4, 1-7 (2009).
[0132] Herein, the phrases "an antibody that recognizes an antigen" and "an antibody specific for an antigen" are used interchangeably with the term "an antibody that specifically binds to an antigen."
[0133] As used herein, an "isolated antibody" refers to an antibody that is substantially free of other antibodies with different antigenic specificities (e.g., an isolated antibody that specifically binds to FAM19A5 is substantially free of antibodies that specifically bind to antigens other than FAM19A5). However, an isolated antibody that specifically binds to a FAM19A5 epitope may have cross-reactivity with other FAM19A5 proteins from different species.
[0134] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, "binding affinity" as used herein refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed in terms of the dissociation constant (K D Affinity can be measured and / or expressed in a variety of ways known in the art, including but not limited to the equilibrium dissociation constant (K D ) and the equilibrium association constant (K A ). K D According to k 关 / k 开 The quotient is calculated and expressed as molar concentration (M), while K A According to k 开 / k 关 Calculate the quotient of K. 开 refers to the binding rate constant of, for example, an antibody to an antigen, and k 关 Refers to, for example, the dissociation of antibodies and antigens. 开 and k 关It can be determined by techniques known to those of ordinary skill in the art, such as immunoassays (e.g., enzyme-linked immunosorbent assay (ELISA)), BIACORE TM Kinetic exclusion assay
[0135] As used herein, the terms "specific binding," "specific recognition," "specific binding," "selective binding," and "selective binding" are analogous terms in the context of antibodies and refer to molecules (e.g., antibodies) that bind to an antigen (e.g., an epitope or an immune complex), and such binding is understood by those skilled in the art. For example, by immunoassays, BIACORE TM 、 3000 instrument (Sapidyne Instruments, Boise, ID) or other assays known in the art, it can be determined that a molecule that specifically binds to an antigen can bind to other peptides or polypeptides, generally with lower affinity. In a specific aspect, a molecule that specifically binds to an antigen has a K affinity for the antigen. A At least 2 logs, 2.5 logs, 3 logs, 4 logs or greater than the K of the molecule when it binds to another antigen A .
[0136] Antibodies usually bind to their cognate antigens with high affinity and specificity, as shown by -5 to 10 -11 M or lower dissociation constant (K D It is generally believed that any value greater than about 10 -4 M's K D As used herein, an antibody that "specifically binds" an antigen is one that binds to the antigen with high affinity and to substantially the same antigen, meaning that when detected by, for example, immunoassays (e.g., ELISA) or surface plasmon resonance (SPR) techniques in BIACORE TM When using the pre-determined antigen for the 2000 instrument, the -7 M or less, preferably 10 -8 M or less, even more preferably 10 -9 M or less, and most preferably 10 -8 M to 10 -10 M or lower K D , but does not bind unrelated antigens with high affinity.
[0137] As used herein, the term "antigen" refers to any natural or synthetic immunogenic substance, such as a protein, peptide, or hapten. The antigen may be FAM19A5 or a fragment thereof.
[0138] As used herein, "epitope" is a term in the art, referring to a local region of an antigen to which an antibody can specifically bind. An epitope can be, for example, a continuous amino acid sequence of a polypeptide (linear or continuous epitope), or an epitope can be, for example, two or more discontinuous regions (conformation, non-linear, discontinuous or discontinuous epitopes) from one or more polypeptides. Epitopes formed by continuous amino acids are generally, but not always, retained when exposed to a denaturing solvent, while epitopes formed by tertiary folding are typically lost when treated with a denaturing solvent. An epitope generally includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20 amino acids in a unique spatial conformation. It is well known in the art that methods for determining which epitopes are bound by a given antibody (i.e., epitope mapping) are used, and include, for example, immunoblotting and immunoprecipitation assays, in which overlapping or continuous peptides from (e.g., from FAM19A5) are tested for reactivity with a given antibody (e.g., anti-FAM19A5 antibody). Methods for determining the spatial conformation of epitopes include techniques in the art and those described herein, for example, x-ray crystallography, two-dimensional nuclear magnetic resonance, and HDX-MS (see, for example, Epitope Mapping Protocols in Methods in Molecular Biology, 66, ed. G.E. Morris (1996)).
[0139] In certain aspects, the epitope to which the antibody binds can be determined by, for example, NMR spectroscopy, X-ray crystallography, ELISA assays, hydrogen / deuterium exchange coupled to mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligopeptide scanning assays, and / or mutagenesis mapping (e.g., site-directed mutagenesis mapping). For X-ray crystallography, crystallization can be accomplished by any method known in the art (e.g., Giege R et al. (1994) Acta Crystallogr D Biol Crystallogr 50(Pt 4): 339-350; McPherson A (1990) Eur J Biochem 189: 1-23; Chayen NE (1997) Structure 5: 1269-1274; McPherson A (1976) J Biol Chem 251: 6300-6303). Antibody:antigen crystals can be studied using well-known X-ray diffraction techniques and refined using computer software such as X-PLOR (Yale University, 1992, published by Molecular Simulations, Inc.; for example, see Meth Enzymol (1985) 114 and 115, edited by Wyckoff HW et al.; US2004 / 0014194), and BUSTER (Bricogne G (1993) Acta Crystallographica D: Biol Crystallogr, 49(Pt 1): 37-60; Bricogne G (1997) Meth Enzymol, 276N. 361-423, Carter CW; Roversi P et al., eds., (2000) Acta Crystallographica D: Biological Crystallography, 56(Pt 10): 1316-1323). Mutagenesis mapping studies can be performed using any method known to those skilled in the art. Relevant mutagenesis techniques include alanine scanning mutagenesis techniques, for example, see Champe M et al., (1995) J Biol Chem 270:1388-1394, and Cunningham BC and Wells JA (1989) Science 244:1081-1085.
[0140] The term "epitope mapping" refers to the process of identifying molecular determinants for antibody-antigen recognition.
[0141] With reference to two or more antibodies, the term "binding to the same epitope" refers to the antibody binding to the same amino acid residue fragment determined using a given method. The technology used to determine whether an antibody binds to the "same epitope on FAM19A5" as the antibody described herein includes, for example, epitope mapping methods, for example, x-ray analysis of crystals of antigen: antibody complexes, which provides atomic resolution of the epitope and hydrogen / deuterium exchange mass spectrometry (HDX-MS). Other methods can monitor the binding of antibodies to antigen fragments or mutant variants of antigens, wherein it is generally believed that the loss of binding caused by modification of amino acid residues within the antigen sequence indicates an epitope component. In addition, epitope mapping can also be performed using computational combinatorial methods. These methods rely on the ability of related antibodies to affinity-free specific short peptides from a combinatorial phage display peptide library. Antibodies with identical VH and VL or identical CDR1, 2, and 3 sequences are expected to bind to the same epitope.
[0142] An antibody that "competes with another antibody for binding to a target" refers to an antibody that (partially or completely) inhibits the binding of another antibody to the target. Using known competition experiments, it can be determined whether two antibodies compete with each other to bind to the target, i.e., whether one antibody inhibits the binding of another antibody to the target and the degree of inhibition. In some aspects, an antibody competes with another antibody for target binding and inhibits the binding of the other antibody to the target by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The level of inhibition or competition can be different, depending on which antibody is the "blocking antibody" (i.e., the first cold antibody to be incubated with the target). Competition assays are performed, for example, as described in Ed Harlow and David Lane, Cold Spring Harb Protoc; 2006; doi: 10.1101 / pdb.prot4277, or in Ed Harlow and David Lane, Using Antibodies (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA) (1999), Chapter 11. Competing antibodies bind to the same epitope, an overlapping epitope, or an adjacent epitope (e.g., as indicated by steric hindrance).
[0143] Other competitive binding assays include: solid phase direct or indirect radioimmunoassays (RIA), solid phase direct or indirect enzyme immunoassays (EIA), sandwich competition assays (see Stahli et al., Methods in Enzymology 9:242 (1983)); solid phase direct biotin-avidin EIA (see Kirkland et al., J. Immunol. 137:3614 (1986)); solid phase direct labeled assays, solid phase direct labeled sandwich assays (see Harlow and Lane, Antibodies: A Laboratory Manual) Manual, Cold Spring Harbor Laboratory Press (1988); solid phase direct labeled RIA using I-125 labeling (see Morel et al., Mol. Immunol. 25(1):7 (1988); solid phase direct biotin-avidin EIA (Cheung et al., Virology 176:546 (1990)); and directly labeled RIA. (Moldenhauer et al., Scand. J. Immunol. 32:77 (1990)).
[0144] "Bispecific" or "bifunctional antibodies" are artificial hybrid antibodies with two different heavy chain / light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods, including fusion of hybridomas or linking of Fab' fragments. For example, see Songsivilai and Lachmann, Clin. Exp. Immunol. 79:315-321 (1990); Kostelny et al., J. Immunol. 148, 1547-1553 (1992).
[0145] As used herein, the term "monoclonal antibody" refers to an antibody that displays a single binding specificity and affinity for a particular epitope, or an antibody composition in which all antibodies display a single binding specificity and affinity for a particular epitope. Thus, the term "human monoclonal antibody" refers to an antibody or antibody composition that displays a single binding specificity and has variable and optionally constant regions derived from human germline immunoglobulin sequences. In certain aspects, human monoclonal antibodies are produced by hybridomas that include B cells obtained from a transgenic non-human animal, such as a transgenic mouse, whose genome includes human heavy and light chain transgenes fused to immortalized cells.
[0146] As used herein, the term "recombinant human antibody" includes all human antibodies prepared, expressed, generated, or isolated using recombinant methods, such as (a) antibodies isolated from transgenic or transchromosomal animals (e.g., mice) for human immunoglobulin genes or hybridomas prepared therefrom, (b) antibodies isolated from host cells transformed to express the antibodies (e.g., transfectomas), (c) antibodies isolated from recombinant, combinatorial human antibody libraries, and (d) antibodies prepared, expressed, generated, or isolated using any other method involving splicing human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies include variable and constant regions that utilize specific human germline immunoglobulin sequences encoded by germline genes, but include subsequent rearrangements and mutations that occur, for example, during antibody maturation. It is known in the art (e.g., see Lonberg (2005) Nature Biotech. 23(9): 1117-1125) that the variable region comprises an antigen binding domain that is encoded by various genes that rearrange to form an antibody specific for a foreign antigen. In addition to rearrangement, the variable region can be further modified by multiple single amino acid changes (called somatic mutations or hypermutations), which increase the affinity of the antibody for foreign antigens. The constant region will change in further response to antigen (i.e., isotype switching). Therefore, in response to antigen, the rearranged and somatically mutated nucleic acid molecules encoding light and heavy chain immunoglobulin polypeptides cannot have sequence identity with the original nucleic acid molecules, but are substantially identical or similar (i.e., have at least 80% identity).
[0147] "HuMAb" refers to an antibody with a variable region, wherein the framework region and the CDR region are derived from human germline immunoglobulin sequences. In addition, if the antibody comprises a constant region, the constant region is also derived from human germline immunoglobulin sequences. The antibodies described herein may include amino acid residues that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo). However, the term "human antibody" as used herein is not intended to include antibodies in which the CDR sequences of the germline of another mammalian species (such as a mouse) have been transplanted onto human framework sequences. The term "human" antibody is synonymous with a "fully human" antibody.
[0148] A "humanized" antibody is an antibody in which some, most, or all of the amino acids outside the CDR domains of a non-human antibody are replaced by corresponding amino acids from human immunoglobulins. In some aspects of the humanized form of an antibody, some, most, or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, while some, most, or all of the amino acids within one or more CDR regions have not been changed. Minor additions, deletions, insertions, substitutions, or modifications of amino acids may be made as long as the ability of the antibody to bind to a specific antigen is not eliminated. A "humanized" antibody retains antigenic specificity similar to that of the original antibody.
[0149] A "chimeric antibody" refers to an antibody whose variable regions are derived from one species and whose constant regions are derived from another species, for example, an antibody whose variable regions are derived from a mouse antibody and whose constant regions are derived from a human antibody.
[0150] As used herein, the term "cross-reactivity" refers to the ability of the antibodies described herein to bind to FAM19A5 from different species. For example, an antibody described herein that binds to human FAM19A5 may also bind to FAM19A5 of another species (e.g., mouse FAM19A5). Cross-reactivity as used herein can be measured by detecting specific reactivity with purified antigen in a binding assay (e.g., SPR, ELISA), or by binding to or otherwise functionally interacting with cells that physiologically express FAM19A5. Methods for determining cross-reactivity include standard binding assays described herein, for example, using BIACORE TM 2000SPR instrument (Biacore AB, Uppsala, Sweden), by BIACORE TM Surface plasmon resonance (SPR) analysis, or flow cytometry techniques.
[0151] As used herein, the term "naturally occurring" means that an object can be found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (including a virus) that can be isolated from a source in nature and has not been intentionally modified by man in the laboratory is naturally occurring.
[0152] "Polypeptide" refers to a chain of at least two consecutively linked amino acid residues, with no upper limit on chain length. One or more amino acid residues in a protein may contain modifications such as, but not limited to, glycosylation, phosphorylation, or disulfide bond formation. A "protein" may include one or more polypeptides.
[0153] As used herein, the term "nucleic acid molecule" is intended to include DNA molecules and RNA molecules. The nucleic acid molecule can be a single-stranded or double-stranded nucleic acid molecule, and can also be a cDNA.
[0154] As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop to which additional DNA fragments can be connected. Another type of vector is a viral vector, in which additional DNA fragments can be connected to the viral genome. Certain vectors are capable of autonomous replication in the host cells into which they are introduced (e.g., bacterial vectors and additional mammalian vectors with bacterial replication origins). Other vectors (e.g., non-additional mammalian vectors) can be integrated into the genome of the host cell after being introduced into the host cell, thereby replicating together with the host genome. In addition, certain vectors are capable of directing the expression of genes operably connected thereto. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). Generally, expression vectors used for recombinant DNA technology exist in the form of plasmids. Since plasmids are the most commonly used vector forms, in this specification, "plasmids" and "vectors" can be used interchangeably. However, other forms of expression vectors are also included, such as viral vectors (e.g., replication-defective retroviruses, adenoviruses, and adeno-associated viruses), which can provide equivalent functions.
[0155] As used herein, the term "recombinant host cell" (or simply "host cell") refers to a cell that contains a nucleic acid that is not naturally present in the cell, and may be a cell into which a recombinant expression vector has been introduced. It should be understood that such terms refer not only to the specific subject cell, but also to the progeny of such a cell. Because certain modifications may occur in subsequent generations due to mutations or environmental influences, such progeny may not actually be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.
[0156] As used herein, the term "linked" refers to the association of two or more molecules. The link may be covalent or non-covalent. It may also be genetic (i.e., recombinant fusion). Such linking can be achieved using a variety of techniques recognized in the art, such as chemical conjugation and recombinant protein production.
[0157] As used herein, the term "therapeutically effective amount" refers to an amount of a drug, alone or in combination with another therapeutic agent, that is effective to "treat" a disease or condition in an individual or to reduce the risk, likelihood, or occurrence of a disease or condition (e.g., diabetic retinopathy or age-related macular degeneration). A "therapeutically effective amount" includes an amount of a drug or therapeutic agent that provides some improvement or benefit to an individual suffering from or at risk of suffering from a disease or condition associated with fibrosis. Thus, a "therapeutically effective" amount is an amount that reduces the risk, likelihood, or occurrence of a disease or condition, or provides some relief, alleviation, and / or reduction in at least one indicator, and / or decrease in at least one clinical symptom of a disease or condition.
[0158] II. Treatment options for retinopathy and / or macular degeneration
[0159] Disclosed herein are methods for treating eye conditions in individuals in need thereof. More specifically, the methods disclosed herein can be used to treat retinopathy, particularly diabetic retinopathy. The methods disclosed herein can also be used to treat macular degeneration, particularly age-related macular degeneration. As described below, eye diseases such as diabetic retinopathy and age-related macular degeneration are associated with decreased retinal potential. Therefore, also provided herein are methods for improving retinal potential in individuals in need thereof (e.g., with diabetic retinopathy or age-related macular degeneration).
[0160] In certain aspects, the methods disclosed herein comprise administering to an individual an antagonist directed against a FAM19A5 protein ("FAM19A5 antagonist"). In certain aspects, the FAM19A5 antagonist is an antisense oligonucleotide, siRNA, shRNA, miRNA, dsRNA, aptamer, PNA, or a vector comprising the same that targets FAM19A5. In other aspects, the FAM19A5 antagonist is an antibody or antigen-binding portion thereof that specifically binds to a FAM19A5 protein ("anti-FAM19A5 antibody"), a polynucleotide encoding an anti-FAM19A5 antibody, or a vector comprising the same. In certain aspects, the anti-FAM19A5 antibody binds to the FAM19A5 protein and reduces FAM19A5 activity.
[0161] Individuals with retinopathy (e.g., diabetic retinopathy) and / or macular degeneration (e.g., age-related macular degeneration) may exhibit one or more of the following characteristics within the retina: (i) decreased retinal electrical potential, (ii) pericyte loss, (iii) increased formation of acellular capillaries, (iv) increased vascular congestion (e.g., within the nerve fiber layer of the retina), (v) increased apoptotic cells (e.g., within the nerve fiber layer and / or inner nuclear layer of the retina), (vi) increased retinal and / or choroidal neovascularization, and (vii) increased astrocyte formation (e.g., increased PDGF staining within the nerve fiber layer and / or ganglion cell layer of the retina). See Examples 6-10.
[0162] Thus, without being bound by any theory, the FAM19A5 antagonists disclosed herein (e.g., anti-FAM19A5 antibodies) can treat retinopathy and / or macular degeneration by reducing, alleviating, and / or reversing one or more of the above-described properties. In certain aspects, the FAM19A5 antagonists are capable of neutralizing the FAM19A5 protein, e.g., FAM19A5 neutralizers. In another aspect, the FAM19A5 antagonists are anti-FAM19A5 antibodies. In certain aspects, the anti-FAM19A5 antibodies are neutralizing antibodies.
[0163] In some aspects, FAM19A5 antagonists can improve the retinal potential of an individual (e.g., someone with diabetic retinopathy or age-related macular degeneration). In some aspects, the improvement in retinal potential includes an increase in A-wave, B-wave, and / or oscillatory potential values compared to a reference value (e.g., a corresponding value for a DR or AMD individual not treated with a FAM19A5 antagonist disclosed herein). In some aspects, the A-wave, B-wave, and / or oscillatory potential values increase by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to a reference value.
[0164] In some aspects, the FAM19A5 antagonists disclosed herein (e.g., anti-FAM19A5 antibodies) can reduce or prevent pericyte loss in the retina of an individual (e.g., with diabetic retinopathy or age-related macular degeneration). In some aspects, pericyte loss in the retina is reduced by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, compared to a reference value (e.g., a corresponding value for a DR or AMD individual not treated with a FAM19A5 antagonist disclosed herein).
[0165] In certain aspects, the FAM19A5 antagonists disclosed herein can reduce and / or inhibit the formation of acellular capillaries in the retina of an individual (e.g., with diabetic retinopathy or age-related macular degeneration). In certain aspects, the formation of acellular capillaries is reduced and / or inhibited by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to a reference value (e.g., a corresponding value in an individual with DR or AMD not treated with a FAM19A5 antagonist disclosed herein).
[0166] In certain aspects, a FAM19A5 antagonist (e.g., an anti-FAM19A5 antibody) can reduce and / or inhibit vascular congestion in the retina of a subject (e.g., suffering from diabetic retinopathy or age-related macular degeneration). In certain aspects, vascular congestion in the retina is reduced and / or inhibited by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to a reference value (e.g., a corresponding value in a DR or AMD subject not treated with a FAM19A5 antagonist disclosed herein).
[0167] In some aspects, the FAM19A5 antagonists disclosed herein can reduce and / or inhibit apoptosis of retinal cells in individuals (e.g., those with diabetic retinopathy or age-related macular degeneration). In some aspects, the frequency of apoptosis in retinal cells is reduced by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to a reference value (e.g., a corresponding value in an individual with DR or AMD who has not been treated with a FAM19A5 antagonist disclosed herein).
[0168] In certain aspects, FAM19A5 antagonists can reduce and / or inhibit neovascularization (e.g., retinal and / or choroidal neovascularization) in the retina of an individual (e.g., with diabetic retinopathy or age-related macular degeneration). In certain aspects, neovascularization (e.g., retinal and / or choroidal neovascularization) in the retina is reduced and / or inhibited by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to a reference value (e.g., a corresponding value in an individual with DR or AMD who has not been treated with a FAM19A5 antagonist disclosed herein).
[0169] In some aspects, FAM19A5 antagonists are used to reduce and / or inhibit PDGF expression in the retina of an individual (e.g., suffering from diabetic retinopathy or age-related macular degeneration). In some aspects, PDGF expression in the retina is at least reduced and / or inhibited by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to a reference value (e.g., a corresponding value for a DR or AMD individual not treated with a FAM19A5 antagonist disclosed herein). In some aspects, reducing and / or inhibiting PDGF expression is associated with a reduction in astrocyte formation in the retina of an individual.
[0170] In certain aspects, the term "reference" as used herein refers to a corresponding individual (e.g., with diabetic retinopathy or age-related macular degeneration) who has not received a composition disclosed herein (e.g., a FAM19A5 antagonist, e.g., an anti-FAM19A5 antibody). The term "reference" may also refer to the same individual (e.g., with diabetic retinopathy or age-related macular degeneration), but prior to administration of a composition disclosed herein. In certain aspects, the term "reference" refers to the average number of individuals (e.g., with diabetic retinopathy or age-related macular degeneration).
[0171] In certain aspects, the retinopathy that can be treated by the present disclosure includes diabetic retinopathy. In certain aspects, the diabetic retinopathy is non-proliferative diabetic retinopathy (NPDR). In other aspects, the diabetic retinopathy is proliferative diabetic retinopathy (PDR). In certain aspects, the diabetic retinopathy is diabetic maculopathy. In more aspects, the diabetic retinopathy is diabetic macular edema. In certain aspects, the diabetic retinopathy is any retinopathy associated with ischemic damage in the retina.
[0172] In some aspects, the macular degeneration that can be treated by the present disclosure includes age-related macular degeneration (AMD). In some aspects, age-related macular degeneration is early AMD. In other aspects, age-related macular degeneration is mid-term AMD. In more aspects, age-related macular degeneration is late AMD (i.e., geographic atrophy). In some aspects, age-related macular degeneration is dry (non-exudative) AMD. In other aspects, age-related macular degeneration is wet (neovascular or exudative) AMD.
[0173] In certain aspects, the subject that can be treated by the present method is a non-human animal, such as a rat or mouse. In other aspects, the subject that can be treated by the methods disclosed herein is a human.
[0174] In some aspects, through intraocular administration or any other application of compositions disclosed herein (such as FAM19A5 antagonists) can be delivered, FAM19A5 antagonists disclosed herein (for example, anti-FAM19A5 antibodies), bispecific molecules or immunoconjugates or their compositions are delivered to the subfascia, subconjunctiva, suprachoroidal space, vitreous and similar positions in the individual eye. In some aspects, intraocular administration includes intravitreal administration.
[0175] When administering a FAM19A5 antagonist disclosed herein or a composition thereof (eg, an anti-FAM19A5 antibody), the dosage range is about 0.0001 to 100 mg / kg.
[0176] In certain aspects, a FAM19A5 antagonist or a composition thereof can be administered in combination with one or more other agents (e.g., therapeutic agents) to treat retinopathy (e.g., diabetic retinopathy) and / or macular degeneration (e.g., age-related macular degeneration), such as standard therapies, e.g., (i) corticosteroids, (ii) anti-angiogenesis inhibitors (e.g., anti-VEGF inhibitors), (iii) laser therapy (e.g., laser photocoagulation), (iv) antioxidants. Other currently available treatment options that can be used in combination with a FAM19A5 antagonist or a composition thereof include, but are not limited to, surgery (e.g., vitrectomy) and control of modifiable risk factors (e.g., lowering blood sugar and cholesterol levels, stopping smoking).
[0177] III. FAM19A5 antagonists
[0178] In certain aspects, the FAM19A5 antagonists useful in the present disclosure are antisense oligonucleotides, siRNA, shRNA, miRNA, dsRNA, aptamers, PNA (peptide nucleic acid) that specifically target FAM19A5, or vectors comprising the same. In other aspects, the FAM19A5 antagonists are antibodies or antigen-binding portions thereof that specifically bind to FAM19A5 protein ("anti-FAM19A5 antibodies"), polynucleotides encoding anti-FAM19A5 antibodies, or vectors comprising the same.
[0179] In the methods disclosed herein, useful antibodies include monoclonal antibodies characterized by specific functional characteristics or properties. For example, the antibodies specifically bind to human FAM19A5, including soluble FAM19A5 and membrane-bound FAM19A5. In addition to specifically binding to soluble and / or membrane-bound human FAM19A5, the antibodies described herein also (a) bind to human FAM19A5 with a K of 10 nM or less. D Binds to soluble human FAM19A5; (b) with a K of 10 nM or lower D Binds to membrane-bound human FAM19A5; or both (a) and (b).
[0180] In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, specifically binds to soluble human FAM19A5 or membrane-bound human, e.g., K D is 10 -7 M or lower, 10 -8 M (10nM) or lower, 10 -9 M (1nM) or lower, 10 -10 M (0.1nM) or lower, 10 -11 M or lower, or 10 -12 M or lower, such as 10 -12 M-10 -7 M, 10 -11 M-10 -7 M, 10 -10 M-10 -7 M, or 10 -9 M-10 -7 M, for example 10 -12 M, 5X10 -12 M, 10 -11 M, 5X10 -11 M, 10 -10 M, 5X10 -10 M, 10 -9 M, 5X10 -9 M, 10-8 M, 5X10 -8 M, 10 -7 M, or 5X10 -7 M. Standard assays known in the art can be used to evaluate the ability of antibodies from various species to bind to human FAM19A5, including, for example, ELISA, immunoblotting, and RIA. Suitable assays are described in detail in the Examples. The binding kinetics (e.g., binding affinity) of the antibody can also be assessed by standard assays known in the art, such as ELISA, BIACORE TM Analysis or
[0181] In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, is expressed as 10 -7 M or lower, 10 -8 M (10nM) or lower, 10 -9 M (1nM) or lower, 10 -10 M or lower, 10 -12 M-10 -7 M, 10 -11 M-10 -7 M, 10 -10 M-10 -7 M, 10 -9 M-10 -7 M or 10 -8 M-10 -7 M's K D Binds to soluble human FAM19A5. In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, binds to soluble human FAM19A5 with a K of 10 nM or less. D , for example, 0.1 to 10 nM, 0.1 to 5 nM, 0.1 to 1 nM, 0.5 to 10 nM, 0.5 to 5 nM, 0.5 to 1 nM, 1 to 10 nM, 1 to 5 nM, or 5 to 10 nM binding to soluble FAM19A5. In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, has a K of about 1 pM, 2 pM, 3 pM, 4 pM, 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 100 pM, 200 pM, 300 pM, 400 pM, 500 pM, 600 pM, 700 pM, 800 pM, or 900 pM, or about 1 nM, 2 nM, 3 nM, 4 nM, 5 nM, 6 nM, 7 nM, 8 nM, or 9 nM, or about 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, or 90 nM as determined by ELISA. D Specifically binds soluble human FAM19A5.
[0182] In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, is expressed as 10 -7 M or lower, 10 -8 M (10nM) or lower, 10 -9 M (1nM) or lower, 10 -10 M or lower, 10 -12 M-10 -7 M, 10 -11 M-1 -7 M, 10 -10 M-10 -7 M, 10 -9 M-10 -7 M or 10 -8 M-10 -7 M's K D In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, has a K of 10 nM or less as determined by ELISA. D , for example, 0.1 to 10 nM, 0.1 to 5 nM, 0.1 to 1 nM, 0.5 to 10 nM, 0.5 to 5 nM, 0.5 to 1 nM, 1 to 10 nM, 1 to 5 nM, or 5 to 10 nM specifically binds to membrane-bound human FAM19A5. In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, has a K of about 1 pM, 2 pM, 3 pM, 4 pM, 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 20 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 100 pM, 200 pM, 300 pM, 400 pM, 500 pM, 600 pM, 700 pM, 800 pM, or 900 pM, or about 1 nM, 2 nM, 3 nM, 4 nM, 5 nM, 6 nM, 7 nM, 8 nM, or 9 nM, or about 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, or 90 nM as determined by ELISA. D Binds to membrane-bound human FAM19A5.
[0183] In certain aspects, the anti-FAM19A5 antibodies or antigen-binding portions thereof useful in the methods disclosed herein cross-compete for binding to (or inhibit binding of) an anti-FAM19A5 antibody comprising CDRs or variable regions disclosed herein.
[0184] In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, inhibits binding of a reference antibody comprising a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, (i) wherein the heavy chain CDR1, CDR2, and CDR3 of the reference antibody comprise the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13, respectively, and the light chain CDR1, CDR2, and CDR3 of the reference antibody comprise the amino acid sequences of SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25; (ii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 27, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 28. NO:28; (iii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:17, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:18, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:19, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:29, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO:30, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:31; (iv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:20, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:21, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:22, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:32, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO:33, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:34; (v) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:89, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: the amino acid sequence of SEQ ID NO: 90, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 91, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 92, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 93, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 94;(vi) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 95, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 96, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 97, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 98, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 99, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 100; (vii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 101, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 102, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 103, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 104, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 105, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 106; (viii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 107, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: NO: 108, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 109, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 110, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 111, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 112; (ix) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 113, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 114, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 115, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 116, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 118; (x) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 119, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: NO: 121, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 122, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 123, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 124;(xi) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 125, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 126, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 127, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 128, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 129, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 130; (xii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 131, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 132, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 133, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 134, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 135, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 136; (xiii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 137, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: NO: 138, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 139, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 140, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 141, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 142; (xiv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 143, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 144, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 145, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 146, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 147, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 148; or (xv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 149, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 150, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 151. NO: 151, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 152, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 153, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 154.
[0185] In certain aspects, the reference antibody comprises (a) heavy and light chain variable region sequences comprising SEQ ID NOs: 35 and 39, respectively; (b) heavy and light chain variable region sequences comprising SEQ ID NOs: 36 and 40, respectively; (c) heavy and light chain variable region sequences comprising SEQ ID NOs: 37 and 41, respectively; (d) heavy and light chain variable region sequences comprising SEQ ID NOs: 38 and 42, respectively; (e) heavy and light chain variable region sequences comprising SEQ ID NOs: 155 and 166, respectively; (f) heavy and light chain variable region sequences comprising SEQ ID NOs: 156 and 167, respectively; (g) heavy and light chain variable region sequences comprising SEQ ID NOs: 157 and 168, respectively; (h) heavy and light chain variable region sequences comprising SEQ ID NOs: 158 and 169, respectively; (i) heavy and light chain variable region sequences comprising SEQ ID NOs: 159 and 170, respectively; (j) heavy and light chain variable region sequences comprising SEQ ID NOs: 171 and 172, respectively. NO: 160 and 171; (k) heavy chain and light chain variable region sequences comprising SEQ ID NO: 161 and 172, respectively; (l) heavy chain and light chain variable region sequences comprising SEQ ID NO: 162 and 173, respectively; (m) heavy chain and light chain variable region sequences comprising SEQ ID NO: 163 and 174, respectively; (n) heavy chain and light chain variable region sequences comprising SEQ ID NO: 164 and 175, respectively; or (o) heavy chain and light chain variable region sequences comprising SEQ ID NO: 165 and 176, respectively.
[0186] In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, inhibits the binding of such a reference antibody to human FAM19A5 by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%, or 100%. Competing antibodies bind to the same epitope, overlapping epitope, or adjacent epitope (e.g., as demonstrated by steric hindrance). Competition assays known in the art, such as RIAs and EIAs, can be used to determine whether two antibodies compete with each other for target binding.
[0187] In certain aspects, the anti-FAM19A5 antibodies, or antigen-binding portions thereof, bind to the same FAM19A5 epitope as a reference antibody disclosed herein comprising a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, (i) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 11, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 23, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 25; or (ii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 26, and the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: NO: 27, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 28; (iii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 31; (iv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 20, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 21, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 22, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 32, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 33, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 34; (v) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: NO:89, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:90, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:91, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:92, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO:93, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:94;(vi) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 95, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 96, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 97, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 98, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 99, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 100; (vii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 101, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 102, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 103, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 104, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 105, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 106; (viii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 107, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: NO: 108, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 109, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 110, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 111, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 112; (ix) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 113, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 114, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 115, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 116, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 117, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 118; (x) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 119, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 120, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: NO: 121, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 122, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 123, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 124;(xi) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 125, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 126, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 127, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 128, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 129, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 130; (xii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 131, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 132, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 133, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 134, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 135, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 136; (xiii) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 137, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 138 NO: 138, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 139, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 140, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 141, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 142; (xiv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 143, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 144, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 145, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 146, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 147, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 148; or (xv) wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 149, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 150, and the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 151. NO: 151, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 152, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 153, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 154.
[0188] In certain aspects, the reference antibody comprises (a) heavy and light chain variable region sequences comprising SEQ ID NOs: 35 and 39, respectively; (b) heavy and light chain variable region sequences comprising SEQ ID NOs: 36 and 40, respectively; (c) heavy and light chain variable region sequences comprising SEQ ID NOs: 37 and 41, respectively; (d) heavy and light chain variable region sequences comprising SEQ ID NOs: 38 and 42, respectively; (e) heavy and light chain variable region sequences comprising SEQ ID NOs: 155 and 166, respectively; (f) heavy and light chain variable region sequences comprising SEQ ID NOs: 156 and 167, respectively; (g) heavy and light chain variable region sequences comprising SEQ ID NOs: 157 and 168, respectively; (h) heavy and light chain variable region sequences comprising SEQ ID NOs: 158 and 169, respectively; (i) heavy and light chain variable region sequences comprising SEQ ID NOs: 159 and 170, respectively; (j) heavy and light chain variable region sequences comprising SEQ ID NOs: 171 and 172, respectively. NO: 160 and 171; (k) heavy chain and light chain variable region sequences comprising SEQ ID NO: 161 and 172, respectively; (l) heavy chain and light chain variable region sequences comprising SEQ ID NO: 162 and 173, respectively; (m) heavy chain and light chain variable region sequences comprising SEQ ID NO: 163 and 174, respectively; (n) heavy chain and light chain variable region sequences comprising SEQ ID NO: 164 and 175, respectively; or (o) heavy chain and light chain variable region sequences comprising SEQ ID NO: 165 and 176, respectively.
[0189] For example, techniques for determining whether two antibodies bind to the same epitope include epitope mapping methods, such as crystallographic x-ray analysis of antigen:antibody complexes, which provides atomic resolution of the epitope, and hydrogen / deuterium exchange mass spectrometry (HDX-MS), methods for monitoring antibody binding to antigen fragments or mutant variants of the antigen (in which loss of binding resulting from modification of amino acid residues within the antigen sequence is generally considered to be an indication of epitope composition), and computational combined methods of epitope mapping.
[0190] For example, an anti-FAM19A5 antibody or antigen-binding portion thereof useful in the methods disclosed herein can bind to at least one epitope of mature human FAM19A5 by binding the antibody to a fragment of human FAM19A5. In certain aspects, the anti-FAM19A5 antibody or antigen-binding portion thereof binds to a fragment of the amino acid sequence of TLDRDSSQPRRTIARQTARC (SEQ ID NO: 6 or amino acid residues 42 to 61 of SEQ ID NO: 2), such as an epitope having at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of SEQ ID NO: 6. In certain aspects, an anti-FAM19A5 antibody, or an antigen-binding portion thereof, binds to SEQ ID NO: 2 at one or more amino acids corresponding to amino acid residues 46 to 51 (i.e., DSSQPR), e.g., amino acid residues 46, 50, and 52 (i.e., D---PR), e.g., amino acid residues 46, 47, 48, and 50 (i.e., DSS-P) of SEQ ID NO: 2. In certain aspects, an anti-FAM19A5 antibody, or an antigen-binding portion thereof, binds to an epitope located within the amino acid sequence of CDMLPCLEGEGCDLLINRSG (SEQ ID NO: 9 or amino acids 90 to 109 of SEQ ID NO: 2), e.g., an epitope having at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of SEQ ID NO: 9. In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, binds to SEQ ID NO: 9 at one or more amino acid residues 99 to 107 (i.e., EGCDLLINR), e.g., amino acid residues 102, 103, 105, and 107 (i.e., DL-IR), e.g., amino acid residues 99, 100, 102, 103, 105, and 107 (i.e., EG-DL-IR), e.g., amino acid residues 99, 100, and 107 (i.e., EG------R) of SEQ ID NO: 4.
[0191] In some aspects, the at least one epitope has an amino acid sequence that is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 6. In some aspects, the at least one epitope has an amino acid sequence that is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 9.
[0192] In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, binds only to an epitope of human FAM19A5 of SEQ ID NO: 5, 6, 7, 8, 9 or 10, or a fragment within the amino acid sequence of SEQ ID NO: 5, 6, 7, 8, 9 or 10, such as an epitope having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids of SEQ ID NO: 5, 6, 7, 8, 9 or 10.
[0193] In certain aspects, the anti-FAM19A5 antibodies or antigen-binding portions thereof of the present disclosure bind to SEQ ID NO: 6 or a fragment thereof in its native conformation (i.e., undenatured). In certain aspects, the anti-FAM19A5 antibodies or antigen-binding portions thereof of the present disclosure bind to SEQ ID NO: 9 or a fragment thereof in its native conformation (i.e., undenatured). In other aspects, the at least one epitope has an amino acid sequence that is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 5, and has an amino acid sequence that is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 10. In certain aspects, the anti-FAM19A5 antibodies or antigen-binding portions thereof bind to both glycosylated and unglycosylated human FAM19A5.
[0194] In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, further binds to one or more additional FAM19A5 epitopes. Thus, certain anti-FAM19A5 antibodies, or antigen-binding portions thereof, bind to the epitope of SEQ ID NO:6 and an additional epitope, or to the epitope of SEQ ID NO:9 and an additional epitope. Other anti-FAM19A5 antibodies, or antigen-binding portions thereof, can bind to the epitope of SEQ ID NO:5, the epitope of SEQ ID NO:9, and an additional epitope. In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, binds to the epitope of SEQ ID NO:6, the epitope of SEQ ID NO:10, and an additional epitope. In certain aspects, the one or more additional FAM19A5 epitopes are selected from QLAAGTCEIVTLDR (SEQ ID NO: 5, epitope F1), TLDRDSSQPRRTIARQTARC (SEQ ID NO: 6, epitope F2), TARCACRKGQIAGTTRARPA (SEQ ID NO: 7, epitope F3), ARPACVDARIIKTKQWCDML (SEQ ID NO: 8, epitope F4), CDMLPCLEGEGCDLLINRSG (SEQ ID NO: 9, epitope F5) or NRSGWTCTQPGGRIKTTTVS (SEQ ID NO: 10, epitope F6), or a fragment located within the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10, or any combination thereof. Fragments located within the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10, including fragments having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids of any one of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10. In some aspects, the one or more additional FAM19A5 epitopes are selected from SEQ ID NO: 5, 6, 7, 8, 9 or 10, or a fragment located within the amino acid sequence of SEQ ID NO: 5, 6, 7, 8, 9 or 10, for example, a fragment having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids of SEQ ID NO: 5, 6, 7, 8, 9 or 10 or any combination thereof.In some aspects, anti-FAM19A5 antibodies or antigen binding portions thereof of the present disclosure bind to any one of one or more additional epitopes in its native conformation (i.e., not denatured). In some aspects, anti-FAM19A5 antibodies or antigen binding portions thereof simultaneously bind to one or more additional FAM19A5 epitopes of glycosylation and non-glycosylation.
[0195] In certain aspects, an anti-FAM19A5 antibody, or an antigen-binding portion thereof, binds to at least one FAM19A5 epitope identified as EP2, EP4, and / or EP8, wherein EP2 comprises, consists essentially of, or consists of the amino acids DSSQP (SEQ ID NO: 66), wherein EP4 comprises, consists essentially of, or consists of the amino acids ARCACRK (SEQ ID NO: 68), wherein EP8 comprises, consists essentially of, or consists of the amino acids TCTQPGGR (SEQ ID NO: 72). In certain aspects, the at least one epitope has an amino acid sequence that is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to EP2, EP4, or EP8. In certain aspects, an anti-FAM19A5 antibody, or an antigen-binding portion thereof, binds only to EP2. In certain aspects, an anti-FAM19A5 antibody, or an antigen-binding portion thereof, binds to both EP4 and EP8.
[0196] In certain aspects, an anti-FAM19A5 antibody, or an antigen-binding portion thereof, binds to at least one FAM19A5 epitope identified as EP6, EP7, or EP8, wherein EP6 comprises the amino acids KTKQWCDML (SEQ ID NO: 70), wherein EP7 comprises the amino acids GCDLLINR (SEQ ID NO: 71), and wherein EP8 comprises the amino acids TCTQPGGR (SEQ ID NO: 72). In certain aspects, the at least one epitope has an amino acid sequence that is at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to EP6, EP7, or EP8. In certain aspects, an anti-FAM19A5 antibody, or an antigen-binding portion thereof, binds only to EP6, EP7, or EP8. In certain aspects, an anti-FAM19A5 antibody, or an antigen-binding portion thereof, binds to EP6, EP7, and EP8. In certain aspects, an anti-FAM19A5 antibody, or an antigen-binding portion thereof, binds to EP7 and EP8. In certain aspects, the anti-FAM19A5 antibody, or antigen-binding portion thereof, binds EP7.
[0197] In certain aspects, the anti-FAM19A5 antibody, or antigen binding portion thereof, binds one or more FAM19A5 epitopes selected from the group consisting of SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, and any combination thereof.
[0198] In some aspects, provided herein are antibodies or their antigen-binding portions thereof that bind to FAM19A5 (e.g., people FAM19A5) with an affinity 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more higher than that of another protein in the FAM19A family, the affinity being measured by, for example, immunoassay (e.g., ELISA), surface plasmon resonance, or kinetic exclusion assays. In a specific aspect, provided herein are antibodies or their antigen-binding portions that bind to FAM19A5 (e.g., people FAM19A5) and have no cross-reactivity with another protein in the FAM19A family (e.g., immunoassay).
[0199] In certain aspects, the anti-FAM19A5 antibody is not a natural antibody, or is not a naturally occurring antibody. For example, the anti-FAM19A5 antibody has different post-translational modifications than naturally occurring antibodies (e.g., by having more, fewer, or different types of post-translational modifications).
[0200] IV. Exemplary Anti-FAM19A5 Antibodies
[0201] Specific antibodies that can be used in the methods disclosed herein are antibodies, such as monoclonal antibodies, having CDR and / or variable region sequences disclosed herein, as well as antibodies having at least 80% identity (e.g., at least 85%, at least 90%, at least 95%, or at least 99% identity) to their variable region or CDR sequences. Tables 2 and 3 provide the amino acid sequences of the VH and VL CDRs of different anti-FAM19A5 antibodies, respectively. The CDRs of the following antibodies were identified using the Kabat numbering scheme (see above): 1-65, 3-2, 2-13, 1-28, P2-C12, 13B4, 13F7, 15A9, P1-A03, P1-A08, P1-F02, P2-A01, P2-A03, P2-F07, P2-F11, SS01-13, SS01-13-s5, and S5-2.GKNG. The CDRs of the following antibodies were identified using the IMGT numbering system (see above): 1-7A-IT, PI low, 1-30, 1-17, 1-32, 4-11, 6-10, 2-13D, 2-13D-37, 2-13D-37-1.5W-41, and 2-13D-37-3W-16. Tables 4 and 5 provide the VH and VL amino acid sequences of various anti-FAM19A5 antibodies of the present disclosure, respectively.
[0202] Table 2 Variable heavy chain CDR amino acid sequence (according to Kabat system)
[0203]
[0204]
[0205] Table 3 Variable light chain CDR amino acid sequence (according to the Kabat system)
[0206]
[0207]
[0208] Table 4: Variable heavy chain amino acid sequences
[0209]
[0210]
[0211]
[0212] Table 5: Variable light chain amino acid sequences
[0213]
[0214]
[0215] Thus, provided herein are isolated anti-FAM19A5 antibodies or antigen-binding portions thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NOs: 35-38, 155-165, or 232-240 (see Table 4). In other aspects, the isolated anti-FAM19A5 antibodies or antigen-binding portions thereof comprise a heavy chain variable region CDR selected from the group consisting of SEQ ID NOs: 35-38, 155-165, or 232-240 (see Table 4).
[0216] Also provided herein are isolated anti-FAM19A5 antibodies or antigen-binding portions thereof comprising a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NOs: 39-42, 166-176, or 241-250 (see Table 5). In other aspects, the isolated anti-FAM19A5 antibodies or antigen-binding portions thereof comprise a light chain variable region CDR selected from the group consisting of SEQ ID NOs: 39-42, 166-176, or 241-250.
[0217] In certain aspects, the isolated anti-FAM19A5 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region CDR selected from the group consisting of SEQ ID NOs: 35-38, 155-165, or 232-240, and a light chain variable region CDR selected from the group consisting of SEQ ID NOs: 39-42, 166-176, or 241-250.
[0218] Also provided herein are isolated anti-FAM19A5 antibodies, or antigen-binding portions thereof, comprising a heavy chain variable region and a light chain variable region, (i) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 35, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39; (ii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 40; (iii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 37, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 41; (iv) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 38, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 42; (v) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 155, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 166; (vi) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: NO: 156, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 167; (vii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 157, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 168; (viii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 158, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 169; (ix) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 159, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 170; (x) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 160, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 171; (xi) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 161, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 172; (xii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: NO: 162, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 173; (xiii) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 163, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 174; (xiv) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 164, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 175;and (xv) wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 165, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 176. In certain aspects, the isolated anti-FAM19A5 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the VH sequence listed in Table 4, and VL comprises the VL sequence listed in Table 5. ;
[0219] Provided herein are isolated anti-FAM19A5 antibodies, or antigen-binding portions thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NOs: 35-38, 155-165, or 232-240 (see Table 4).
[0220] Also provided herein are isolated anti-FAM19A5 antibodies, or antigen-binding portions thereof, comprising a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NOs: 39-42, 166-176, or 232-240 (see Table 5).
[0221] Also provided are isolated anti-FAM19A5 antibodies, or antigen-binding portions thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NOs: 35-38, 155-165, or 232-240 (see Table 4), and wherein the light chain variable region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NOs: 39-42, 166-176, or 241-250 (see Table 5).
[0222] In certain aspects, the present disclosure provides an isolated anti-FAM19A5 antibody, or antigen-binding portion thereof, comprising:
[0223] (a) heavy and light chain variable region sequences comprising SEQ ID NOs: 35 and 39, respectively;
[0224] (b) heavy and light chain variable region sequences comprising SEQ ID NOs: 36 and 40, respectively;
[0225] (c) heavy and light chain variable region sequences comprising SEQ ID NOs: 37 and 41, respectively;
[0226] (d) heavy and light chain variable region sequences comprising SEQ ID NOs: 38 and 42, respectively;
[0227] (e) heavy and light chain variable region sequences comprising SEQ ID NOs: 155 and 166, respectively;
[0228] (f) heavy and light chain variable region sequences comprising SEQ ID NOs: 156 and 167, respectively;
[0229] (g) heavy and light chain variable region sequences comprising SEQ ID NOs: 157 and 168, respectively;
[0230] (h) heavy and light chain variable region sequences comprising SEQ ID NOs: 158 and 169, respectively;
[0231] (i) heavy and light chain variable region sequences comprising SEQ ID NOs: 159 and 170, respectively;
[0232] (j) heavy and light chain variable region sequences comprising SEQ ID NOs: 160 and 171, respectively;
[0233] (k) heavy and light chain variable region sequences comprising SEQ ID NOs: 161 and 172, respectively;
[0234] (l)) comprising the heavy and light chain variable region sequences of SEQ ID NOs: 162 and 173, respectively;
[0235] (m) heavy and light chain variable region sequences comprising SEQ ID NOs: 163 and 174, respectively;
[0236] (n) heavy and light chain variable region sequences comprising SEQ ID NOs: 164 and 175, respectively;
[0237] (o) heavy and light chain variable region sequences comprising SEQ ID NOs: 165 and 176, respectively;
[0238] (p) heavy and light chain variable region sequences comprising SEQ ID NOs: 232 and 241, respectively;
[0239] (q) heavy and light chain variable region sequences comprising SEQ ID NOs: 233 and 242, respectively;
[0240] (r) heavy and light chain variable region sequences comprising SEQ ID NOs: 234 and 242, respectively;
[0241] (s) heavy and light chain variable region sequences comprising SEQ ID NOs: 235 and 243, respectively;
[0242] (t) heavy and light chain variable region sequences comprising SEQ ID NOs: 236 and 244, respectively;
[0243] (u) heavy and light chain variable region sequences comprising SEQ ID NOs: 236 and 245, respectively;
[0244] (v) heavy and light chain variable region sequences comprising SEQ ID NOs: 236 and 246, respectively;
[0245] (w) heavy and light chain variable region sequences comprising SEQ ID NOs: 236 and 247, respectively;
[0246] (x) heavy and light chain variable region sequences comprising SEQ ID NOs: 236 and 248, respectively;
[0247] (y) heavy and light chain variable region sequences comprising SEQ ID NOs: 236 and 249, respectively;
[0248] (z) heavy and light chain variable region sequences comprising SEQ ID NOs: 237 and 250, respectively;
[0249] (aa) heavy and light chain variable region sequences comprising SEQ ID NOs: 238 and 250, respectively;
[0250] (bb) heavy and light chain variable region sequences comprising SEQ ID NOs: 239 and 250, respectively; or
[0251] (cc) Heavy and light chain variable region sequences comprising SEQ ID NOs: 240 and 250, respectively.
[0252] In certain aspects, the anti-FAM19A5 antibodies of the present disclosure, or antigen-binding portions thereof, comprise (i) 2-13 heavy chain CDR1s, CDR2s, and CDR3s, or combinations thereof, and / or 2-13 light chain CDR1s, CDR2s, and CDR3s, or any combination thereof; (ii) 3-2 heavy chain CDR1s, CDR2s, and CDR3s, or combinations thereof, and / or 3-2 light chain CDR1s, CDR2s, and CDR3s, or any combination thereof; (iii) 1-65 heavy chain CDR1s, CDR2s, and CDR3s, or combinations thereof, and / or 1-65 light chain CDR1s, CDR2s, and CDR3s, or any combination thereof; (iv) 1-28 heavy chain CDR1s, CDR2s, and CDR3s, or combinations thereof, and / or 1 -28, or any combination thereof; (v) the heavy chain CDR1, CDR2, and CDR3, or any combination thereof, of P2-C12, and / or the light chain CDR1, CDR2, and CDR3, or any combination thereof, of P2-C12; (vi) the heavy chain CDR1, CDR2, and CDR3, or any combination thereof, of 13B4, and / or the light chain CDR1, CDR2, and CDR3, or any combination thereof, of 13B4; (vii) the heavy chain CDR1, CDR2, and CDR3, or any combination thereof, of 13F7, and / or the light chain CDR1, CDR2, and CDR3, or any combination thereof, of 13F7; (viii) the heavy chain CDR1, CDR2, and CDR3, or any combination thereof, of 15A9. , and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of 15A9; (ix) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of P1-A03, and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of P1-A03; (x) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of P1-A08, and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of P1-A08; (xi) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of P1-F02, and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of P1-F02; (xii) the heavy chain CDR1, CDR2 and CDR3 of P2-A01, (xiii) the heavy chain CDR1, CDR2, and CDR3 of P2-A03 or a combination thereof, and / or the light chain CDR1, CDR2, and CDR3 of P2-A03 or any combination thereof; (xiv) the heavy chain CDR1, CDR2, and CDR3 of P2-F07 or a combination thereof, and / or the light chain CDR1, CDR2, and CDR3 of P2-F07 or any combination thereof; (xv) the heavy chain CDR1, CDR2, and CDR3 of P2-F11 or a combination thereof, and / or the light chain CDR1, CDR2, and CDR3 of P2-F11 or any combination thereof;(xvi) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of SS01-13, and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of SS01-13; (xvii) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of SS01-13-s5, and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of SS01-13-s5; (xviii) the heavy chain CDR1, CDR2 and CDR3 or any combination thereof of S5-2.GKNG, and / or the light chain CDR1, CDR2 and CDR3 or any combination thereof of S5-2.GKNG; (xix) heavy chain CDR1, CDR2 and CDR3 or any combination thereof of 1-7A-IT, and / or light chain CDR1, CDR2 and CDR3 or any combination thereof of 1-7A-IT; (xx) heavy chain CDR1, CDR2 and CDR3 or any combination thereof with a low PI value, and / or light chain CDR1, CDR2 and CDR3 or any combination thereof with a low PI value; (xxi) heavy chain CDR1, CDR2 and CDR3 or any combination thereof of 1-30, and / or light chain CDR1, CDR2 and CDR3 or any combination thereof of 1-30; (xxii) heavy chain CDR1, CDR2 and CDR3 or any combination thereof of 1-17, and / or or light chain CDR1s, CDR2s, and CDR3s of 1-17 or any combination thereof; (xxiii) heavy chain CDR1s, CDR2s, and CDR3s of 1-32 or any combination thereof, and / or light chain CDR1s, CDR2s, and CDR3s of 1-32 or any combination thereof; (xxiv) heavy chain CDR1s, CDR2s, and CDR3s of 4-11 or any combination thereof, and / or light chain CDR1s, CDR2s, and CDR3s of 4-11 or any combination thereof; (xxv) heavy chain CDR1s, CDR2s, and CDR3s of 6-10 or any combination thereof, and / or light chain CDR1s, CDR2s, and CDR3s of 6-10 or any combination thereof; (xxviii) heavy chain CDR1s, CDR2s, and CDR3s of 1-32 or any combination thereof, and / or light chain CDR1s, CDR2s, and CDR3s of 1-32 or any combination thereof; (xxiv) heavy chain CDR1s, CDR2s, and CDR3s of 4-11 or any combination thereof, and / or light chain CDR1s, CDR2s, and CDR3s of 4-11 or any combination thereof; (xxviii) heavy chain CDR1s, CDR2s, and CDR3s of 6-10 or any combination thereof, and / or light chain CDR1s, CDR2s, and CDR3s of 6-10 or any combination thereof; (xxviv) i) the heavy chain CDR1, CDR2, and CDR3, or any combination thereof, of 2-13D, and / or the light chain CDR1, CDR2, and CDR3, or any combination thereof, of 2-13D; (xxvii) the heavy chain CDR1, CDR2, and CDR3, or any combination thereof, of 2-13D-37, and / or the light chain CDR1, CDR2, and CDR3, or any combination thereof, of 2-13D-37; (xxviii) the heavy chain CDR1, CDR2, and CDR3, or any combination thereof, of 2-13D-37-1.5W-41, and / or the light chain CDR1, CDR2, and CDR3, or any combination thereof, of 2-13D-37-1.5W-41;or (xxiv) the heavy chain CDR1, CDR2, and CDR3 of 2-13D-37-3W-16, or any combination thereof, and / or the light chain CDR1, CDR2, and CDR3 of 2-13D-37-3W-16, or any combination thereof. Table 2 provides the amino acid sequences of the VH CDR1, CDR2, and CDR3 of various anti-FAM19A5 antibodies disclosed herein. Table 3 provides the amino acid sequences of the VLC DDR1, CDR2, and CDR3 of various anti-FAM19A5 antibodies disclosed herein.
[0253] In certain aspects, an anti-FAM19A5 antibody of the disclosure, or an antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0254] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 11; and / or
[0255] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 12; and / or
[0256] (c) VH CDR3 comprising the amino acid sequence of SEQ ID NO:13.
[0257] In specific aspects, the antibody, or antigen-binding portion thereof, comprises one, two, or all three of the above-described VHCDRs.
[0258] In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0259] (a) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 23; and / or
[0260] (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and / or
[0261] (c) VL CDR3 comprising the amino acid sequence of SEQ ID NO:25.
[0262] In specific aspects, the antibody, or antigen-binding portion thereof, comprises one, two, or all three of the above-described VL CDRs.
[0263] In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0264] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 11;
[0265] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 12;
[0266] (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 13;
[0267] (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 23;
[0268] (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and / or
[0269] (f) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 25.
[0270] In certain aspects, an anti-FAM19A5 antibody of the disclosure, or an antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0271] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 14; and / or
[0272] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15; and / or
[0273] (c) VH CDR3 comprising the amino acid sequence of SEQ ID NO:16.
[0274] In specific aspects, the antibody, or antigen-binding portion thereof, comprises one, two, or all three of the above-described VH CDRs.
[0275] In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0276] (a) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 26; and / or
[0277] (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 27; and / or
[0278] (c) VL CDR3 comprising the amino acid sequence of SEQ ID NO:28.
[0279] In specific aspects, the antibody, or antigen-binding portion thereof, comprises one, two, or all three of the above-described VL CDRs.
[0280] In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0281] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 14;
[0282] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
[0283] (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 16;
[0284] (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 26;
[0285] (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 27; and / or
[0286] (f) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 28.
[0287] In certain aspects, an anti-FAM19A5 antibody of the disclosure, or an antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0288] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 17; and / or
[0289] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 18; and / or
[0290] (c) VH CDR3 comprising the amino acid sequence of SEQ ID NO: 19.
[0291] In specific aspects, the antibody, or antigen-binding portion thereof, comprises one, two, or all three of the above-described VH CDRs.
[0292] In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0293] (a) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 29; and / or
[0294] (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 30; and / or
[0295] (c) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 31.
[0296] In specific aspects, the antibody, or antigen-binding portion thereof, comprises one, two, or all three of the above-described VL CDRs.
[0297] In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0298] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 17;
[0299] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 18;
[0300] (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 19;
[0301] (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 29;
[0302] (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 30; and / or
[0303] (f) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 31.
[0304] In certain aspects, an anti-FAM19A5 antibody of the disclosure, or an antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0305] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 20; and / or
[0306] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 21; and / or
[0307] (c) VH CDR3 comprising the amino acid sequence of SEQ ID NO:22.
[0308] In specific aspects, the antibody, or antigen-binding portion thereof, comprises one, two, or all three of the above-described VH CDRs.
[0309] In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0310] (a) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 32; and / or
[0311] (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 33; and / or
[0312] (c) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 34.
[0313] In specific aspects, the antibody, or antigen-binding portion thereof, comprises one, two, or all three of the above-described VL CDRs.
[0314] In certain aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, that specifically binds human FAM19A5 comprises:
[0315] (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 20;
[0316] (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 21;
[0317] (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 22;
[0318] (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 32;
[0319] (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 33; and / or
[0320] (f) VL CDR3 comprising the amino acid sequence of SEQ ID NO: 34.
[0321] In specific aspects, an anti-FAM19A5 antibody, or antigen-binding portion thereof, comprises one, two, three, four, five, or six of the above-mentioned CDRs.
[0322] The VH domains described herein, or one or more CDRs thereof, can be linked to a constant domain to form a heavy chain, such as a full-length heavy chain. Similarly, the VL domains described herein, or one or more CDRs thereof, can be linked to a constant domain to form a light chain, such as a full-length light chain. The full-length heavy chain and the full-length light chain are combined to form a full-length antibody.
[0323] Therefore, in a specific aspect, the present invention provides an antibody comprising an antibody light chain and a heavy chain (e.g., a separate light chain and a heavy chain). Regarding the light chain, in a specific aspect, the light chain of the antibody described herein is a kappa light chain. In another specific aspect, the light chain of the antibody described herein is a lambda light chain. In another specific aspect, the light chain of the antibody described herein is a human kappa light chain or a human lambda light chain. In a specific embodiment, the antibody described herein that specifically binds to a FAM19A5 polypeptide (e.g., human FAM19A5) includes a light chain comprising any VL or VLCDR amino acid sequence described herein, and the constant region of the light chain includes the amino acid sequence of a human kappa light chain constant region. In a specific aspect, the antibody described herein that specifically binds to a FAM19A5 polypeptide (e.g., human FAM19A5) includes a light chain comprising a VL or VLCDR amino acid sequence described herein, wherein the constant region of the light chain includes the amino acid sequence of a human lambda light chain constant region. Non-limiting examples of human constant region sequences are described in the art, eg, see US Pat. No. 5,693,780 and Kabat EA et al. (1991) supra.
[0324] With regard to the heavy chain, in certain aspects, the heavy chain of the antibody described herein can be an α (a), δ (d), ε (e), γ (g) or μ (m) heavy chain. In another specific aspect, the heavy chain of the antibody may include a human α (a), δ (d), ε (e), γ (g) or μ (m) heavy chain. In one aspect, the antibody described herein that specifically binds to FAM19A5 (e.g., human FAM19A5) includes a heavy chain comprising a VH or VHCDR amino acid sequence as described herein, wherein the constant region of the heavy chain includes the amino acid sequence of a human γ (g) heavy chain constant region. In another embodiment, the antibody described herein that specifically binds to FAM19A5 (e.g., human FAM19A5) includes a heavy chain comprising a VH or VHCDR amino acid sequence disclosed herein, wherein the constant region of the heavy chain includes the amino acids of a human heavy chain described herein or known in the art. Non-limiting examples of human constant region sequences are described in the art, eg, see US Pat. No. 5,693,780 and Kabat EA et al. (1991) supra.
[0325] In certain aspects, antibodies described herein that specifically bind to FAM19A5 (e.g., human FAM19A5) include a VL domain and a VH domain, including VH or VHCDR and VL and VLCDR as described herein, wherein the constant region includes the amino acid sequence of the constant region of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule or human IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule. In another specific aspect, antibodies described herein that specifically bind to FAM19A5 (e.g., human FAM19A5) include a VL domain and a VH domain, including any amino acid sequence described herein, wherein the constant region includes the amino acid sequence of the constant region of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule, any subclass of immunoglobulin molecule (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2). In certain aspects, the constant region comprises the amino acid sequence of a naturally occurring human IgG constant region, including subclasses (e.g., IgG1, IgG2, IgG3, or IgG4) and allotypes (e.g., G1m, G2m, G3m, and nG4m) and variants thereof. For example, see Vidarsson G et al., Front Immunol. 5:520 (published online on October 20, 2014) and Jefferis R. and Lefranc MP, Monoclonal Antibodies (mAbs) 1:4, 1-7 (2009). In certain aspects, the constant region comprises the amino acid sequence of a constant region of human IgG1, IgG2, IgG3, or IgG4, or variants thereof.
[0326] In certain aspects, the anti-FAM19A5 antibodies disclosed herein, or antigen-binding portions thereof, do not have Fc effector functions, such as complement-dependent cytotoxicity (CDC) and / or antibody-dependent cellular phagocytosis (ADCP). Effector functions are mediated by the Fc region, and the residues closest to the hinge region in the CH2 domain of the Fc region are responsible for the effector functions of the antibody because it contains a large portion of overlapping binding sites for C1q (complement) and IgG-Fc receptors (FcγR) on effector cells of the innate immune system. At the same time, the Fc effector function levels of IgG2 and IgG4 antibodies are lower than those of IgG1 and IgG3 antibodies. Effector functions of antibodies can be reduced or avoided by various methods known in the art, including (1) using antibody fragments lacking an Fc region (e.g., such as Fab, F(ab')2, single-chain Fv (scFv), or sdAbs composed of monomeric VH or VL domains); (2) generating aglycosylated antibodies, which can be generated by, for example, deleting or changing the residues to which sugars are attached, enzymatically removing sugars, producing the antibody in cells cultured in the presence of glycosylation inhibitors, or expressing the antibody in cells that cannot glycosylate proteins (e.g., bacterial host cells, e.g., see U.S. Patent Publication No. 20120100140); (3) employing antibodies from the IgG subclass with reduced effector functions. (4) generating an Fc region having reduced or no Fc function. For example, see U.S. Patent Publication No. 20120100140 and U.S. and PCT applications cited therein and An et al. Monoclonal Antibodies (mAbs) 1: 6,572-579 (2009).
[0327] Thus, in certain aspects, the anti-FAM19A5 antibodies disclosed herein, or antigen-binding portions thereof, are Fab, Fab', F(ab')2, Fv, single-chain Fv (scFv), or sdAbs consisting of monomeric VH or VL domains. Such antibody fragments are well known in the art and are described above.
[0328] In certain aspects, the anti-FAM19A5 antibodies disclosed herein, or antigen-binding portions thereof, comprise an Fc region with reduced or no Fc effector function. In certain aspects, the constant region comprises the amino acid sequence of a human IgG2 or IgG4 Fc region, and in certain aspects, the anti-FAM19A5 antibody is of the IgG2 / IgG4 isotype. In certain aspects, the anti-FAM19A5 antibody comprises a chimeric Fc region comprising a CH2 domain from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, or a chimeric Fc region comprising a hinge region from IgG2 and a CH2 domain from IgG4, or an Fc region with a mutation that results in reduced or no Fc function. Fc regions with reduced or no Fc effector function include Fc regions known in the art. For example, see Lau C. et al., J. Immunol., 191: 4769-4777 (2013); An et al., Monoclonal Antibodies (mAbs), 1: 6,572-579 (2009); and U.S. Patent Publication No. 20120100140 and the U.S. patents and publications and PCT publications cited therein. One of ordinary skill in the art can also readily prepare an Fc region with reduced or no Fc effector function.
[0329] V. Nucleic Acid Molecules
[0330] Another aspect described herein relates to one or more nucleic acid molecules encoding any one of the antibodies described herein or its antigen-binding portion thereof. Nucleic acid can exist in the form of intact cells, cell lysates or partially purified or substantially purified. When separated from other cellular components or other contaminants (such as other cellular nucleic acids (such as other chromosomal DNA, such as chromosomal DNA connected to naturally isolated DNA) or protein purification using standard techniques (including alkali / SDS treatment, CsCl banding, column chromatography, restriction enzymes, agarose gel electrophoresis and other technologies well known in the art), nucleic acid is "isolated" or "substantially purified". See F.Ausubel et al., eds., (1987) Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York. Nucleic acid as described herein can be, for example, DNA or RNA, and can contain or not contain intron sequences. In some aspects, nucleic acid is a cDNA molecule.
[0331] Nucleic acids as described herein can be obtained using standard molecular biology techniques. For antibodies expressed by hybridomas (e.g., hybridomas prepared from transgenic mice carrying human immunoglobulin genes as further described below), cDNA encoding the light and heavy chains of the antibodies prepared by the hybridomas can be obtained by standard PCR amplification or cDNA cloning techniques. For antibodies obtained from immunoglobulin gene libraries (e.g., using phage display technology), nucleic acids encoding the antibodies can be recovered from the libraries.
[0332] Certain nucleic acid molecules described herein are nucleic acid molecules that encode the VH and VL sequences of various anti-FAM19A5 antibodies disclosed herein. Exemplary DNA sequences encoding the VH sequences of such antibodies are listed in SEQ ID NOs: 43-46 and 177. Exemplary DNA sequences encoding the VL sequences of such antibodies are listed in SEQ ID NOs: 47-50 and 178.
[0333] Table 6: Variable heavy chain polynucleotide sequences
[0334]
[0335]
[0336]
[0337] Table 7: Variable light chain polynucleotide sequences
[0338]
[0339]
[0340]
[0341]
[0342] A method for producing an anti-FAM19A5 antibody disclosed herein, the method comprising expressing the relevant heavy and light chains of the antibody in a cell line comprising nucleotide sequences encoding the heavy and light chains with signal peptides, e.g., SEQ ID NOs: 43 and 47, SEQ ID NOs: 44 and 48, SEQ ID NOs: 45 and 49, SEQ ID NOs: 46 and 50, SEQ ID NOs: 177 and 178, respectively. Host cells comprising these nucleotide sequences are encompassed herein.
[0343] Once the DNA fragments encoding the VH and VL segments are obtained, these DNA fragments can be further manipulated using standard recombinant DNA techniques, for example, to convert the variable region genes into full-length antibody chain genes, Fab fragment genes, or scFv genes. In these manipulations, the DNA fragment encoding VL or VH is operably linked to another DNA fragment encoding another protein (such as an antibody constant region or a flexible linker peptide). The term "operably linked" as used in this context is intended to mean that the two DNA fragments are connected so that the amino acid sequences encoded by the two DNA fragments remain in frame.
[0344] The isolated DNA encoding the VH region can be converted into a full-length heavy chain gene by operably linking the DNA encoding the VH to another DNA molecule encoding the heavy chain constant region (hinge, CH1, CH2 and / or CH3). In the art, the sequences of human heavy chain constant region genes are known (e.g., see Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.: 91-3242), and DNA fragments comprising these regions can be obtained by standard PCR amplification. The heavy chain constant region can be IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region, such as IgG2 and / or IgG4 constant region. For Fab fragment heavy chain genes, the DNA encoding the VH can be operably linked to another DNA molecule encoding only the heavy chain CH1 constant region.
[0345] By making the DNA encoding VL be operably linked to another DNA molecule encoding the light chain constant region CL, the isolated DNA encoding the VL region can be converted into a full-length light chain gene (and a Fab light chain gene). In the art, it is known that there is a sequence of human light chain constant region gene (for example, see Kabat, EA et al. (1991) "Sequences of Proteins of Immunological Interest" Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.: 91-3242), and by standard PCR amplification, DNA fragments including these regions can be obtained. The light chain constant region can be a kappa or lambda constant region.
[0346] To produce an scFv gene, the DNA fragments encoding VH and VL are operably linked to another fragment encoding a flexible linker peptide (e.g., encoding the amino acid sequence (Gly4-Ser)3), so that the VH and VL sequences can be expressed as a continuous single-chain protein, wherein the VL and VH regions are connected by the flexible linker peptide (e.g., see Bird et al. (1988) Science 242:423-426; Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883; McCafferty et al. (1990) Nature 348:552-554).
[0347] In certain aspects, the present disclosure provides a vector comprising an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or antigen-binding portion thereof. In other aspects, the vector can be used for gene therapy.
[0348] Suitable vectors of the present disclosure include expression vectors, viral vectors and plasmid vectors. In one aspect, the vector is a viral vector.
[0349] As used herein, an expression vector refers to any nucleic acid construct that contains the necessary elements for the transcription and translation of an inserted coding sequence, or in the case of an RNA viral vector, contains the necessary elements for replication and translation when introduced into an appropriate host cell. Expression vectors can include plasmids, phagemids, viruses, and derivatives thereof.
[0350] The expression vectors disclosed herein may include polynucleotides encoding antibodies or antigen-binding portions thereof as described herein. In one aspect, the coding sequence of the antibody or antigen-binding portion thereof is operably linked to an expression control sequence. When two nucleic acid sequences used herein are covalently linked so that each constituent nucleic acid sequence retains its functionality, the two nucleic acid sequences are operably linked. When a coding sequence and a gene expression control sequence are covalently linked so that the expression or transcription and / or translation of the coding sequence is under the influence or control of the gene expression control sequence, it is said to be operably linked. If a promoter is induced in the 5' gene expression sequence, resulting in transcription of the coding sequence, and if the nature of the connection between the two DNA sequences does not (1) result in the introduction of a frameshift mutation, (2) interfere with the ability of the promoter region to direct transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into protein, then the two DNA sequences can be said to be operably linked. Therefore, if the gene expression sequence is able to affect the transcription of the coding nucleic acid sequence so that the transcript produced thereby is translated into the desired antibody or antigen-binding portion thereof, then the gene expression sequence will be operably linked to the coding nucleic acid sequence.
[0351] Viral vectors include, but are not limited to, nucleic acid sequences from the following viruses: retroviruses, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, mouse mammary tumor virus, and Rous sarcoma virus; lentiviruses; adenoviruses; adeno-associated viruses; SV40 virus; polyomavirus; Epstein-Barr virus; papillomavirus; herpes virus; vaccinia virus; poliovirus; and RNA viruses, such as retroviruses. Other vectors known in the art are readily available. Certain viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with target genes. Non-cytopathic viruses include retroviruses, whose life cycle includes reverse transcription of genomic viral RNA into DNA, followed by proviral integration into host cell DNA. Retroviruses have been approved for use in human gene therapy trials. The most useful retroviruses are replication-defective (i.e., capable of directing the synthesis of the desired protein but unable to produce infectious particles) retroviruses. This type of genetically modified retroviral expression vector has the general utility of efficient gene transduction in vivo. Standard protocols for producing replication-defective retroviruses (comprising the steps of incorporating foreign genetic material into a plasmid, transfecting a packaging cell line with the plasmid, producing recombinant retroviruses by the packaging cell line, collecting viral particles from tissue culture medium, and infecting target cells with the viral particles) are provided in Kriegler, M., Gene Transfer and Expression, A Laboratory Manual, WH Freeman Co., New York (1990) and Murry, EJ, Methods in Molecular Biology, Vol. 7, Humana Press, Inc., Cliffton, New Jersey (1991).
[0352] In one aspect, the virus is an adeno-associated virus, a double-stranded DNA virus. Adeno-associated virus can be designed as a replication-defective virus and can infect a wide range of cell types and species. It also has advantages such as thermal stability and lipid solvent stability; high transduction frequency in cells of different lineages, including hematopoietic cells; and lack of superinfection inhibition, thereby allowing multiple series of transductions. It has been reported that adeno-associated virus can be integrated into human cell DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and the variability of inserted gene expression characteristics of retroviral infection. In addition, in the absence of selective pressure, wild-type adeno-associated virus infection has been tracked in tissue culture for more than 100 generations, which means that adeno-associated virus genome integration is a relatively stable event. Adeno-associated virus can also act in an extrachromosomal manner.
[0353] In other aspects, the vector is derived from a lentivirus. In certain aspects, the vector is a recombinant lentiviral vector capable of infecting non-dividing cells.
[0354] Typically, the lentiviral genome and proviral DNA have three genes found in retroviruses: gag, pol, and env, flanked by two long terminal repeat (LTR) sequences. The gag gene encodes the internal structural (matrix, capsid, and nucleocapsid) proteins; the pol gene encodes the RNA-guided DNA polymerase (reverse transcriptase), protease, and integrase; and the env gene encodes the viral envelope glycoproteins. The 5' and 3' LTRs serve to promote transcription and polyadenylation of the virion RNA. The LTRs contain all other cis-acting sequences necessary for viral replication. Lentiviruses have additional genes, including vif, vpr, tat, rev, vpu, nef, and vpx (in HIV-1, HIV-2, and / or SIV).
[0355] Adjacent to the 5' LTR are sequences necessary for reverse transcription of the genome (tRNA primer binding site) and efficient encapsidation of viral RNA to form particles (Psi site). If the viral genome is missing sequences necessary for encapsidation (or packaging of retroviral RNA into infectious virions), the cis defect will prevent encapsidation of the genomic RNA.
[0356] However, the mutants thus obtained are still able to direct the synthesis of all virion proteins. The present disclosure provides a method for producing a recombinant lentivirus capable of infecting non-dividing cells, comprising transfecting suitable host cells with two or more vectors carrying packaging functions, namely gag, pol and env, as well as rev and tat. According to the content to be disclosed below, in certain applications, a vector lacking a functional tat gene is required. Thus, for example, a first vector can provide nucleic acids encoding viral gag and viral pol, and another vector can provide nucleic acids encoding viral env to produce packaging cells. A vector providing a heterologous gene (herein referred to as a transfer vector) is introduced into packaging cells to produce production cells, which release infectious viral particles carrying the target exogenous gene.
[0357] According to the configuration of the vector and foreign gene pointed out above, the second vector can provide nucleic acid encoding viral envelope (env) gene. The env gene can be derived from almost any suitable virus, including retrovirus. In some aspects, env protein is a dual-tropic envelope protein, allowing cell transduction of humans and other species.
[0358] Examples of env genes derived from retroviruses include, but are not limited to, Moloney murine leukemia virus (MoMuLV or MMLV), Harvey murine sarcoma virus (HaMuSV or HSV), mouse mammary tumor virus (MuMTV or MMTV), Gibbon ape leukemia virus (GaLV or GALV), human immunodeficiency virus (HIV), and Rous sarcoma virus (RSV). Other env genes may also be used, such as vesicular stomatitis virus (VSV) protein G (VSVG), as well as env genes from hepatitis viruses and influenza viruses.
[0359] The vector providing the viral env nucleic acid sequence is operably associated with the regulatory sequences described in other paragraphs herein.
[0360] In certain aspects, the vector comprises a lentiviral vector in which the HIV virulence genes env, vif, vpr, vpu, and nef are deleted without compromising the ability of the vector to transduce non-dividing cells.
[0361] In certain aspects, the vector comprises a lentiviral vector comprising a U3 region deletion of the 3' LTR. The U3 region deletion can be a complete deletion or a partial deletion.
[0362] In certain aspects, a lentiviral vector of the present disclosure comprising a FVIII nucleotide sequence described herein can be transfected into a cell using (a) a first nucleotide sequence comprising gag, pol, or gag and pol genes and (b) a second nucleotide sequence comprising a heterologous env gene; wherein the lentiviral vector lacks a functional tat gene. In other aspects, the cell is further transfected using a fourth nucleotide sequence comprising a rev gene. In certain aspects, the lentiviral vector lacks a functional gene selected from vif, vpr, vpu, vpx, and nef, or a combination thereof.
[0363] In certain aspects, the lentiviral vector comprises one or more nucleotide sequences encoding a gag protein, a Rev-responsive element, a central polypurine tract (cPPT), or any combination thereof.
[0364] Examples of lentiviral vectors are disclosed in WO9931251, WO9712622, WO9817815, WO9817816, and WO9818934, which are incorporated herein by reference in their entirety.
[0365] Other vectors include plasmid vectors. In the art, plasmid vectors are widely described and are well known to those skilled in the art. For example, see Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 1989. Studies in the past few years have found that because plasmid vectors cannot replicate and integrate into the host genome, plasmid vectors are particularly advantageous for in vivo delivery of genes to cells. However, these plasmids have promoters that are compatible with host cells and can express peptides from operable coding genes within the plasmid. Some commonly used plasmids are available from commercial suppliers, including pBR322, pUC18, pUC19, various pcDNA plasmids, pRC / CMV, various pCMV plasmids, pSV40, and pBlue Script. Other examples of specific plasmids include pcDNA3.1, catalog number V79020; pcDNA3.1 / hygro, catalog number V87020; pcDNA4 / myc-His, catalog number V86320; and pBudCE4.1, catalog number V53220, all from Invitrogen (Carlsbad, CA). Those of ordinary skill in the art are familiar with other plasmids. In addition, plasmids can be custom designed using standard molecular biology techniques to remove and / or add specific DNA segments.
[0366] VI. Antibody Production
[0367] Antibodies or fragments thereof that immunospecifically bind to FAM19A5 (e.g., human FAM19A5) can be produced by any antibody synthesis method known in the art, such as chemical synthesis or recombinant expression techniques. Unless otherwise indicated, the methods described herein utilize conventional techniques in molecular biology, microbiology, genetic analysis, recombinant DNA, organic chemistry, biochemistry, PCR, oligonucleotide synthesis and modification, nucleic acid hybridization, and related fields of the art. For example, these techniques are described in the references cited herein and are fully explained in the literature. See, for example, Maniatis T et al., 1982 Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; Sambrook J et al., (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press; Sambrook J et al., (2001) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA; Ausubel FM et al., Current Protocols in Molecular Biology, John Wiley & Sons (1987 and annual updates); Current Protocols in Immunology, John Wiley & Sons (1987 and annual updates); Gait (ed.) (1984) Oligonucleotide Synthesis: A Practical Method. Eckstein (ed.) (1991) Oligonucleotides and Analogues: A Practical Approach, IRL Press; Birren B et al. (eds.) (1999) Genome Analysis: A Laboratory Manual, Cold Spring Harbor Laboratory Press.
[0368] In a specific aspect, an antibody as described herein refers to an antibody (e.g., a recombinant antibody) that is prepared, expressed, generated, or isolated by any method involving production, such as by synthesis, genetic engineering of a DNA sequence, etc. In certain aspects, such an antibody comprises a sequence (e.g., a DNA sequence or an amino acid sequence) that does not naturally occur within the repertoire of antibodies in an animal or mammal (e.g., a human).
[0369] VII. Pharmaceutical Compositions
[0370] Provided herein are compositions comprising the antibodies or antigen-binding portions thereof described herein of the desired purity in a physiologically acceptable carrier, excipient, or stabilizer (Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, Pennsylvania, USA). Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride, benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol, or benzyl alcohol; alkyl parabens such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; m-cresol); low molecular weight ( less than about 10 residues); polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., zinc-protein complexes); and / or nonionic surfactants such as TWEEN®. TM 、PLURONICS TM or polyethylene glycol (PEG).
[0371] In certain aspects, the pharmaceutical composition comprises an antibody, or antigen-binding portion thereof, bispecific molecule, or immunoconjugate as described herein, in a pharmaceutically acceptable carrier, and optionally one or more additional prophylactic or therapeutic agents. In certain aspects, the pharmaceutical composition comprises an effective amount of an antibody, or antigen-binding portion thereof, as described herein, and optionally one or more additional prophylactic or therapeutic agents, in a pharmaceutically acceptable carrier. In certain aspects, the antibody is the sole active ingredient contained in the pharmaceutical composition. The pharmaceutical compositions described herein can be used to reduce FAM19A5 activity, thereby treating ocular diseases, disorders, or conditions, such as glaucoma.
[0372] Pharmaceutically acceptable carriers for parenteral formulations include aqueous vehicles, non-aqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifiers, polyvalent or chelating agents, and other pharmaceutically acceptable substances. Examples of aqueous vehicles include sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose, and lactated Ringer's injection. Non-aqueous parenteral vehicles include plant-derived fixed oils, cottonseed oil, corn oil, sesame oil, and peanut oil. Antimicrobial agents at bacteriostatic or fungistatic concentrations may be added to parenteral formulations packaged in multidose containers. These antimicrobial agents include phenol or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl parahydroxybenzoates, thimerosal, benzalkonium chloride, and benzethonium chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphates and citrates. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinyl pyrrolidone. Emulsifiers include polysorbate 80 ( 80). Polyvalent metal ion binders or chelators include EDTA. Pharmaceutical carriers also include ethanol, polyethylene glycol, and propylene glycol for water-miscible vehicles; and sodium hydroxide, hydrochloric acid, citric acid, or lactic acid for pH adjustment.
[0373] The pharmaceutical compositions disclosed herein can be formulated for administration to any individual. In certain aspects, the pharmaceutical compositions disclosed herein can be delivered via any route, including to intraocular locations such as the subfascial, subconjunctival, suprachoroidal, and intravitreal spaces. In certain aspects, the pharmaceutical compositions disclosed herein are delivered to an individual via ocular administration. In certain aspects, intraocular administration includes intravitreal administration. Parenteral administration is also contemplated herein, including subcutaneous, intramuscular, or intravenous injection. Injections can be prepared in conventional forms, either as liquid solutions, suspensions, solid forms suitable for dissolution or suspension in liquids prior to injection, or emulsions. Injections, solutions, and emulsions also contain one or more excipients. For example, suitable excipients include water, saline, dextrose, glycerol, or ethanol. In addition, if desired, the pharmaceutical composition to be administered may also contain small amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, pH buffers, stabilizers, solubilizing agents, and the like, for example, sodium acetate, sorbitan laurate, triethanolamine oleate, and cyclodextrins.
[0374] Preparations for parenteral administration of antibodies include sterile solutions ready for injection, sterile dry soluble products (such as lyophilized powders) ready for combination with a solvent before use, including subcutaneous injection tablets, sterile suspensions ready for injection, sterile dry insoluble products ready for combination with a vehicle before use, and sterile emulsions. The solution can be either an aqueous solution or a non-aqueous solution.
[0375] If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents such as glucose, polyethylene glycol, and polypropylene glycol, and mixtures thereof.
[0376] Topical mixtures comprising antibodies for topical and systemic administration are prepared according to the described procedures. The mixtures thus obtained may be solutions, suspensions, emulsions, etc., and may be formulated into creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, rinses, sprays, suppositories, bandages, skin patches, or any other formulations suitable for topical administration.
[0377] The antibodies or antigen-binding portions thereof described herein can be formulated as a topical aerosol for administration, for example, by inhalation (e.g., see U.S. Patent Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivering steroids useful for treating inflammatory diseases, particularly asthma). These formulations for respiratory administration can be in the form of aerosols or solutions for nebulizers, or as finely divided powders for insufflation (alone or in combination with an inert carrier such as lactose). In this case, in one aspect, the formulation particles are less than 50 microns in diameter, and in one aspect, the formulation particles are less than 10 microns in diameter.
[0378] The antibodies or antigen-binding portions thereof described herein are formulated for topical or local administration, such as topical administration to the skin and mucous membranes, for example, in the eye, in the form of gels, creams, and lotions, as well as for ocular or intracisternal or intraspinal administration. Topical administration is contemplated for transdermal delivery, as well as for administration to the eye or mucous membranes, or for inhalation therapy. Nasal solutions of the antibodies may also be administered alone or in combination with other pharmaceutically acceptable excipients.
[0379] Those skilled in the art are familiar with transdermal patches, including iontophoretic and electrophoretic devices, which can be used to administer antibodies. For example, such patches are disclosed in U.S. Patent Nos. 6,267,983, 6,261,595, 6,256,533, 6,167,301, 6,024,975, 6,010715, 5,985,317, 5,983,134, 5,948,433, and 5,860,957.
[0380] In certain aspects, pharmaceutical compositions comprising the antibodies or antigen-binding portions thereof described herein are lyophilized powders that can be reconstituted for administration as solutions, emulsions, or other mixtures. They can also be reconstituted and formulated as solids or gels. The lyophilized powder is prepared by dissolving the antibodies or antigen-binding portions thereof described herein, or pharmaceutically acceptable derivatives thereof, in a suitable solvent. In certain aspects, the lyophilized powder is sterile. The solvent may contain excipients to enhance stability or other pharmacological components of the powder or a reconstituted solution prepared from the powder. Excipients that may be used include, but are not limited to, dextrose, sorbitol, fructose, corn syrup, xylitol, glycerol, glucose, sucrose, or other suitable agents. The solvent may also contain a buffer such as citrate, sodium phosphate, or potassium phosphate, or other such buffers known to those skilled in the art, and in one aspect, the pH is approximately neutral. The solution is then sterile filtered and then lyophilized under standard conditions known to those skilled in the art to provide the desired formulation. In one aspect, the resulting solution is dispensed into vials and lyophilized. Each vial will contain a single or multiple doses of the compound. The lyophilized powder can be stored under appropriate conditions, for example, from about 4°C to room temperature.
[0381] The lyophilized powder is reconstituted with water for injection to provide a formulation for parenteral administration. Upon reconstitution, the lyophilized powder is added to sterile water or other suitable carrier. The exact dosage depends on the compound selected and can be determined empirically.
[0382] The antibodies, or antigen-binding portions thereof, bispecific molecules, or immunoconjugates described herein, as well as other compositions provided herein, can also be formulated to target specific tissues, receptors, or other parts of the body of an individual in need of treatment. Those skilled in the art are familiar with many such targeting methods. All such targeting methods for use in the compositions of the present invention are contemplated herein. For non-limiting examples of targeted approaches, see, e.g., U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542, and 5,709,874. In a specific aspect, the anti-FAM19A5 antibodies described herein, or antigen-binding portions thereof, can be used to treat glaucoma and / or reduce, ameliorate, or inhibit glaucoma-associated inflammation.
[0383] Compositions for in vivo administration can be sterile compositions, which can be readily accomplished, for example, by filtration through sterile filtration membranes.
[0384] VIII. Kit
[0385] Provided herein are kits comprising one or more antibodies, or antigen-binding portions thereof, bispecific molecules, or immunoconjugates thereof as described herein. In a specific aspect, provided herein are pharmaceutical packs or kits comprising one or more containers filled with one or more ingredients of a pharmaceutical composition as described herein, such as one or more antibodies, or antigen-binding portions thereof, as provided herein, optionally with instructions for use. As described herein, in certain aspects, the kit comprises a pharmaceutical composition as described herein and any prophylactic or therapeutic agent.
[0386] Example
[0387] Example 1
[0388] Evaluation of retinal potential difference after in vivo administration of anti-FAM19A5 antibody in a diabetic mouse model
[0389] Retinopathy
[0390] To initially evaluate the therapeutic efficacy of anti-FAM19A5 antibodies for diabetic retinopathy, type 2 diabetic db / db mice (B6.BKS(D)-Leprdb / j) (25 weeks old) were selected. Briefly, after the mice were stabilized for one week, they were intravitreally injected with a human IgG control antibody or anti-FAM19A5 antibody (clone 1-65 or 3-2) using a minipump system (7 doses, 4 μg / eye every two weeks). Normal (i.e., non-diabetic wild-type) mice served as controls. Retinal potentials were then assessed using electroretinography (ERG).
[0391] The ERG is a diagnostic test that measures the electrical activity (i.e., retinal potentials) generated by various cells in the retina, including photoreceptors (rods and cones), retinal cells (bipolar and amacrine cells), and ganglion cells. In general, when a bright stimulus flashes, the ERG of a healthy eye will show a complex waveform consisting of an initial negative deflection ("A wave"), followed by a B wave that rises increasingly steeply and peaks increasingly rapidly, i.e., a superimposed high-frequency oscillation called an "oscillatory potential" (OP). The A wave is dominated by the common response of the rods, while the scotopic B wave is dominated by the response of the rod bipolar neurons. The OP is found in the inner plexiform layer, where bipolar cells, amacrine cells, and ganglion cells interact. Wilsey et al., Curr Opin Ophthalmol 27(2): 118-124 (2016). By evaluating these values, the health of the different cells in the retina can be assessed.
[0392] For ERG evaluation of retinal potentials, the pupils of the eyes of the animals in the different treatment groups were dilated and topically treated with 2.5% phenylephrine hydrochloride. The animals were then shaved, anesthetized (using ketamine (80 mg / kg) and xylazine (16 mg / kg), followed by 0.5% procaine hydrochloride), and electrodes were attached to the skin, tail, and cornea. The retinal potential was assessed by flashing white light (0.9 logcdsec / m 2 ) stimulates the retina. When evaluating intraocular electrical activity (i.e., "retinal potential difference") in different animals, the values of A-wave amplitude (from the trough of the A wave to the baseline), B-wave amplitude (from the trough of the A wave to the peak of the B wave), and oscillatory potential (OP) (the amplitude and duration of the small oscillations observed on the rising branch of the B wave) are measured.
[0393] like Figures 1A-1C As shown, mice that received anti-FAM19A5 antibodies (clones 1-65 or 3-2) showed improvements in A-waves, B-waves, and oscillatory potentials compared to mice that received control IgG antibodies. This indicates that animals that received anti-FAM19A5 antibodies had restored normal retinal function.
[0394] Example 2
[0395] Evaluation of morphological changes in diabetic retinopathy mouse models after treatment with anti-FAM19A5 antibodies
[0396] To evaluate whether anti-FAM19A5 antibody treatment leads to changes in retinal morphology, the type 2 diabetic db / db mice of Example 1 were sacrificed and both eyes were removed.
[0397] Once removed, one eye of each animal was placed in 10% neutral formaldehyde for one day. Then, the cornea, lens, and sclera were removed, and the remaining eye tissue was washed five times with distilled water while shaking for 1 hour. After the last wash, the distilled water was removed, and the eye tissue was dissolved in 0.1MTris buffer and incubated in 3% trypsin at 37°C for 2 hours. Next, the retinal blood vessels were separated from the rest of the retinal tissue, attached to a slide, and stained with periodic acid-Schiff (PAS) to evaluate the retinal microvasculature and obtain characteristic markers of early diabetic retinopathy (e.g., pericyte loss and acellular capillary formation).
[0398] The remaining animal eyes were pre-fixed in 4% glutaraldehyde and then in 10% formaldehyde for three days. The eyes were then placed in disposable containers and embedded in paraffin blocks. Frozen tissues were then sectioned and mounted on slides for further analysis. Hematoxylin and eosinophil (H&E), TUNEL assays, and immunohistochemistry (IHC) were performed to analyze vascular congestion, vascular markers (CD31 and VEGF), and retinal cell protection.
[0399] Figure 2A Provided are microscopic images (100x magnification) of representative areas of the retina from animals belonging to the different treatment groups. In mice that received anti-FAM19A5 antibodies (clones 1-65 or 3-2), the endothelial cell to pericyte ratio (E / P ratio) and the frequency and length of acellular capillaries detected were similar to those of normal, healthy animals. Figures 2B-2D In contrast, mice treated with human IgG control antibody had a much higher E / P ratio, indicating pericyte loss. Figure 2B Cell-free capillary formation in human IgG control mice ( Figure 2C ) are also more numerous and the acellular capillaries are longer ( Figure 2D This result indicates that anti-FAM19A5 antibodies can prevent pericyte loss, protect retinal microvasculature, and prevent the formation of acellular capillaries in a model of diabetic retinopathy.
[0400] In addition, if Figure 3 As shown, vascular congestion within the retinal nerve fiber layer of mice treated with anti-FAM19A5 antibodies (bottom two panels) was also greatly reduced compared to mice receiving human IgG control antibodies (top right panel). TUNEL assays showed that apoptotic cells in both the retinal nerve fiber layer and the inner nuclear layer of mice treated with anti-FAM19A5 antibodies were reduced compared to the corresponding layers in the retina of mice treated with human IgG control antibodies. Figure 4 This suggests that anti-FAM19A5 antibodies can protect retinal cells from damage caused by diabetes.
[0401] Finally, if Figure 5 As shown, the nerve fiber layer of mice treated with a human IgG control antibody showed extensive CD31 and VEGF staining, indicating the presence of neovascularization, a sign of advanced diabetic retinopathy. In contrast, mice treated with anti-FAM19A5 antibodies (clones 1-65 or 3-2) showed greatly reduced CD31 and VEGF staining. This result suggests that anti-FAM19A5 antibodies can effectively block neovascularization in diabetic retinopathy models.
[0402] Overall, the above data suggest that anti-FAM19A5 antibodies can improve many potential lesions associated with retinopathy, such as diabetic retinopathy, thereby playing a therapeutic role in the disease.
[0403] Example 3
[0404] Evaluation of the effect of anti-FAMI9A5 antibody on choroidal neovascularization in a mouse model of age-related macular degeneration
[0405] To evaluate the effects of anti-FAM19A5 antibody treatment on age-related macular degeneration (AMD), a mouse model of choroidal neovascularization (CNV) was employed. More specifically, the CNV model is an animal model of wet AMD in humans. Briefly, after one week of stabilization, C57BL / 6 mice were treated with dilated pupils (topical treatment with 2.5% phenylephrine hydrochloride). They were then treated with 2% fluorescein (Sigma) intraperitoneally for vascular staining. Approximately 3-5 minutes after fluorescein injection, the mice were anesthetized and wet AMD-like lesions were induced at four sites on the optic nerve using a Phoenix ophthalmic laser photocoagulation device (240 mW, 70 ms duration). Figure 6. Subsequently, on the day of CNV induction (i.e., day 0), and on days 3 and 7 after CNV induction, mice were given intravitreal injections of either human IgG control antibody or anti-FAM19A5 antibody (4 μg / eye). On day 13 after CNV induction, the extent of choroidal neovascularization was measured using fundus fluorescence angiography (FFA) and the ImageJ program. Corrected total fluorescence (CTF = integrated density - (selected lesion area x mean fluorescence of background reading)) was calculated. Retinal tomography was performed using image-guided optical coherence tomography (OCT) to measure the extent of neovascular lesions. Neovascular lesions were quantified using the ImageJ program.
[0406] like Figure 7A As shown, after CNV induction and before antibody treatment (day 0, left column), the fluorescence intensity observed at four sites exposed to the laser (indicated by arrows) was similar in both treatment groups. However, on day 13 after CNV induction, the CTF values of mice treated with anti-FAM19A5 antibody were statistically lower than those of mice treated with human IgG control antibody. Figure 7B . By image-guided optical coherence tomography (OCT) (see Figures 8A-8C ) and H&E staining (see Figure 10B ), confirmed this effect. These results suggest that anti-FAM19A5 antibodies can inhibit and / or reduce laser-induced choroidal neovascularization.
[0407] Example 4
[0408] Evaluation of retinal potential difference after administration of anti-FAM19A5 antibody in a mouse model of age-related macular degeneration
[0409] To further evaluate the effect of anti-FAM19A5 antibody treatment on age-related macular degeneration, the retinal potential of the mice in Example 3 was assessed using electroretinography (ERG). Briefly, the pupils of the eyes of the animals in the different treatment groups were dilated and topically treated with 2.5% phenylephrine hydrochloride. The animals were then anesthetized and electrodes were attached to the skin, tail, and cornea. The retinal potential was assessed using a flashing white light (0.9 logcdsec / m 2 ) stimulates the retina. To assess the electrical activity in the eyes of different animals (i.e., "retinal potential difference"), the B wave value was measured as described in Example 1 above.
[0410] like Figure 9 As shown, the B-wave retinal potential of CNV-induced mice treated with anti-FAM19A5 antibody was improved compared with that of mice in the human IgG antibody group. This result indicates that the administration of anti-FAM19A5 antibody to CNV-induced mice restored normal retinal function.
[0411] Example 5
[0412] Evaluation of morphological changes after anti-FAM19A5 antibody treatment in a mouse model of age-related macular degeneration
[0413] Next, in order to evaluate whether the administration of anti-FAM19A5 antibodies causes morphological changes in the retina, the CNV-induced mice of Examples 3 and 4 were sacrificed and their eyes were removed. The eyes were then fixed in 10% neutral formaldehyde for 48 hours. The fixed eyes were then embedded in paraffin blocks and subjected to H&E and IHC analysis. The inhibitory effect of anti-FAM19A5 antibodies on choroidal neovascularization shown in Example 3 was confirmed using H&E. Platelet-derived growth factor (PDGF) was expressed using IHC staining. PDGF is known to be secreted by retinal neurons and plays an important role in the formation of astrocytes and choroidal neovascularization.
[0414] like Figure 10A and 10B As shown in Figure 3, in CNV-induced mice treated with anti-FAMT9A5 antibody, the volume of choroidal neovascularization was significantly reduced on day 13 after CNV induction compared with the human IgG-treated group. This result confirms the earlier data (see Example 3) demonstrating the inhibitory effect of anti-FAM19A5 on choroidal neovascularization. Figure 11 As shown, PDGF staining in the nerve fiber layer and ganglion cell layer of the retina of CNV-induced mice treated with anti-FAM19A5 antibody was significantly reduced compared with that in the IgG-treated group.
[0415] Example 6
[0416] Evaluation of the inhibitory effect of anti-FAM19A5 antibodies on drusen formation
[0417] As mentioned above, drusen are tiny yellow or white accumulations of extracellular material (mainly proteins and lipids) that accumulate between the Bruch's membrane and the retinal pigment epithelium (RPE) of the eye. To evaluate whether the administration of anti-FAM19A5 antibodies can inhibit the formation of drusen, male APP / PS-1 / tau transgenic dementia mice (C57BL / 6; 4 months old) were used. Briefly, mice were intravenously injected with anti-FAM19A5 antibodies at a dose of 0.7 mg / kg, twice a week for 8 weeks. Age-matched non-treated blank wild-type C57BL / 6 and APP / PS-1 / tau transgenic mice were used as controls. Eight weeks after the initial antibody administration, the animals were sacrificed and their eyes were removed. Once removed, the eyes were fixed with 4% paraformaldehyde (PFA) at 4°C for 24 hours. Afterwards, the eyes were frozen in a plastic mold containing OCT compound (Lot No. 686794, Sigma, USA). The frozen ocular tissues were then sliced (thickness: 25 μm) using a microtome (Cryostats CM1860, Leica, Germany) at −20° C. The tissue sections were then mounted on glass slides and stained with oligomeric Aβ and Alexa647 phalloidin to observe the formation of drusen.
[0418] like Figure 12 As shown, in untreated APP / PS-1 / tau transgenic mice, oligomeric Aβ was strongly expressed in the periphery of the photoreceptor cells, while drusen (indicated by positive phalloidin staining) were strongly expressed in the periphery of the retinal tissue, cones, and ganglion cell layer. In contrast, in APP / PS-1 / tau transgenic mice treated with anti-FAM19A5 antibody, oligomeric Aβ and drusen staining were negligible, similar to that in untreated wild-type C57BL / 6 control mice.
[0419] The above results confirmed that anti-FAM19A5 antibody can inhibit the formation of oligomeric Aβ and drusen in the retina (including surrounding tissues).
[0420] Overall, the above data suggest that anti-FAM19A5 antibodies can also improve many potential lesions associated with macular degeneration, such as age-related macular degeneration, thereby playing a therapeutic role in the disease.
[0421] Example 7
[0422] Evaluation of the inhibitory effect of anti-FAM19A5 antibody on diabetic retinopathy after intravenous injection
[0423] To evaluate the therapeutic effect of anti-FAM19A5 antibodies on diabetic retinopathy after intravenous injection, type 2 diabetic db / db mice (such as the mice described in Example 1) were used. Briefly, the animals were stabilized and then treated with one of the following: (i) human IgG antibodies, (ii) aflibercept ( Regeneron Pharmaceuticals), or (iii) anti-FAM19A5 antibody (clone 1-30). Human IgG antibody and human IgG antibody were used as negative and positive controls, respectively. Blank mice (i.e., animals without diabetic retinopathy) were used as additional controls. Different treatment regimens were administered, injected into the vitreous cavity of mice using a micropump system (a total of 7 doses, 2 μL / eye, once every two weeks), and also intravenously through the tail vein (a total of 7 doses, 100 μL, once every two weeks). The treatment groups are shown in Table 8 below.
[0424] Table 8. Treatment groups
[0425]
[0426] The overall health of the animals was monitored regularly, for example, by measuring blood glucose levels and / or body weight in the serum. After the last dose, the mice were euthanized and both eyes of the animals were removed. Once removed, the eyes were prepared on OCT blocks and then fixed for trypsin digestion analysis, hematoxylin and eosin staining (H&E staining), TUNEL analysis, and immunofluorescence staining, as described in Example 2, with details below. Trypsin digestion analysis was performed to assess whether the microvasculature had pericyte loss and acellular capillary formation (i.e., a marker of early diabetic retinopathy). H&E staining, TUNEL analysis, and immunofluorescence staining were performed to analyze vascular congestion, vascular markers (CD31 and VEGF), and retinal cell protection.
[0427] H&E analysis
[0428] After the tissue sections were frozen and mounted on slides (see Example 2), the slides were dried at room temperature for about an hour. The slides were then stained with hematoxylin for 3-5 minutes and cleaned with hydrochloric acid solution for 30 seconds. The slides were then immersed in eosin solution for one minute and cleaned again in hydrochloric acid solution. Next, the slides were cleaned in 80%-100% ethanol for 3 minutes and reacted with carboxylate and xylene for 5 minutes, respectively. The stained slides were observed using a microscope (NanoZoomer 2.0RS, Hamamatsu).
[0429] TUNEL assay
[0430] The slides containing frozen tissue sections (see Example 2) were dried at room temperature for about 1 hour. Once dry, the slides were soaked in 1% paraformaldehyde for 10 minutes and then washed twice with PBS for 5 minutes. Next, the slides were immersed in equilibrium buffer for 10 minutes. The tissue samples were then treated with TdT enzyme in a humidified chamber at 37°C for 2 hours. The slides were then washed four times with PBS for 2 minutes. The stained slides were completely dried at room temperature. Once dry, the tissue samples were stained with DAPI and observed with a fluorescence microscope (LEICADM2500).
[0431] Immunofluorescence analysis
[0432] Slides containing frozen tissue sections (see Example 2) were dried at room temperature for approximately 1 hour. Once dry, tissue samples were treated with a 5% (v / v) Triton X-100 solution in PBS and washed three times with PBS for 5 minutes. Next, the tissues were blocked with normal donkey serum and a 3% (v / v) BSA, 0.5% Triton X-100 solution for 1 hour. Subsequently, tissue staining was performed overnight at 4°C with anti-VEGF and / or anti-CD31 primary antibodies (diluted 1:300 with 3% (v / v) BSA and 0.5% Triton X-100 in PBS). The following day, the samples were washed three times with PBS for 5 minutes. Tissue samples were then incubated with a secondary antibody (Alexa Fluor 555 donkey anti-rabbit IgG, diluted 1:500 with 3% (v / v) BSA and 0.5% Triton X-100 in PBS) for 1 hour at room temperature. The samples were then washed three times with PBS for 5 minutes, stained with DAPI, and observed using a fluorescence microscope (LEICA DM 2500).
[0433] result
[0434] As shown in Table 9 (below) and Figure 13A and 13C As shown in the data presented in Example 2, animals treated with anti-FAM19A5 antibody (both intravenous and intravitreal administration) had lower E / P ratios (i.e., the ratio of endothelial cells to pericytes) than animals treated with anti-human IgG alone ("negative control"). Even compared to the positive control group (i.e., animals treated with aflibercept), the effect of anti-FAM19A5 administration on the E / P ratio was greater and similar to the ratio observed in the blank (i.e., healthy) animals. The best effect was observed with intravitreal administration, but significant therapeutic effects were also observed with intravenous administration. Similar results were observed when the number of acellular capillaries in the eyes of the animals was measured (see Tables 9 and Figure 13B ).
[0435] Table 9. Histological analysis
[0436] Treatment group EP ratio Average AC blank 1.62±0.20 1.78±1.00 Negative control 2.66±0.56 3.36±2.02 Positive control 2.04±0.33 2.20±1.28 Anti-FAM19A5 antibody (intravitreal administration) 1.38±0.43 1.97±0.97 Anti-FAM19A5 antibody (intravenous injection) 1.66±0.38 1.94±1.17
[0437] The route of administration also did not appear to have a significant effect on the ability of anti-FAM19A5 antibodies to reduce vascular congestion and protect retinal cells from damage caused by diabetes (see Figure 14 ). At the same time, Figure 15 As shown, TUNEL assays showed that the number of apoptotic cells in the retinal nerve fiber layer and inner nuclear layer of mice treated with anti-FAM19A5 antibody by intravenous injection was lower than that in the corresponding layers of the retina of mice treated with human IgG control antibody. This effect was similar to that of animals treated with anti-FAM19A5 antibody by intravitreal injection (see Figure 14 and 15 Similar results were observed when the expression of CD31 and VEGF (markers of neovascularization) was evaluated. Compared with control animals (i.e., animals treated with human IgG control antibody alone), CD31 and VEGF expression was greatly reduced in both animals treated with anti-FAM19A5 antibody by intravitreal injection or intravenous injection (see Figure 16A and 16B ).
[0438] Overall, the above data confirm the results of Example 2 (i.e., intravitreal administration) and further demonstrate that anti-FAM19A5 antibodies have therapeutic effects on diabetic retinopathy after both intravenous and intravitreal administration.
[0439] It should be understood that the Detailed Description section, and not the Summary and Abstract sections, is intended to interpret the claims. The Summary and Abstract sections may set forth one or more but not all exemplary aspects of the present disclosure as contemplated by the inventors and, thus, are not intended to limit the present disclosure and the appended claims in any way.
[0440] The present disclosure is described above with reference to functional building blocks, and examples are given of how the specified functions and their relationships are implemented. For ease of description, the boundaries of these functional building blocks are arbitrarily defined herein. Alternative boundaries may be defined as long as the specified functions and their relationships are appropriately implemented.
[0441] The above description of specific aspects will fully reveal the general nature of the present disclosure so that others can easily modify and / or adapt these specific aspects to various applications by applying knowledge within the technical scope of the art without undue experimentation and without departing from the general concepts of the present disclosure. Therefore, based on the teachings and guidance set forth herein, such adaptations and modifications are intended to be within the meaning and range of equivalents of the various aspects disclosed. It should be understood that the wording or terminology used herein is intended to be descriptive and not limiting, so that the skilled person can interpret the terms or wording of this specification in light of the teachings and guidance.
[0442] The breadth and scope of the present disclosure should not be limited by any of the above-described exemplary aspects, but should be defined only in accordance with the following claims and their equivalents.
[0443] All publications, patents, patent applications, internet sites, and accession / database sequences (including both polynucleotide and polypeptide sequences) cited herein are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, internet site, or accession / database sequence were specifically and individually indicated to be incorporated by reference. Sequence Listing <110> Newrock Scientific Co., Ltd. <120> Uses of anti-FAM19A5 antibodies <130> 3763.012PC01 / CK / DKC <150> US 62 / 746,194 <151> 2018-10-16 <160> 301 <170> PatentIn version 3.5 <210> 1 <211> 132 <212> PRT <213> Homo Sapiens <400> 1 Met Ala Pro Ser Pro Arg Thr Gly Ser Arg Gln Asp Ala Thr Ala Leu 1 5 10 15 Pro Ser Met Ser Ser Thr Phe Trp Ala Phe Met Ile Leu Ala Ser Leu 20 25 30 Leu Ile Ala Tyr Cys Ser Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 35 40 45 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 50 55 60 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 65 70 75 80 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 85 90 95 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 100 105 110 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 115 120 125 Thr Thr Val Ser 130 <210> 2 <211> 125 <212> PRT <213> Homo Sapiens <400> 2 Met Gln Leu Leu Lys Ala Leu Trp Ala Leu Ala Gly Ala Ala Leu Cys 1 5 10 15 Cys Phe Leu Val Leu Val Ile His Ala Gln Phe Leu Lys Glu Gly Gln 20 25 30 Leu Ala Ala Gly Thr Cys Glu Ile Val Thr Leu Asp Arg Asp Ser Ser 35 40 45 Gln Pro Arg Arg Thr Ile Ala Arg Gln Thr Ala Arg Cys Ala Cys Arg 50 55 60 Lys Gly Gln Ile Ala Gly Thr Thr Arg Ala Arg Pro Ala Cys Val Asp 65 70 75 80 Ala Arg Ile Ile Lys Thr Lys Gln Trp Cys Asp Met Leu Pro Cys Leu 85 90 95 Glu Gly Glu Gly Cys Asp Leu Leu Ile Asn Arg Ser Gly Trp Thr Cys 100 105 110 Thr Gln Pro Gly Gly Arg Ile Lys Thr Thr Thr Val Ser 115 120 125 <210> 3 <211> 53 <212> PRT <213> Homo Sapiens <400> 3 Met Tyr His His Arg Glu Trp Pro Ala Arg Ile Ile Lys Thr Lys Gln 1 5 10 15 Trp Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu 20 25 30 Ile Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys 35 40 45 Create Thr Thr Thr Val 50 <210> 4 <211> 1501 <212> DNA <213> Homo Sapiens <400> 4 ggcggcggag gatggcgcgc gcggggccg cacgtggagg ccggcgcggg ggcgcggca 60 gggccggctg ctgagacgcg ctgctgcccc ccgcgcggc gcgcggctt caatggcgcc 120 atcgcccagg accggcagcc ggcaagatgc gaccgccctg cccagcatgt cctcaacttt 180 ctgggcgtc atgatcctgg ccagcctgct catcgcctac tgcagtcagc tggccgccgg 240 cacctgtgag attgtgacct tggaccggga cagcagccag cctcggagga cgatcgcccg 300 gcagaccgcc cgctgtgcgt gtagaaaggg gcagatcgcc ggcaccacga gagcccggcc 360 cgcctgtgtg gacgcaagaa tcatcaagac caagcagtgg tgtgacatgc ttccgtgtct 420 ggagggggaa ggctgcgact tgttaatcaa ccggtcaggc tggacgtgca cgcagcccgg 480 cggggata aagaccacca cggtctcctg acaaacacag cccctgaggg ggccccggga 540 gtggccttg ctccctggag agcccacgtc tcagccacag ttctccactc gcctcggact 600 tcacccgttc tctgccgccc gcccactccg tttccctgtg gtccgtgaag gacggcctca 660 ggccttggca tcctgagctt cggtctgtcc agccgacccg aggaggccgg actcagacac 720 ataggcgggg ggcggcacct ggcatcagca atacgcagtc tgtgggagcc cggccgcgcc 780 cagcccccgc cgaccgtggc gttggccctg ctgtcctcag aggaggagga ggaggaggca 840 gctccggcag ccacagaagg ctgcagccca gcccgcctga gacacgacgc ctgccccagg 900 ggactgtcag gcacagaagc ggcctcctcc cgtgccccag actgtccgaa ttgcttttat 960 tttcttatac tttcagtata ctccatagac caaagagcaa aatctatctg aacctggacg 1020 caccctcact gtcagggtcc ctggggtcgc ttgtgcgggc gggagggcaa tggtggcaga 1080 gacatgctgg tggccccggc ggagcggaga gggcggccgt ggtggaggcc tccaccccag 1140 gagcaccccg cacaccctcg gaggacgggc ttcggctgcg cggaggccgt ggcacacctg 1200 cgggaggcag cgacggcccc cacgcagacg ccgggaacgc aggccgcttt attcctctgt 1260 acttagatca acttgaccgt actaaaatcc ctttctgttt taaccagtta aacatgcctc 1320 ttctacagct ccatttttga tagttggata atccagtatc tgccaagagc atgttgggtc 1380 tcccgtgact gctgcctcat cgatacccca tttagctcca gaaagcaaag aaaactcgag 1440 taacacttgt ttgaaagaga tcattaaatg tattttgcaa agcccaaaaa aaaaaaaaaa 1500 a 1501 <210> 5 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Epitope F1 <400> 5 Gln Leu Ala Ala Gly Thr Cys Glu Ile Val Thr Leu Asp Arg 1 5 10 <210> 6 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Epitope F2 <400> 6 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 7 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Epitope F3 <400> 7 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 1 5 10 15 Ala Arg Pro Ala 20 <210> 8 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Epitope F4 <400> 8 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 1 5 10 15 Cys Asp Met Leu 20 <210> 9 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Epitope F5 <400> 9 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 1 5 10 15 Asn Arg Ser Gly 20 <210> 10 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Epitope F6 <400> 10 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 1 5 10 15 Thr Thr Val Ser 20 <210> 11 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 2-13 Antibody VH-CDR1 <400> 11 Ser His Gly Met Phe 1 5 <210> 12 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 2-13; 2-13D; 2-13D-37; 2-13D-37-1.5W-41; 2-13D-37-3W-16 VH-CDR2 <400> 12 Glu Ile Thr Asn Asp Gly Ser Gly Thr Asn Tyr Gly Ser Ala Val Lys 1 5 10 15 Gly <210> 13 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> 2-13; 2-13D; 2-13D-37 VH-CDR3 <400> 13 Ser Thr Tyr Glu Cys Pro Gly Gly Phe Ser Cys Trp Gly Asp Thr Gly 1 5 10 15 Gln Ile Asp Ala 20 <210> 14 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 3-2 Antibody VH-CDR1 <400> 14 Ser Phe Asn Met Phe 1 5 <210> 15 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 3-2 Antibody VH-CDR2 <400> 15 Gln Ile Ser Ser Ser Gly Ser Ser Thr Asn Tyr Ala Pro Ala Val Arg 1 5 10 15 Gly <210> 16 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> 3-2; 1-7A-IT; Low-PI; 1-30; 1-17; 1-32; 4-11; 6-10 VH-CDR3 <400> 16 Ser Ser Tyr Asp Cys Pro Tyr Gly His Cys Ser Ser Gly Val Asp Ser 1 5 10 15 Ala Gly Glu Ile Asp Ala 20 <210> 17 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 1-65; SS01-13; SS01-13-s5; S5-2.GKNG VH-CDR1 <400> 17 Ser Tyr Gln Met Gly 1 5 <210> 18 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> 1-65; SS01-13 VH-CDR2 <400> 18 Val Ile Asn Lys Ser Gly Ser Asp Thr Ser 1 5 10 <210> 19 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> 1-65; SS01-13; SS01-13-s5; S5-2.GKNG VH-CDR3 <400> 19 Gly Ser Ala Ser Tyr Ile Thr Ala Ala Thr Ile Asp Ala 1 5 10 <210> 20 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody VH-CDR1 <400> 20 Gly Phe Asp Phe Ser Asp Tyr Gly 1 5 <210> 21 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody VH-CDR2 <400> 21 Ile Arg Ser Asp Gly Ser Asn Pro 1 5 <210> 22 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody VH-CDR3 <400> 22 Ala Lys Asp Gly Asn Gly Tyr Cys Ala Leu Asp Ala Tyr Arg Ser Gly 1 5 10 15 Gly Tyr Ser Cys Gly Val Tyr Pro Gly Ser Ile Asp Ala 20 25 <210> 23 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> 2-13 Antibody VL-CDR1 <400> 23 Ser Gly Gly Ser Tyr Ser Tyr Gly 1 5 <210> 24 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 2-13; 2-13D; 2-13D-37; 2-13D-37-1.5W-41; 2-13D-37-3W-16 VL-CDR2 <400> 24 Trp Asp Asp Glu Arg Pro Ser 1 5 <210> 25 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 2-13; 2-13D; 2-13D-37; 2-13D-37-1.5W-41; 2-13D-37-3W-16 VL-CDR3 <400> 25 Gly Thr Glu Asp Ile Ser Gly Thr Ala Gly Val 1 5 10 <210> 26 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> 3-2; 1-7A-IT; 1-17; 1-32; 4-11; 6-10 VL-CDR1 <400> 26 Ser Gly Gly Gly Ser Tyr Ala Gly Ser Tyr Tyr Tyr Gly 1 5 10 <210> 27 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 3-2 Antibody VL-CDR2 <400> 27 Glu Ser Asn Lys Arg Pro Ser 1 5 <210> 28 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> 3-2; 1-7A-IT VL-CDR3 <400> 28 Gly Ser Trp Asp Ser Ser Asn Gly Gly Ile 1 5 10 <210> 29 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 1-65 Antibody VL-CDR1 <400> 29 Ser Gly Gly Gly Ser Ser Gly Tyr Gly Tyr Gly 1 5 10 <210> 30 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 1-65 Antibody VL-CDR2 <400> 30 Trp Asn Asp Lys Arg Pro Ser 1 5 <210> 31 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> 1-65; ss01-13; SS01-13-S5; S5-2.GKNG VL-CDR3 <400> 31 Gly Asn Asp Asp Tyr Ser Ser Asp Ser Gly Tyr Val Gly Val 1 5 10 <210> 32 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody VL-CDR1 <400> 32 Gly Tyr Gly Tyr Gly 1 5 <210> 33 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody VL-CDR2 <400> 33 Gln Asn Asp 1 <210> 34 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody VL-CDR3 <400> 34 Gly Ser Glu Asp Ser Ser Thr Leu Ala Gly Ile 1 5 10 <210> 35 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> 2-13 Antibody VH <400> 35 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser His 20 25 30 Gly Met Phe Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Tyr Val 35 40 45 Ala Glu Ile Thr Asn Asp Gly Ser Gly Thr Asn Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Phe Cys 85 90 95 Ala Arg Ser Thr Tyr Glu Cys Pro Gly Gly Phe Ser Cys Trp Gly Asp 100 105 110 Thr Gly Gln Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile Val Ser 115 120 125 Ser <210> 36 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> 3-2 Antibody VH <400> 36 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Asn Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val 35 40 45 Ala Gln Ile Ser Ser Ser Gly Ser Ser Thr Asn Tyr Ala Pro Ala Val 50 55 60 Arg Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Pro Gly Ala Glu Asp Thr Gly Thr Tyr Tyr Cys 85 90 95 Ala Lys Ser Ser Tyr Asp Cys Pro Tyr Gly His Cys Ser Ser Gly Val 100 105 110 Asp Ser Ala Gly Glu Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile 115 120 125 Val Ser Ser 130 <210> 37 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> 1-65 Antibody VH <400> 37 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gln Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Val Ile Asn Lys Ser Gly Ser Asp Thr Ser Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Phe Cys 85 90 95 Ala Lys Gly Ser Ala Ser Tyr Ile Thr Ala Ala Thr Ile Asp Ala Trp 100 105 110 Gly His Gly Thr Glu Val Ile Val Ser Ser 115 120 <210> 38 <211> 136 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody VH <400> 38 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Asp Phe Ser Asp Tyr 20 25 30 Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ala Ile Arg Ser Asp Gly Ser Asn Pro Ser Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Lys Asp Asn Gly Arg Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Asn Gly Tyr Cys Ala Leu Asp Ala Tyr Arg Ser Gly 100 105 110 Gly Tyr Ser Cys Gly Val Tyr Pro Gly Ser Ile Asp Ala Trp Gly His 115 120 125 Gly Thr Glu Val Ile Val Ser Ser 130 135 <210> 39 <211> 104 <212> PRT <213> Artificial Sequence <220> <223> 2-13 Antibody VL <400> 39 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Ser Tyr Ser Tyr Gly Trp Phe Gln Gln 20 25 30 Lys Ser Pro Gly Ser Ala Leu Val Thr Val Ile Tyr Trp Asp Asp Glu 35 40 45 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ala Leu Ser Gly Ser 50 55 60 Thr Asn Thr Leu Thr Ile Thr Gly Val Gln Ala Asp Asp Glu Ala Val 65 70 75 80 Tyr Phe Cys Gly Thr Glu Asp Ile Ser Gly Thr Ala Gly Val Phe Gly 85 90 95 Ala Gly Thr Thr Leu Thr Val Leu 100 <210> 40 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> 3-2 Antibody VL <400> 40 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Gly Ser Tyr Ala Gly Ser Tyr Tyr Tyr 20 25 30 Gly Trp Tyr Gln Gln Lys Ala Pro Gly Ser Ala Pro Val Thr Leu Ile 35 40 45 Tyr Glu Ser Asn Lys Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Thr Ser Gly Ser Thr Ala Thr Leu Thr Ile Thr Gly Val Gln Ala 65 70 75 80 Asp Asp Glu Ala Ile Tyr Tyr Cys Gly Ser Trp Asp Ser Ser Asn Gly 85 90 95 Gly Ile Phe Gly Ala Gly Thr Thr Leu Thr Val Leu 100 105 <210> 41 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> 1-65 Antibody VL <400> 41 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Gly Ser Ser Gly Tyr Gly Tyr Gly Trp 20 25 30 Tyr Gln Gln Lys Ser Pro Ser Ser Ala Pro Leu Thr Val Ile Tyr Trp 35 40 45 Asn Asp Lys Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys 50 55 60 Ser Gly Ser Thr His Thr Leu Thr Ile Thr Gly Val Gln Ala Glu Asp 65 70 75 80 Glu Ala Val Tyr Phe Cys Gly Asn Asp Asp Tyr Ser Ser Asp Ser Gly 85 90 95 Tyr Val Gly Val Phe Gly Ala Gly Thr Thr Leu Thr Val Leu 100 105 110 <210> 42 <211> 104 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody VL <400> 42 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Leu Glu Gly Thr Val 1 5 10 15 Glu Ile Thr Cys Ser Gly Ser Gly Tyr Gly Tyr Gly Trp Tyr Gln Gln 20 25 30 Lys Ser Pro Gly Ser Ala Pro Val Thr Val Ile Tyr Gln Asn Asp Lys 35 40 45 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys Ser Gly Ser 50 55 60 Thr Gly Thr Leu Thr Ile Thr Gly Val Gln Val Glu Asp Glu Ala Val 65 70 75 80 Tyr Tyr Cys Gly Ser Glu Asp Ser Ser Thr Leu Ala Gly Ile Phe Gly 85 90 95 Ala Gly Thr Thr Leu Thr Val Leu 100 <210> 43 <211> 388 <212> DNA <213> Artificial Sequence <220> <223> 2-13 Antibody VH <400> 43 gccgtgacgt tggacgagtc cgggggcggc ctccagacgc ccggaggagc gctcagcctc 60 gtctgcaagg cctccgggtt caccttcagc agccatggca tgttctgggt gcgacagacg 120 cccggcaagg ggttggaata tgtcgctgaa attaccaatg atggtagtgg cacaaactac 180 gggtcggcgg tgaagggccg tgccaccatc tcgagggaca acgggcagag cacagtgagg 240 ctgcagctga acaacctcag ggctgaggac accggcacct acttctgcgc cagatctact 300 tatgaatgtc ctggtggttt tagttgttgg ggtgatactg gtcaaataga cgcatggggc 360 cacgggaccg aagtcatcgt ctcctcca 388 <210> 44 <211> 394 <212> DNA <213> Artificial Sequence <220> <223> 3-2 Antibody VH <400> 44 gccgtgacgt tggacgagtc cgggggcggc ctccagacgc ccggaggagc gctcagcctc 60 gtctgcaagg cctccgggtt caccttcagc agcttcaaca tgttctgggt gcgacaggcg 120 cccggcaagg ggctggaata cgtcgctcaa attagcagca gtggtagtag cacaaactac 180 gcacccgcgg tgaggggccg tgccaccatc tcgagggaca acgggcagag cacagtgagg 240 ctgcagctga acaaccccgg ggctgaagac accggcacct actactgcgc caaaagtagt 300 tatgactgtc cttacggtca ttgtagtagt ggtgttgata gtgctggtga gatcgacgca 360 tggggccacg ggaccgaagt catcgtctcc tcca 394 <210> 45 <211> 366 <212> DNA <213> Artificial Sequence <220> <223> 1-65 Antibody VH <400> 45 gccgtgacgt tggacgagtc cgggggcggc ctccagacgc ccggaggagc gctcagcctc 60 gtctgcaagg cctccgggtt caccttcagc agctatcaga tgggctgggt gcgacaggcg 120 cccggcaagg ggctggaatg ggtcggtgtt attaacaaga gtggtagtga cacatcatac 180 gggtcggcgg tgaagggccg tgccaccatc tcgagggaca acgggcagag cacagtgagg 240 ctgcagctga acaacctcag ggctgaggac accggcacct acttctgcgc caaaggttct 300 gctagttata taactgctgc taccatcgac gcatggggcc acgggaccga agtcatcgtc 360 tcctcc 366 <210> 46 <211> 408 <212> DNA <213> Artificial Sequence <220> <223> 1-28 Antibody VH <400> 46 gccgtgacgt tggacgagtc cgggggcggc ctccagacgc ccggaggagc gctcagcctc 60 gtctgcaagg cctccgggtt cgacttcagc gattatggca tgggttgggt gcgacaggct 120 ccaggcaagg ggctggagtg ggttgctgct attagaagtg atggtagtaa cccatcatac 180 gggtcggcgg tgaagggccg tgccaccatc tcgaaggaca acgggcgaag cacagtgagg 240 ctgcagctga acaacctcag ggctgaggac accgccacct actactgcgc caaggatggt 300 aatggttact gtgctctcga tgcttatcgt agtggtggtt atagttgtgg tgtttatcct 360 ggtagcatcg acgcatgggg ccacgggacc gaagtcatcg tctcctcc 408 <210> 47 <211> 315 <212> DNA <213> Artificial Sequence <220> <223> 2-13 Antibody VL <400> 47 ggccctgact cagccgtcct cggtgtcagc aaacccagga gaaaccgtca agataacctg 60 ctccgggggt agctatagct atggctggtt ccagcagaag tctcctggca gtgcccttgt 120 cactgtgatc tactgggatg atgagagacc ctcggacatc ccttcacgat tctccggtgc 180 cctatccggc tccacaaaca cattaaccat cactggggtc caagccgacg acgaggctgt 240 ctatttctgt gggactgaag acatcagcgg cactgctggt gtatttgggg ccgggacaac 300 cctgaccgtc ctggg 315 <210> 48 <211> 327 <212> DNA <213> Artificial Sequence <220> <223> 3-2 Antibody VL <400> 48 ggccctgact cagccgtcct cggtgtcagc aaacccagga gaaaccgtca agatcacctg 60 ctccgggggt ggcagctatg ctggaagtta ctattatggc tggtaccagc agaaggcacc 120 tggcagtgcc cctgtcactc tgatctatga aagcaacaag agaccctcgg acatcccttc 180 acgattctcc ggttccacat ctggctccac agccacacta accatcactg gggtccaagc 240 cgatgacgag gctatctatt actgtgggag ctgggacagt agcaatggtg gtatatttgg 300 ggccgggaca accctgaccg tcctagg 327 <210> 49 <211> 331 <212> DNA <213> Artificial Sequence <220> <223> 1-65 Antibody VL <400> 49 ggccctgact cagccgtcct cggtgtcagc aaaccctggg gaaactgtca agatcacctg 60 ctccgggggt ggtagcagtg gctatggtta tggctggtat cagcagaagt cacctagcag 120 tgcccctctc actgtgatct actggaacga caagagaccc tcggacatcc cttcacgatt 180 ctccggttcc aaatccggct ccacacacac attaaccatc actggggtcc aagccgagga 240 cgaggctgta tatttctgtg ggaatgatga ctacagcagt gatagtggat atgtcggtgt 300 atttggggcc gggacaaccc tgaccgtcct a 331 <210> 50 <211> 312 <212> DNA <213> Artificial Sequence <220> <223> 1-28 Antibody VL <400> 50 gccctgactc agccgtcctc ggtgtcagca aacctggaag gaaccgtcga gatcacctgc 60 tccgggagtg gctatggtta tggctggtat cagcagaagt ctcctggcag tgcccctgtc 120 actgtgatct atcagaacga caagagaccc tcggacatcc cttcacgatt ctccggttcc 180 aaatccggct ccacggggcac attaaccatc actggggtcc aagtcgagga cgaggctgtc 240 tattactgtg ggagtgaaga cagcagcact cttgctggta tatttggggc cgggacaacc 300 ctgaccgtcc ta 312 <210> 51 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> M3 mutant <400> 51 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Ile Glu Glu Arg Ser Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 52 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> M4 mutant <400> 52 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Val Lys Cys Ser Cys Phe Pro Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 53 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> M5 mutant <400> 53 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Asn Lys Pro Ser Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 54 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> M6 mutant <400> 54 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Leu Gln Arg Trp Trp 50 55 60 Cys Gln Met Glu Leu Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 55 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> M7 mutant <400> 55 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Glu Cys Lys Thr Leu Pro 65 70 75 80 Asp Asn Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 56 <211> 101 <212> PRT <213> Artificial Sequence <220> <223> M8 mutant <400> 56 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Ser Cys Ser Ser Gly Asn Lys Ile Lys 85 90 95 Thr Thr Thr Val Ser 100 <210> 57 <211> 459 <212> PRT <213> Artificial Sequence <220> <223> 2-13 Antibody HC <400> 57 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser His 20 25 30 Gly Met Phe Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Tyr Val 35 40 45 Ala Glu Ile Thr Asn Asp Gly Ser Gly Thr Asn Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Phe Cys 85 90 95 Ala Arg Ser Thr Tyr Glu Cys Pro Gly Gly Phe Ser Cys Trp Gly Asp 100 105 110 Thr Gly Gln Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile Val Ser 115 120 125 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 130 135 140 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 145 150 155 160 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 165 170 175 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 180 185 190 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 195 200 205 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 210 215 220 Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 225 230 235 240 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 245 250 255 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 260 265 270 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 275 280 285 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 290 295 300 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 305 310 315 320 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 325 330 335 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 340 345 350 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu 355 360 365 Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 370 375 380 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 385 390 395 400 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 405 410 415 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 420 425 430 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 435 440 445 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 58 <211> 461 <212> PRT <213> Artificial Sequence <220> <223> 3-2 Antibody HC <400> 58 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Asn Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val 35 40 45 Ala Gln Ile Ser Ser Ser Gly Ser Ser Thr Asn Tyr Ala Pro Ala Val 50 55 60 Arg Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Pro Gly Ala Glu Asp Thr Gly Thr Tyr Tyr Cys 85 90 95 Ala Lys Ser Ser Tyr Asp Cys Pro Tyr Gly His Cys Ser Ser Gly Val 100 105 110 Asp Ser Ala Gly Glu Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile 115 120 125 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 130 135 140 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 145 150 155 160 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 165 170 175 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 180 185 190 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 195 200 205 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 210 215 220 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 225 230 235 240 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 245 250 255 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 260 265 270 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 275 280 285 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 290 295 300 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 305 310 315 320 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 325 330 335 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 340 345 350 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 355 360 365 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 370 375 380 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 385 390 395 400 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 405 410 415 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 420 425 430 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 435 440 445 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 460 <210> 59 <211> 452 <212> PRT <213> Artificial Sequence <220> <223> 1-65 Antibody HC <400> 59 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gln Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Val Ile Asn Lys Ser Gly Ser Asp Thr Ser Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr Phe Cys 85 90 95 Ala Lys Gly Ser Ala Ser Tyr Ile Thr Ala Ala Thr Ile Asp Ala Trp 100 105 110 Gly His Gly Thr Glu Val Ile Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 60 <211> 466 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody HC <400> 60 Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser Gly Phe Asp Phe Ser Asp Tyr 20 25 30 Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ala Ile Arg Ser Asp Gly Ser Asn Pro Ser Tyr Gly Ser Ala Val 50 55 60 Lys Gly Arg Ala Thr Ile Ser Lys Asp Asn Gly Arg Ser Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Asn Gly Tyr Cys Ala Leu Asp Ala Tyr Arg Ser Gly 100 105 110 Gly Tyr Ser Cys Gly Val Tyr Pro Gly Ser Ile Asp Ala Trp Gly His 115 120 125 Gly Thr Glu Val Ile Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 130 135 140 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 145 150 155 160 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 165 170 175 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 180 185 190 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 195 200 205 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 210 215 220 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 225 230 235 240 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 245 250 255 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 260 265 270 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 275 280 285 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 290 295 300 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 305 310 315 320 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 325 330 335 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 340 345 350 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 355 360 365 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 370 375 380 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 385 390 395 400 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 405 410 415 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 420 425 430 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 435 440 445 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 450 455 460 Gly Lys 465 <210> 61 <211> 211 <212> PRT <213> Artificial Sequence <220> <223> 2-13 Antibody LC <400> 61 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Ser Tyr Ser Tyr Gly Trp Phe Gln Gln 20 25 30 Lys Ser Pro Gly Ser Ala Leu Val Thr Val Ile Tyr Trp Asp Asp Glu 35 40 45 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ala Leu Ser Gly Ser 50 55 60 Thr Asn Thr Leu Thr Ile Thr Gly Val Gln Ala Asp Asp Glu Ala Val 65 70 75 80 Tyr Phe Cys Gly Thr Glu Asp Ile Ser Gly Thr Ala Gly Val Phe Gly 85 90 95 Ala Gly Thr Thr Leu Thr Val Leu Arg Ser Val Ala Ala Pro Ser Val 100 105 110 Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser 115 120 125 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln 130 135 140 Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val 145 150 155 160 Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu 165 170 175 Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 180 185 190 Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg 195 200 205 Gly Glu Cys 210 <210> 62 <211> 215 <212> PRT <213> Artificial Sequence <220> <223> 3-2 Antibody LC <400> 62 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Gly Ser Tyr Ala Gly Ser Tyr Tyr Tyr 20 25 30 Gly Trp Tyr Gln Gln Lys Ala Pro Gly Ser Ala Pro Val Thr Leu Ile 35 40 45 Tyr Glu Ser Asn Lys Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Thr Ser Gly Ser Thr Ala Thr Leu Thr Ile Thr Gly Val Gln Ala 65 70 75 80 Asp Asp Glu Ala Ile Tyr Tyr Cys Gly Ser Trp Asp Ser Ser Asn Gly 85 90 95 Gly Ile Phe Gly Ala Gly Thr Thr Leu Thr Val Leu Arg Ser Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 63 <211> 217 <212> PRT <213> Artificial Sequence <220> <223> 1-65 Antibody LC <400> 63 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Pro Gly Glu Thr Val 1 5 10 15 Lys Ile Thr Cys Ser Gly Gly Gly Ser Ser Gly Tyr Gly Tyr Gly Trp 20 25 30 Tyr Gln Gln Lys Ser Pro Ser Ser Ala Pro Leu Thr Val Ile Tyr Trp 35 40 45 Asn Asp Lys Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys 50 55 60 Ser Gly Ser Thr His Thr Leu Thr Ile Thr Gly Val Gln Ala Glu Asp 65 70 75 80 Glu Ala Val Tyr Phe Cys Gly Asn Asp Asp Tyr Ser Ser Asp Ser Gly 85 90 95 Tyr Val Gly Val Phe Gly Ala Gly Thr Thr Leu Thr Val Leu Arg Ser 100 105 110 Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 115 120 125 Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 130 135 140 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly 145 150 155 160 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr 165 170 175 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 180 185 190 Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val 195 200 205 Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 64 <211> 211 <212> PRT <213> Artificial Sequence <220> <223> 1-28 Antibody LC <400> 64 Ala Leu Thr Gln Pro Ser Ser Val Ser Ala Asn Leu Glu Gly Thr Val 1 5 10 15 Glu Ile Thr Cys Ser Gly Ser Gly Tyr Gly Tyr Gly Trp Tyr Gln Gln 20 25 30 Lys Ser Pro Gly Ser Ala Pro Val Thr Val Ile Tyr Gln Asn Asp Lys 35 40 45 Arg Pro Ser Asp Ile Pro Ser Arg Phe Ser Gly Ser Lys Ser Gly Ser 50 55 60 Thr Gly Thr Leu Thr Ile Thr Gly Val Gln Val Glu Asp Glu Ala Val 65 70 75 80 Tyr Tyr Cys Gly Ser Glu Asp Ser Ser Thr Leu Ala Gly Ile Phe Gly 85 90 95 Ala Gly Thr Thr Leu Thr Val Leu Arg Ser Val Ala Ala Pro Ser Val 100 105 110 Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser 115 120 125 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln 130 135 140 Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val 145 150 155 160 Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu 165 170 175 Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 180 185 190 Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg 195 200 205 Gly Glu Cys 210 <210> 65 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> EP1 Epitope <400> 65 Ile Val Thr Leu Asp 1 5 <210> 66 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> EP2 Epitope <400> 66 Asp Ser Ser Gln Pro 1 5 <210> 67 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> EP3 Epitope <400> 67 Arg Thr Ile Ala Arg 1 5 <210> 68 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> EP4 Epitope <400> 68 Ala Arg Cys Ala Cys Arg Lys 1 5 <210> 69 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> EP5 Epitope <400> 69 Ala Arg Pro Ala 1 <210> 70 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> EP6 Epitope <400> 70 Lys Thr Lys Gln Trp Cys Asp Met Leu 1 5 <210> 71 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> EP7 Epitope <400> 71 Gly Cys Asp Leu Leu Ile Asn Arg 1 5 <210> 72 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> EP8 Epitope <400> 72 Thr Cys Thr Gln Pro Gly Gly Arg 1 5 <210> 73 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-01-BSA (#1) <400> 73 Thr Ala Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 74 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-02-BSA (#2) <400> 74 Thr Leu Ala Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 75 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-03-BSA (#3) <400> 75 Thr Leu Asp Arg Ala Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 76 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-04-BSA (#4) <400> 76 Thr Leu Asp Arg Asp Ala Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 77 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-05-BSA (#5) <400> 77 Thr Leu Asp Arg Asp Ser Ala Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 78 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-06-BSA (#6) <400> 78 Thr Leu Asp Arg Asp Ser Ser Ala Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 79 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-07-BSA (#7) <400> 79 Thr Leu Asp Arg Asp Ser Ser Gln Ala Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 80 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-08-BSA (#8) <400> 80 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Ala Thr Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 81 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-09-BSA (#9) <400> 81 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Ala Ile Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 82 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-10-BSA (#10) <400> 82 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ala Ala Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 83 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-11-BSA (#11) <400> 83 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Arg Arg Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 84 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-12-BSA (#12) <400> 84 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Ala Gln 1 5 10 15 Thr Ala Arg Cys 20 <210> 85 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> F2-12-BSA (#13) <400> 85 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 1 5 10 15 Thr Val Arg Cys 20 <210> 86 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> Wild-type FAM19A5 Isoform 2 (without signal peptide) <400> 86 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 87 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> M1 mutant <400> 87 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Val Ile 1 5 10 15 Ala Ala His Arg Asp Ser Ser Gln Pro Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 88 <211> 100 <212> PRT <213> Artificial Sequence <220> <223> M2 mutant <400> 88 Gln Phe Leu Lys Glu Gly Gln Leu Ala Ala Gly Thr Cys Glu Ile Val 1 5 10 15 Thr Leu Asp Arg Cys Cys Asn Lys Asn Arg Arg Thr Ile Ala Arg Gln 20 25 30 Thr Ala Arg Cys Ala Cys Arg Lys Gly Gln Ile Ala Gly Thr Thr Arg 35 40 45 Ala Arg Pro Ala Cys Val Asp Ala Arg Ile Ile Lys Thr Lys Gln Trp 50 55 60 Cys Asp Met Leu Pro Cys Leu Glu Gly Glu Gly Cys Asp Leu Leu Ile 65 70 75 80 Asn Arg Ser Gly Trp Thr Cys Thr Gln Pro Gly Gly Arg Ile Lys Thr 85 90 95 Thr Thr Val Ser 100 <210> 89 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> P2-C12 antibodyVH CDR1 <400> 89 Thr Tyr Ala Val Thr 1 5 <210> 90 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> P2-C12antibodyVH CDR2 <400> 90 Tyr Ile Asn Trp Arg Gly Gly Thr Ser Tyr Ala Asn Trp Ala Lys Gly 1 5 10 15 <210> 91 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> P2-C12antibodyVH CDR3 <400> 91 Asp Ala Ser Ser Gly Ala Ala Phe Gly Ser Tyr Gly Met Asp Pro 1 5 10 15 <210> 92 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> P2-C12 antibodyVL CDR1 <400> 92 Gln Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ser 1 5 10 <210> 93 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> P2-C12antibodyVL CDR2 <400> 93 Glu Ala Ser Lys Leu Ala Ser 1 5 <210> 94 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> P2-C12antibodyVL CDR3 <400> 94 Gln Gln Gly Tyr Ser Ser Thr Asn Val Trp Asn Ala 1 5 10 <210> 95 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> 13B4antibodyVH CDR1 <400> 95 Ser Ser Asn Trp Trp Ser 1 5 <210> 96 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> 13B4antibodyVH CDR2 <400> 96 Glu Ile Tyr His Gly Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys Gly 1 5 10 15 <210> 97 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 13B4antibodyVH CDR3 <400> 97 Trp Gln Leu Val Gly Gly Leu Asp Val 1 5 <210> 98 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 13B4antibodyVL CDR1 <400> 98 Ser Gly Asp Lys Leu Gly Asn Val Tyr Ala Ser 1 5 10 <210> 99 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 13B4antibodyVL CDR2 <400> 99 Gln Asp Asn Lys Arg Pro Ser 1 5 <210> 100 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 13B4antibodyVL CDR3 <400> 100 Gln Ala Trp Asp Ser Ser Thr Ala Val 1 5 <210> 101 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 13F7antibodyVH CDR1 <400> 101 Gly Tyr Ser Trp Thr 1 5 <210> 102 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> 13F7antibodyVH CDR2 <400> 102 Glu Ile Ser His Phe Gly Ser Ala Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 103 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> 13F7antibodyVH CDR3 <400> 103 Ala Leu Arg Gly Thr Tyr Ser Arg Phe Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 104 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> 13F7antibodyVL CDR1 <400> 104 Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp 1 5 10 15 <210> 105 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 13F7antibodyVL CDR2 <400> 105 Leu Gly Ser Asn Arg Ala Ser 1 5 <210> 106 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 13F7antibodyVL CDR3 <400> 106 Met Gln Ala Arg Gln Thr Pro Leu Thr 1 5 <210> 107 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 15A9antibodyVH CDR1 <400> 107 Ser Tyr Tyr Trp Ser 1 5 <210> 108 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> 15A9antibodyVH CDR2 <400> 108 Tyr Ile Tyr Pro Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 109 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> 15A9antibodyVH CDR3 <400> 109 Val Asn Pro Phe Gly Tyr Tyr Tyr Ala Met Asp Val 1 5 10 <210> 110 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 15A9antibodyVL CDR1 <400> 110 Arg Ala Ser Gln Ser Ile Ser Thr Ser Leu Asn 1 5 10 <210> 111 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 15A9antibodyVL CDR2 <400> 111 Gly Ala Ser Thr Leu Gln Ser 1 5 <210> 112 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 15A9antibodyVL CDR3 <400> 112 Gln Glu Ser Ala Ser Ile Pro Arg Thr 1 5 <210> 113 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> P1-A03antibodyVH CDR1 <400> 113 Ser Asp Tyr Met Ser 1 5 <210> 114 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> P1-A03antibodyVH CDR2 <400> 114 Ile Ile Tyr Pro Ser Thr Thr Thr Tyr Tyr Ala Ser Trp Ala Lys Gly 1 5 10 15 <210> 115 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> P1-A03antibodyVH CDR3 <400> 115 Gly Ser Asn Trp Ser Ser Gly Met Asn Leu 1 5 10 <210> 116 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> P1-A03antibodyVL CDR1 <400> 116 Leu Ala Ser Glu Asp Ile Tyr Ser Gly Ile Ser 1 5 10 <210> 117 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> P1-A03antibodyVL CDR2 <400> 117 Gly Ala Ser Asn Leu Glu Ser 1 5 <210> 118 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> P1-A03antibodyVL CDR3 <400> 118 Leu Gly Gly Tyr Ser Tyr Ser Ser Thr Gly Leu Thr 1 5 10 <210> 119 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> P1-A08antibodyVH CDR1 <400> 119 Thr Tyr Tyr Met Ser 1 5 <210> 120 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> P1-A08antibodyVH CDR2 <400> 120 Ile Val Tyr Pro Ser Gly Thr Thr Tyr Tyr Ala Asn Trp Ala Lys Gly 1 5 10 15 <210> 121 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> P1-A08antibodyVH CDR3 <400> 121 Gly Asp Ser Phe Gly Tyr Gly Leu 1 5 <210> 122 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> P1-A08antibodyVL CDR1 <400> 122 Thr Ala Asp Thr Leu Ser Arg Ser Tyr Ala Ser 1 5 10 <210> 123 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> P1-A08antibodyVL CDR2 <400> 123 Arg Asp Thr Ser Arg Pro Ser 1 5 <210> 124 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> P1-A08antibodyVL CDR3 <400> 124 Ala Thr Ser Asp Gly Ser Gly Ser Asn Tyr Gln Tyr Val 1 5 10 <210> 125 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> P1-F02antibodyVH CDR1 <400> 125 Asn Tyr Tyr Met Gly 1 5 <210> 126 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> P1-F02antibodyVH CDR2 <400> 126 Ile Ile Tyr Ala Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly 1 5 10 15 <210> 127 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> P1-F02antibodyVH CDR3 <400> 127 Ile Asp Ile Gly Val Gly Asp Tyr Gly Trp Ala Tyr Asp Arg Leu Asp 1 5 10 15 Leu <210> 128 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> P1-F02antibodyVL CDR1 <400> 128 Leu Ala Ser Glu Asp Ile Tyr Ser Gly Ile Ser 1 5 10 <210> 129 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> P1-F02antibodyVL CDR2 <400> 129 Gly Ala Ser Asn Leu Glu Ser 1 5 <210> 130 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> P1-F02antibodyVL CDR3 <400> 130 Leu Gly Gly Tyr Ser Tyr Ser Ser Ile Thr 1 5 10 <210> 131 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> P2-A01antibodyVH CDR1 <400> 131 Gly Tyr Tyr Met Ser 1 5 <210> 132 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> P2-A01antibodyVH CDR2 <400> 132 Ile Ile Tyr Pro Ser Gly Ser Thr Asp Tyr Ala Ser Trp Ala Lys Gly 1 5 10 15 <210> 133 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> P2-A01antibodyVH CDR3 <400> 133 Val Ala Gly Tyr Val Gly Tyr Gly Tyr Glu Thr Phe Phe Asp Ile 1 5 10 15 <210> 134 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> P2-A01antibodyVL CDR1 <400> 134 Leu Ala Ser Glu Asp Ile Tyr Ser Gly Ile Ser 1 5 10 <210> 135 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> P2-A01antibodyVL CDR2 <400> 135 Gly Ala Ser Asn Leu Glu Ser 1 5 <210> 136 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> P2-A01antibodyVL CDR3 <400> 136 Leu Gly Gly Val Thr Tyr Ser Ser Thr Gly Thr His Leu Thr 1 5 10 <210> 137 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> P2-A03antibodyVH CDR1 <400> 137 Asn Tyr Asp Met Ser 1 5 <210> 138 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> P2-A03antibodyVH CDR2 <400> 138 Phe Met Asp Thr Asp Gly Ser Ala Tyr Tyr Ala Thr Trp Ala Lys Gly 1 5 10 15 <210> 139 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> P2-A03antibodyVH CDR3 <400> 139 Arg Gly Ser Ser Tyr Tyr Gly Gly Ile Asp Ile 1 5 10 <210> 140 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> P2-A03antibodyVL CDR1 <400> 140 Gln Ala Ser Gln Ser Ile Gly Gly Asn Leu Ala 1 5 10 <210> 141 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> P2-A03antibodyVL CDR2 <400> 141 Arg Ala Ser Thr Leu Ala Ser 1 5 <210> 142 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> P2-A03antibodyVL CDR3 <400> 142 Gln Ser Pro Ala Tyr Asp Pro Ala Ala Tyr Val Gly Asn Ala 1 5 10 <210> 143 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> P2-F07antibodyVH CDR1 <400> 143 Ser Tyr Tyr Met Asn 1 5 <210> 144 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> P2-F07antibodyVH CDR2 <400> 144 Ile Ile Tyr Pro Ser Gly Thr Thr Tyr Tyr Ala Gly Trp Ala Lys Gly 1 5 10 15 <210> 145 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> P2-F07antibodyVH CDR3 <400> 145 Thr Val Ser Gly Tyr Phe Asp Ile 1 5 <210> 146 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> P2-F07antibodyVL CDR1 <400> 146 Leu Ala Ser Glu Asp Ile Tyr Ser Ala Leu Ala 1 5 10 <210> 147 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> P2-F07antibodyVL CDR2 <400> 147 Gly Thr Ser Asn Leu Glu Ser 1 5 <210> 148 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> P2-F07antibodyVL CDR3 <400> 148 Gln Gly Tyr Ser Ser Tyr Pro Leu Thr 1 5 <210> 149 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> P2-F11antibodyVH CDR1 <400> 149 Ser Tyr Gly Val Ser 1 5 <210> 150 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> P2-F11antibodyVH CDR2 <400> 150 Tyr Ile Ala Asn Asn Tyr Asn Pro His Tyr Ala Ser Trp Ala Lys Gly 1 5 10 15 <210> 151 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> P2-F11antibodyVH CDR3 <400> 151 Asp Asn Tyr Gly Met Asp Pro 1 5 <210> 152 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> P2-F11antibodyVL CDR1 <400> 152 Gln Ala Ser Gln Ser Val Tyr Asn Asn Lys Asn Leu Ala 1 5 10 <210> 153 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> P2-F11antibodyVL CDR2 <400> 153 Ala Ala Ser Thr Leu Ala Ser 1 5 <210> 154 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> P2-F11antibodyVL CDR3 <400> 154 Gln Gly Glu Phe Ser Cys Ser Ser Ala Asp Cys Asn Ala 1 5 10 <210> 155 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> P2-C12antibodyVH <400> 155 Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Thr Tyr Ala 20 25 30 Val Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly 35 40 45 Tyr Ile Asn Trp Arg Gly Gly Thr Ser Tyr Ala Asn Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Met 65 70 75 80 Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp 85 90 95 Ala Ser Ser Gly Ala Ala Phe Gly Ser Tyr Gly Met Asp Pro Trp Gly 100 105 110 Pro Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 156 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> 13B4antibodyVH <400> 156 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly 1 5 10 15 Thr Leu Ser Leu Asn Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser 20 25 30 Asn Trp Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Glu Ile Tyr His Gly Gly Thr Thr Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Gly Arg Val Thr Met Ser Val Asp Lys Thr Lys Asn Gln Phe Ser 65 70 75 80 Leu Arg Leu Ser Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Gln Leu Val Gly Gly Leu Asp Val Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 157 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> 13F7antibodyVH <400> 157 Gln Val Gln Leu Gln Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Asn Ala Glu Ser Phe Asn Gly Tyr 20 25 30 Ser Trp Thr Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Ser His Phe Gly Ser Ala Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Ala Thr Ile Ser Ala Asp Lys Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ala Leu Arg Gly Thr Tyr Ser Arg Phe Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 158 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> 15A9antibodyVH <400> 158 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Pro Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Asn Leu Lys Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Asn Pro Phe Gly Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 159 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> P1-A03antibodyVH <400> 159 Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Asp Tyr 20 25 30 Met Ser Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile Gly 35 40 45 Ile Ile Tyr Pro Ser Thr Thr Thr Tyr Tyr Ala Ser Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Glu Leu Lys Met 65 70 75 80 Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly 85 90 95 Ser Asn Trp Ser Ser Gly Met Asn Leu Trp Gly Pro Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 160 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> P1-A08antibodyVH <400> 160 Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Thr Tyr Tyr 20 25 30 Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly 35 40 45 Ile Val Tyr Pro Ser Gly Thr Thr Tyr Tyr Ala Asn Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Thr Ala Ser Thr Thr Val Asp Leu Met Ile Thr 65 70 75 80 Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Asp 85 90 95 Ser Phe Gly Tyr Gly Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 161 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> P1-F02antibodyVH <400> 161 Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asn Tyr Tyr 20 25 30 Met Gly Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile Gly 35 40 45 Ile Ile Tyr Ala Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Met Thr 65 70 75 80 Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ile Asp 85 90 95 Ile Gly Val Gly Asp Tyr Gly Trp Ala Tyr Asp Arg Leu Asp Leu Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 162 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> P2-A01antibodyVH <400> 162 Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr 1 5 10 15 Pro Leu Thr Leu Ser Cys Thr Ala Ser Gly Phe Phe Leu Se...
Claims
1. A pharmaceutical composition comprising an antagonist to a family of sequence similarity 19 member A5 ("FAM19A5") protein, i.e., a FAM19A5 antagonist, for preparing a medicament for treating diabetic retinopathy or age-related macular degeneration. The FAM19A5 antagonist is an antibody or antigen-binding portion thereof that specifically binds to the FAM19A5 protein, i.e., an anti-FAM19A5 antibody, a polynucleotide encoding the anti-FAM19A5 antibody, or a vector comprising the polynucleotide thereof. The anti-FAM19A5 antibody includes heavy chain CDR1, CDR2 and CDR3 and light chain CDR1, CDR2 and CDR3, (i) Of which, the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 27, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 28; or (ii) of which: The heavy chain CDR1 is composed of the amino acid sequence shown in SEQ ID NO: 17, the heavy chain CDR2 is composed of the amino acid sequence shown in SEQ ID NO: 18, and the heavy chain CDR3 is composed of the amino acid sequence shown in SEQ ID NO:
19. The light chain CDR1 is composed of the amino acid sequence shown in SEQ ID NO: 29, the light chain CDR2 is composed of the amino acid sequence shown in SEQ ID NO: 30, and the light chain CDR3 is composed of the amino acid sequence shown in SEQ ID NO:
31.
2. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The diabetic retinopathy is non-proliferative diabetic retinopathy (NPDR).
3. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The diabetic retinopathy is proliferative diabetic retinopathy.
4. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The age-related macular degeneration refers to dry (atrophic) macular degeneration.
5. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The age-related macular degeneration refers to wet (neovascular or exudative) macular degeneration.
6. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The age-related macular degeneration is (i) early AMD, (ii) intermediate AMD, or (iii) late AMD (geographic atrophy).
7. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: Age-related macular degeneration is associated with the accumulation or aggregation of drusen, neovascularization, decreased retinal electrical potential, astrogenesis, or any combination thereof within an individual's retina.
8. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibody specifically binds to at least one FAM19A5 epitope, namely, SEQ ID NO: 6 or SEQ ID NO:
9.
9. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), (i) the VH consists of the amino acid sequence shown in SEQ ID NO: 36, and the VL consists of the amino acid sequence shown in SEQ ID NO: 40; or (ii) The VH comprises the amino acid sequence of SEQ ID NO: 37, and the VL comprises the amino acid sequence of SEQ ID NO:
41.
10. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibody includes Fab, Fab', F(ab')2, Fv or single-chain Fv (scFv).
11. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibody is selected from the group consisting of IgG1, IgG2, IgG3, IgG4 and variants thereof.
12. Use of the pharmaceutical composition according to claim 11 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibody is IgG2, IgG4 or a combination thereof.
13. Use of the pharmaceutical composition according to claim 12 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibodies include IgG2 / IgG4 isotype antibodies.
14. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibody includes a constant region without Fc function.
15. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibody is a chimeric antibody, a human antibody or a humanized antibody.
16. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibody is linked to a molecule having a second binding moiety, thereby forming a bispecific molecule.
17. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The anti-FAM19A5 antibody is linked to a reagent, thereby forming an immunoconjugate.
18. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: Further included are therapeutic agents.
19. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The pharmaceutical composition is formulated with a pharmaceutically acceptable carrier.
20. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The pharmaceutical composition is administered intraocularly.
21. Use of the pharmaceutical composition according to claim 20 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: Intraocular administration includes intravitreal administration.
22. Use of the pharmaceutical composition according to claim 1 in preparing a medicament for treating diabetic retinopathy or age-related macular degeneration, wherein: The pharmaceutical composition is administered intravenously.
